The influence of maternal metabolic  phenotype on breast milk composition and on the maternal and infant urinary metabolome by Andreas, Nicholas James
  
The influence of maternal metabolic  
phenotype on breast milk composition and on the 
 maternal and infant urinary metabolome 
 
 
Nicholas James Andreas 
 
 
 
Imperial College London 
Department of Medicine 
 
 
Thesis submitted for the degree of Doctor of Philosophy 
 
2015 
Maternal phenotype and breast milk composition  
2 
 
Declaration of Originality 
I, Nicholas Andreas, confirm that the work presented in this thesis is my own. Where information has 
been derived from other sources, I confirm that this has been indicated. Portions of this thesis have 
been published in peer reviewed journals, this has been indicated where this is the case.  
 
Copyright Declaration 
‘The copyright of this thesis rests with the author and is made available under a Creative Commons 
Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or 
transmit the thesis on the condition that they attribute it, that they do not use it for commercial 
purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, 
researchers must make clear to others the licence terms of this work’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maternal phenotype and breast milk composition  
3 
 
Acknowledgements 
 
I would like to express my thanks to: 
 
• My supervisors Professor Neena Modi and Professor Elaine Holmes for giving me the opportunity 
to work on this great project 
 
• Dr Matthew Hyde, Dr Isabel Garcia-Perez, Dr Maria Gomez-Romero, Dr Anthony Dona and Dr 
Bronwen Herbert for all their help in the organisation of my study and assisting with analysis 
 
• Suzan Jeffries, for all her help in the organisation of the study, recruitment and sample collection 
 
• My colleagues Dr James Parkinson, Dr Shalini Santhakumaran for helping with various aspects of 
my research 
 
• Westminster Medical School Research Trust for providing funding for my research 
 
• My parents, Margaret and Francis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Maternal phenotype and breast milk composition  
4 
 
Abstract 
 
The main objective of my research is to describe the influence of maternal phenotype on human 
breast milk composition. My primary objective is to establish whether maternal Body Mass Index 
(BMI) influences breast milk metabolomic and endocrine profiles, macronutrient content, and 
maternal and infant urinary metabolomes.  
 
I first focused on milk sample preparation techniques prior to metabonomic analysis. Due to milk 
containing complex structures, such as milk lipid globules and casein micelles, it is difficult to analyse 
because of interference with the analytical techniques employed. I therefore optimised sample 
preparation methods prior to analysis. I also conducted a systematic review of all published literature 
relevant to the hormonal content of human milk. 
 
I investigated human milk metabolomic profiles using 1H NMR spectroscopy and liquid 
chromatography-mass spectrometry. I examined appetite regulating hormones using immunoassay 
techniques, and macronutrient content using mid infrared spectroscopy. I also investigated the 
metabolomic profile of mothers’ and infants urine using 1H NMR spectroscopy. 
 
My principal conclusions from this work are that breast milk metabolomic profile and macronutrient 
content are highly conserved across mothers, and not influenced by maternal BMI. The systematic 
literature review indicated that milk leptin concentration is positively correlated with maternal BMI, 
whilst evidence pertaining to other hormones was either inconclusive or lacking. Of particular note in 
the metabonomic analyses were the diverse profiles observed of Human Milk Oligosaccharides 
secreted into mothers’ milk. These are genetically determined, and have developmental and 
protective effects for infants. 
 
With regard to urinary metabolomic profiles, an association was observed between maternal BMI and 
maternal metabolome, but not infant urinary metabolome. Metabolites discriminating between 
mothers’ with different BMI were present across a range of chemical shifts, from the aromatic region 
associated with metabolites resulting from co-metabolism with the gut microbiota, to the aliphatic 
region.   
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Chapter 1 
Background 
 
1.1  Introduction  
How infants are best fed is an evocative question with people’s beliefs, environment, and 
socioeconomic status, in addition to many other factors, all influencing infant feeding. Infants have 
always been fed substances other than their own mother’s breast milk due to these cultural, health 
and practical reasons. Artificial formula manufacturers have incrementally improved their 
formulations to more closely reflect that of human breast milk. For example, many manufacturers 
now include long chain polyunsaturated fatty acids such as Docosahexaenoic acid (DHA) and 
arachidonic acid (AA), citing evidence of improved intelligence scores for infants receiving increased 
intakes of these compounds (Birch et al., 2000). 
Breast milk has been shown to confer many advantages to the infant, with a systematic review and 
meta-analysis, including 43 studies, reporting breast feeding to be associated with a reduction in the 
risk of acute otitis media, severe lower respiratory tract infections, atopic dermatitis, asthma, obesity, 
type 1 and 2 diabetes, childhood leukaemia, sudden infant death syndrome and necrotising 
enterocolitis (Ip et al., 2007). 
The World Health Organisation (WHO) and many other international institutions recommend that 
infants are exclusively breastfed for the first six months of their lives (Kramer and Kakuma, 2004). This 
recommendation is based on evidence demonstrating  breast fed infants have a significantly reduced 
risk of gastrointestinal infections (Kramer and Kakuma, 2004).  
Despite decades of research into improving infant formula, it is not possible to capture the vast 
complexity of human breast milk within a standardised formula. The composition of human breast 
milk is tailored specifically towards infant requirements, changing in response to factors such as time 
since last feed and length of lactation, matching the infant’s needs according to its age and other 
factors, such as sex (Fujita et al., 2012). This means the composition of breast milk is widely believed 
to be specifically tailored by each mother to reflect the needs of her infant.  
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Even with the known beneficial outcomes associated with breastfeeding, it has been proposed that 
human breast milk may not always be the most appropriate source of nutrition for some infants. In 
one such study, researchers demonstrated a long term negative metabolic effect of breast feeding 
among infants of diabetic mothers. In this study, infant Body Mass Index (BMI) at two years of age was 
found to be positively correlated with the quantity of ‘diabetic’ breast milk the babies received during 
the first week of life (odds ratio 2.47, 95% CI 1.25–4.87), (Plagemann et al., 2002). 
Similarly, an analysis of outcomes in children of mothers with either gestational diabetes or type 1 
diabetes found a positive association between the volume of diabetic breast milk ingested in the first 
week post-partum and  increased relative body weight of children (Rodekamp et al., 2005).The authors 
adjusted for type of maternal diabetes and maternal blood glucose, however, it is difficult to isolate 
the effects of altered breast milk composition from the other effects of diabetes, for example 
alterations in the gut microbiota. 
The same authors also investigated the impact of breast feeding on psychomotor and 
neuropsychological development in children of diabetic mothers.  Here, the authors did not find any 
Figure 1: Advertisement (left) for infant formula, on the right a poster promoting breast-feeding in 
the UK. The global baby food market size in 2010 was estimated to be worth 36.7 billion U.S. dollars 
(Statista, 2014). http://www.independent.co.uk/life-style/health-and-families/health-news/the-
posters-that-celebrate-cool-multitasking-breasts-816224.html. http://www.wikiart.org/en/alphonse-
mucha/nestl%C3%A9-s-food-for-infants-1897 
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impact of receiving breast milk from diabetic mothers on the infant psychomotor parameters, 
although they did observe an association between the volumes of breast milk received from diabetic 
mothers and delayed onset of speaking. However, after the model was adjusted for various factors, 
including birth weight and socioeconomic status, the hazard ratio was reduced to non-significance, 
suggesting that this association was explained by other confounding factors (Rodekamp et al., 2006).  
Another example of when breast milk is not considered optimal or sufficient for infant requirements 
is for premature or low birth weight infants. In the case of these infants, breast milk may not match 
the nutritional needs, and may require fortification in order to increase the energy, protein, vitamin, 
sodium, calcium and phosphorus content, (Edmond and Bahl, 2006). 
Since the last century various studies have examined the effects of maternal characteristics on breast 
milk composition. Important factors influencing breast milk composition–such as the gradual increase 
in fat concentrations throughout a feed have well defined effects and have robust evidence supporting 
them. Other potential influences, including mode of delivery and maternal BMI, have less high quality 
evidence to support the claims made on their effect on breast milk composition. 
What is clear is that there is a lack of knowledge regarding how certain maternal characteristics 
influence breast milk composition, and how these alterations in composition may subsequently 
impact infant and later health outcomes.  
Throughout this thesis the hypothesis that maternal characteristics, specifically maternal BMI, alters 
breast milk composition, exerting a measurable effect on both the nutritional and hormonal content 
is investigated.  
In this chapter, the current knowledge on breast milk synthesis is reviewed, as well as the different 
nutritional and non-nutritional components of breast milk. In addition, previous literature 
investigating the differences between breast milk from overweight and obese mothers in comparison 
to lean mothers is reviewed. Furthermore, evidence detailing the potential of breast milk to 
programme infant metabolism, resulting in lifelong effects on offspring physiology and appetite 
regulation is reviewed.  
Previous researchers’ observations on factors known to influence breast milk composition are 
assessed, and this information is used to inform the design of this study, to reduce the effects of 
confounding factors as far as possible. Also evaluated are the advantages and disadvantages of 
methodologies previously used to measure breast milk composition, and the metabonomic 
techniques used throughout this thesis are subsequently described. Finally, areas of uncertainty 
present in this field are summarized, and investigated in the subsequent chapters. 
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1.2 Breast milk synthesis 
The mammary epithelium employs five separate processes operating in parallel during the synthesis 
of breast milk, transforming precursors derived from either the blood or interstitial fluid into breast 
milk components. These five processes are; exocytosis, lipid synthesis and secretion, transmembrane 
secretion, transcytosis and the paracellular pathway, outlined in Figure 2.  
 
 
 
 
 
 
 
Exocytosis contributes towards the majority of components secreted into the aqueous fraction of 
breast milk (Pathway I, Figure 2), including citrate, nucleotides, calcium, phosphate and glucose, which 
are packaged into secretory vesicles. Secretory vesicles then fuse with the apical plasma membrane, 
releasing their contents into the milk (Neville, 1998). 
Lipid synthesis and secretion involves fatty acids and glycerol being combining into triacylglycerides in 
the smooth endoplasmic reticulum of mammary alveolar cells. The triacylglycerols then merge into 
droplets which travel to the apex of the alveolar cell (Pathway II, Figure 2). The lipid becomes encased 
in the apical plasma membrane, and eventually buds off as a milk fat globule into the milk. The milk 
fat globule membrane provides the infant with dietary phospholipids and cholesterol as well as 
preventing the fat globules from coalescing together, maintaining lipid as an emulsification (Neville, 
1998). 
Figure 2: Diagram of an alveolar cell from a lactating mammary gland. BM, basement membrane; 
MFG, milk fat globule; N, nucleus; TJ, tight junction; SV, secretory vesicle; RER, rough endoplasmic 
reticulum. Adapted from (Neville, 1998). 
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Transport across the apical membrane appears to be restricted to a few small molecules such as 
sodium and potassium. It is unclear what the function of this pathway is (Pathway 3, Figure 2) (Neville, 
1998). 
Transcytosis allows whole proteins to cross the mammary epithelium from the interstitial fluid. 
(Pathway IV, Figure 2). At the basal surface of the mammary alveolar cells, proteins bind to their 
respective receptors; this protein-receptor complex is then taken up via endocytosis and transferred 
to the apical membrane where the extracellular portion of the receptor is cleaved and secreted, 
together with the protein. Proteins including immunoglobulins, hormones and growth factors are 
thought to be secreted into milk via this mechanism (Neville, 1998). 
The paracellular pathway (Pathway V, Figure 2) permits metabolites to be secreted between epithelial 
cells. This pathway is closed once mature milk begins to be secreted as the tight junctions close, but 
molecules as large as immunoglobulins are able to be transported in this manner (Neville, 1998). 
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1.3  Breast milk composition 
There is a vast collection of published scientific data documenting the various constituents of human 
breast milk. The methods employed to measure the presence and concentrations of these compounds 
are wide and varied. 
Generally speaking, the macronutrient composition of mature breast milk, consisting of protein, fat 
and carbohydrate is approximately 9.0g/L of protein, 39.0 g/L of fat and 71.9g/L of carbohydrate. 
(Michaelsen et al., 1990). However, as we shall see, this is a gross simplification, as breast milk is an 
extremely complex and highly variable biofluid, its composition changing due to many different 
influences.  
A database containing a large number of breast milk metabolites, their concentrations, and at which 
point during lactation they were measured, as documented by previous literature was complied, 
presented in Appendix 1A. Macromolecules that contribute to the nutritional and immunologic value 
of breast milk are outlined below. 
1.3.1 Protein 
Proteins present in milk can be divided into two fractions, casein and whey proteins, according to their 
solubility. Whey proteins are more soluble, and present in solution, whilst caseins are found as casein 
micelles, suspended in solution. 
 
Figure 3: Structure of a casein micelle of bovine origin, image from a scanning electron 
microscope. Reprinted with permission from Elsevier, International Dairy Journal, Volume 14, 
Issue 12, Dalgleish et al., 2004. 
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Proteins present in significant quantities in the whey fraction are α-lactalbumin, lactoferrin, 
immunoglobulins, serum albumin and lysozyme. a-Lactalbumin is a mammary-specific protein and is 
the major milk protein found in human milk. 
Casein refers to milk proteins possessing a low solubility at pH 4.0-5.0 (Lawrence RA, 2005). Three 
types of casein are present in human milk ɑ -, β- and k-casein. Stabilising the insoluble ɑ- and β-caseins 
is k-casein, forming a colloidal suspension, the casein micelle. Calcium phosphate is present in high 
concentrations in casein micelles, casein itself contains a high proline content and lacks disulfide 
bonds, causing the micelles to form a tangled web structure (Holt and Horne, 1996). The total protein 
content of human breast milk consists of 17% casein, the lowest casein concentration of any studied 
species (Lonnerdal et al., 1987). 
A major fraction of breast milk protein content, particularly early on in lactation, is formed by the 
immunoglobulins found in milk, IgA being the most predominant form, followed by IgG. These provide 
immunological protection to the infant whist its own immune system matures (Hurley and Theil, 
2011). 
Lactocytes produce approximately 80-90% of the proteins present in breast milk, these are first 
synthesised on the rough endoplasmic reticulum and then transported to the Golgi apparatus where 
they are packaged into secretory vesicles, leaving the cell via exocytosis. The majority of the rest of 
the proteins secreted into breast milk are taken up via transcytosis (Neville M, 1983).  
1.3.2 Non-protein nitrogen 
Non-protein nitrogen, incorporating molecules such as urea, creatinine, creatine, uric acid, small 
peptides and free amino acids are known to vary from 20 -38% of total nitrogen present in human 
breast milk. A portion of this nitrogen is available to the neonate for the synthesis of non-essential 
amino acids. The ratio of essential to non-essential amino acids stays relatively constant throughout 
lactation (Chavalittamrong et al., 1981) Non-protein nitrogen also includes nucleotides, many of which 
perform key roles in various cell processes, such as altering enzymatic activities and acting as 
metabolic mediators, examples of which include adenine and cytosine (Uauy et al., 1994).  
1.3.3 Lipids 
The lipids in breast milk are present as an emulsion. The vast majority of lipids secreted are 
triacylglycerides, contributing towards 98% of the lipid fraction. The remainder predominantly 
consists of diacylglycerides, monoacylglycerides, free fatty acids, phospholipids and cholesterol. These 
components are packaged into milk fat lipid globules, with the phospholipids making up the bulk of 
the membrane of the globules and the triacylglycerols found in the core (Lopez and Menard, 2011). 
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These globules usually range from 1-10 µm across, with an average diameter in mature milk of 4µm 
(Michalski et al., 2005). 
 
Figure 4: An optical microscopy image of milk fat lipid globules, displaying the structure of milk. 
Reprinted with permission from (Zou et al., 2012), American Chemical Society. 
Analysis of non-polar metabolites in breast milk is essential. Lipids are one of the major energy sources 
in breast milk, contributing 40-55% of the total energy of breast milk (Koletzko et al., 2001), and are 
essential for neurodevelopment (Roncada et al., 2013). As well as these, short chain fatty acids (SCFA) 
are not only an important source of energy (Donohoe et al., 2011), but their presence in breast milk 
is essential for normal maturation of the gastrointestinal tract (Peng et al., 2009).  
The fatty acid profile of breast milk has been studied in many different geographical regions, making 
it difficult to distinguish the effects of race and diet on the fatty acid composition of breast milk. In 
The Gambia, a study of 23 rural mothers found that the most abundant fatty acid was oleic acid (18:1), 
making up almost half of the total fat (Prentice et al., 1989). However this is thought to be 
exceptionally high as the diet of these women contains a high amount of groundnuts, accounting for 
around 75% of dietary fat. However, further studies in western populations have also found oleic acid 
concentrations in breast milk to be high, accounting for 30-40g/100g fat (Koletzko et al., 1988).  
 
De novo synthesis of fatty acids accounts for approximately 17% of the total fat in breast milk (Prentice 
et al., 1989). A study focusing on well-nourished Sudanese women found that long chain 
polyunsaturated fatty acids, molecules with a chain length of more than 20 carbon atoms-plus 2 or 
more double bonds, constitute ~2% of the total fatty acids present in breast milk (Laryea et al., 1995).  
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Breast milk is known to contain over 200 fatty acids; however, many of these are present in very low 
concentrations. It has been observed that the positions fatty acids occupy along the glycerol backbone 
are highly conserved, commonly appearing in preferential positions (Martin et al., 1993). For example, 
fatty acids present in the highest concentrations in breast milk, oleic, palmitic and linoleic acid were 
found at the sn-1, sn-2 and sn-3 position respectively, and these distributions were consistent over 
time (Martin et al., 1993). It appears that the distribution of fatty acids along glycerol influences their 
availability; palmitic acid at the sn-2 position seems to be absorbed more readily. Significantly, this 
positional conservation is often not observed in artificial formulas, and was observed to influences 
plasma lipid profile, including cholesterol concentration (Innis et al., 1993). 
Sphingomyelins, present in the milk fat globule membrane, are especially important for central 
nervous system myelinisation, and have been shown to improve the neurobehavioral development of 
low-birth-weight infants (Tanaka et al., 2013).  
1.3.4 Carbohydrate  
There are a huge variety of different carbohydrates present in milk. As well as lactose, various 
nucleotide sugars, lipid bound carbohydrates and protein bound carbohydrates are also transferred 
to the infant. Of the carbohydrate content, lactose is by far the most abundant; however 
oligosaccharides also make up a significant fraction (Coppa et al., 1993). Lactose, a disaccharide, 
consists of glucose and galactose covalently bound to one another. 
1.3.5 Human Milk Oligosaccharides  
Human milk oligosaccharides (HMO) are an extremely important component of human milk 
carbohydrate, together contributing to the third largest component in breast milk, totalling 12.9 ± 3.3 
g/L in mature milk and 20.9 ± 4.8 g/L at 4 days post-partum (Coppa et al., 1993). HMO contain from 3 
up to 22 saccharide units per molecule, and are made up of 5 different sugars, found in varying 
different sequences and orientations. The monosaccharide’s which make up the oligosaccharides are 
D-glucose, D-galactose, N-acetylglucosamine, L-fucose and N-acetylneuraminic acid. There are known 
to be over 200 different types of oligosaccharide in human milk, all of which feature lactose at the 
reducing end (German et al., 2008).  
One known influence on breast milk composition known to be modified by maternal characteristics 
relates to the oligosaccharides present in milk, as the composition of these is genetically determined.  
Different profiles of milk oligosaccharides depend on the specific transferase enzymes expressed in 
the lactocytes. 
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Two such genes, important for determining the HMO profile a mother produces, are the Secretor, and 
Lewis blood group genes. The secretor gene encodes for the enzyme α(1,2)-fucosyltransferase (FUT2), 
responsible for linking fucose in a α1-2 linkage to elongate the HMO chain. The enzyme FUT3 is 
encoded for by the Lewis blood group gene; this enzyme catalyses the reaction between fucose in a 
α1-3/4 linkage, creating further fucosylated oligosaccharides. As a result of the different expressions 
of these enzymes, there are four main phenotypes in relation to HMO profile; Se+/Le+, Se-/Le+, Se+/Le- 
and Se-/Le- (Thurl et al., 1997). 
One study investigating breast milk HMO profile demonstrated Se+/Le+ mothers produced all types of 
fucosylated oligosaccharides, whilst Se-/Le+ mothers did not produce α1,2-fucosylated structures, 
such as 2’-fucosyllactose. Se+/Le- mothers secreted α1,2- and α1,3-fucosylated oligosaccharides, but 
not HMO containing α1,4-fucose residues (Pratico et al., 2013). However, it was noted that in Se-/Le+ 
mothers, α1,3-Fucosylated oligosaccharides, such as 3’-fucosyllactose, were between two to fivefold 
higher than in Se+/Le+ mother’s breast milk. This suggests there is an increase in FucT3 activity in non-
secretor mothers, meaning that the total oligosaccharide production is relatively equal between the 
different groups (Pratico et al., 2013).  
 
HMO function as prebiotics, encouraging the growth of certain strains of beneficial bacteria, such as 
bifidobacterium infantis, within the infant gastrointestinal tract, protecting the infant from 
colonisation by pathogenic bacteria (Ward et al., 2006). 
Furthermore, another mechanism by which HMO protect infants against gastrointestinal infection is 
by acting as receptor decoys. A crucial step in the initiation of infection is the binding of pathogens to 
carbohydrates present on intestinal epithelial cells. HMO inhibit this process due to their analogous 
shapes to cell surface carbohydrates, which are recognised and bound to by pathogens, which then 
passes harmlessly from the gastrointestinal tract, i.e. HMO competitively inhibit pathogen binding to 
the infants epithelial cells. Demonstrating this protective capacity, an observational study found a 
significant association between low levels of speciﬁc 2-linked fucosylated oligosaccharides in human 
milk and increased rates of Campylobacter diarrhoea in breast fed infants. Furthermore, infants who 
received milk containing a low concentration of lacto-N-difucohexaose had an increased incidence of 
calcivirus diarrhoea, (Morrow et al., 2004). Breast milk contains relatively equal concentrations of 
HMO between mothers, but it is the structures of the HMO which are genetically determined, and 
furthermore it is the specific structures which inhibit pathogen binding as different pathogen 
receptors have different affinities for specific carbohydrate structures. 
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Figure 5: Structure of 2’- and 3’-fucosyllactose. Reproduced from (Pereira and McDonald, 2012).   
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1.4 Differences In breast milk from overweight/obese mother to lean mothers 
1.4.1 Macronutrient differences in breast milk of mothers with differing BMI 
The overall macronutrient content of breast milk increases with increased maternal BMI, Table 1 
(Michaelsen et al., 1990). Mothers with a BMI of less than 22kg/m2 have been observed to have a 5% 
decrease in the protein content of their breast milk compared to mothers of a higher BMI (Michaelsen 
et al., 1990). This study used an infrared analysis to determine to the concentrations of these nutrients 
in breast milk. 
Table 1: The relationship between nutritional content of breast milk per unit increase in maternal 
BMI. Standard error is shown in brackets. Adapted from (Michaelsen et al., 1990). 
Macronutrient, (g/L) Maternal body mass index (BMI) (kg/m2) 
Protein +0.054 x BMI (0.006) 
Fat +0.58 x BMI (0.06) 
Carbohydrate +0.056 x BMI (0.014) 
 
Further research has highlighted differences in the nutritional content of breast milk from Otomi 
Indian mothers of a high and low BMI. In this study, mothers breast milk fat concentrations were 
significantly lower in the low BMI group in comparison to the high BMI group at 6 months post-partum, 
29.1±8.7 vs 35.7±9.2mg/g, p=0.04, in the low and high BMI group respectively.  
Furthermore, breast milk fat concentrations were positively correlated with maternal body fat, as 
measured by deuterium dilution, at three and six months post-partum, r=0.32 and 0.40; p=0.04 and 
0.01, respectively. However, it should be noted that, due to the inverse correlation between breast 
milk production and fat concentrations in milk, fat secretion into milk did not differ between groups 
and therefore the growth velocities of the infants did not significantly differ between the low and high 
BMI groups, (Barbosa et al., 1997). This means that although infants of obese mothers were receiving 
milk with a higher caloric density they are provided with less volume, therefore on average receiving 
the same quantity of calories as their peers born to lean mothers. 
Furthermore, breast milk from overweight mothers has been observed to have significantly increased 
glucose concentrations. The mean milk glucose value of mothers with a BMI of below 25kg/m2 was 
32.6±21.8mg/dL, whilst mothers with a BMI above 25kg/m2 was 51.9±20.5mg/dL (Ahuja S, 2011). 
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1.4.2 Differences in non-nutritive compounds in breast milk of mothers with differing BMI 
Many studies have identified a correlation between maternal overweight/obesity and breast milk 
appetite regulating hormone concentrations. For example, the concentration of insulin in breast milk 
has been found to be greater in overweight mothers compared to controls. Milk-borne insulin values 
of mothers with a BMI of below 25kg/m2 and mothers with a BMI above 25kg/m2 were 4.5±7.6μIU/mL 
and 30.1±56.3μIU/mL respectively, (Ahuja S, 2011). Multiple studies explore the link between 
maternal BMI and appetite regulating hormones present in breast milk; these are systematically 
reviewed and investigated in vivo in Chapter 3. 
1.4.3 Evidence from animal models suggests differences in milk composition from overweight 
animals 
Previous research investigating the influence of maternal dietary induced obesity and altered diet 
have previously been undertaken employing animal models. In one such study, changes in milk 
composition, including protein, lactose and fat content, as well as fat composition were determined 
for lean and obese rats fed a highly palatable diet. Milk of the obese rats was found to be more 
calorific, due to an increase in fat content. However, obese rats milk contained less protein than lean 
rats milk (Rolls et al., 1986). 
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1.5 Incidence of overweight and obesity 
In the United Kingdom from 1990 to 2004 there was seen to be a 60% increase in the incidence of 
maternal obesity and over 50% of women of reproductive age are now classified as either overweight 
or obese (Heslehurst et al., 2007). The cost of obesity for the NHS in England is estimated to be 
approximately £1 billion (Heslehurst et al., 2007).  
Worldwide, rates of overweight and obesity have increased dramatically, almost doubling since 1980, 
(WHO, 2013). In 2008, over 1.4 billion adults were overweight, with half a billion of these individuals 
classed as obese. Currently, overweight and obesity kill more people than underweight, accounting 
for at least 2.8 million deaths each year, and is the fifth largest cause of global deaths (WHO, 2013). 
 
Figure 6: Rates of underweight (BMI <18.5kg/m2), overweight (BMI >25kg/m2) and obesity (BMI 
>30kg/m2) from 1980 to 2008 in women aged 20-49 years. Figure reproduced with permission from 
Elsevier, (Black et al., 2013). 
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1.6 Early life programming 
Nutrition received during the period of early development in mammals permanently affects the health 
of the subsequent adult, as well as the individual’s offspring. Sub-optimal maternal nutrition during 
this time is of major concern due to the long lasting negative effects it is able to exert on offspring 
well-being (Ferland-McCollough et al., 2012). 
Professor David Barker at the University of Southampton first described evidence indicating an 
association between low birth weight and an increased likelihood of developing coronary heart 
disease in later life. This association has now been observed for various non-communicable diseases 
such as stroke, diabetes and obesity (Barker, 1995). These findings were later named in the British 
Medical Journal as the ‘Barker Hypothesis’ (Paneth and Susser, 1995); this states conditions in early 
life program an infant’s development, potentially predisposing them to various diseases in later life 
(Barker, 1995).  
 
Figure 7: Two healthy term infants; the infant on the right is at an increased risk of developing non-
communicable diseases in later life compared to its peer due to its low birth weight. Reproduced 
from http://www.beginbeforebirth.org/in-the-womb/fetal-programming. 
Programming is proposed to occur during specific crucial time periods of growth during early life. An 
insult or stimulus, such as malnutrition, causes a disruption of the normal development of the infant. 
Because the infant adapts in response to this environmental insult, it ‘predicts’ the environment it will 
be raised in. However, this does not always reflect the environment the infant is subsequently exposed 
to, therefore, if there is a mismatch between the two, this predisposes the infant to disease, as it is 
poorly adapted to the environment it is raised in (Rogers and Velten, 2011).  
This programming of infant metabolism is relevant to both the developed and developing world; as 
there is often a caloric mismatch; women in the developing world are often malnourished, whilst in 
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the developed world, women often eat unbalanced diets in regard to macronutrient content and are 
often deficient in micronutrients, such as folate, with the developing fetus suffering as a result. 
Much of the evidence for programming suggests its effects are established in utero (Desai and Hales, 
1997). However, it is likely that in addition to this antenatal programming, sub-optimal nutrition in the 
postpartum period, for example receiving formula milk, or breast milk with and altered composition, 
may further contribute towards the programming of infant metabolism. 
A wide range of negative consequences have been observed in infants of obese/overweight mothers, 
including an increased risk of being either large (Ehrenberg et al., 2004), or small (Rajasingam et al., 
2009) for gestational age, both of which are associated with negative outcomes in later life. For 
example, offspring of obese mothers are at an increased risk of being obese themselves (Parsons et 
al., 2001), as well as having an increased risk of developing diabetes, (Wei et al., 2003). However, 
whether this effect is due to the shared environment or genuine programming of infant metabolism 
is under debate, but mounting evidence shows a strong contribution of this effect is due to the shared 
environment, (Lustig, 2006).  
Nonetheless, evidence suggesting programming does play a role in this phenomenon, having 
additional effects over shared environmental factors, comes from sibling studies of obese mothers 
studied before and after maternal bariatric surgery, (Smith et al., 2009). Children born to mothers 
after bariatric surgery were found to have a lower birth weight (2.9+/-0.1kg after maternal surgery vs. 
3.3+/-0.1kg before maternal surgery, p=0.003), and a reduction in the prevalence of macrosomia (1.8 
after maternal surgery vs. 14.8% before maternal surgery, p=0.03) was noted, but no difference in the 
incidence underweight was observed, (Smith et al., 2009).  
When these infants were followed up, individuals who had been born after maternal bariatric surgery 
were shown to have a 3-fold lower prevalence of severe obesity, 11 vs. 35%, p=0.004. Furthermore, 
these infants received many other metabolic benefits, with beneficial effects on cardiometabolic 
markers maintained into adolescence, including better insulin sensitivity and lipid profile, than 
individuals born to mothers before undergoing bariatric surgery. The authors contributed this effect 
to an improved intrauterine environment (Smith et al., 2009).  
Additionally, evidence of metabolic programing during the perinatal period has been proposed to 
occur through the epigenetic modification of DNA. In this study, mice dams were fed a high fat diet 
during pregnancy and lactation. This was seen to induce a co-ordinated and long-lasting change in the 
expression of insulin like growth factor 2, and genes involved in fat metabolism in the offspring (Zhang 
et al., 2009). 
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Human milk is known to contain a vast number of nutrients, however, in addition to these nutritional 
components, breast milk also contains a multitude of hormones and immunological agents, often in 
greater concentrations than in maternal plasma (Savino and Liguori, 2008). These are potent biological 
agents, which have been shown to influence the metabolism of the neonate. 
It is conceivable that the composition of breast milk may signal satiety to the baby as a feedback 
mechanism to control milk intake. For example, it has been reported that the concentration of leptin 
in breast milk of obese women is higher than non-obese women (Houseknecht et al., 1997). Leptin 
down regulates appetite (Dundar et al., 2005a), so high leptin concentrations in milk may reduce the 
intake of milk. This may be a positive mechanism for offspring of obese women as their milk is known 
to be particularly nutrient and energy dense (Michaelsen et al., 1990). Therefore, the higher leptin 
concentration in breast milk may reduce the intake of excess calories, protecting the baby from early 
onset of obesity (Miralles et al., 2006).  
 
 
Figure 8: On the left are two wild type mice, whilst on the right is an ob-/ob- mouse, which cannot 
produce leptin, and is therefore unable to regulate its appetite properly. Reproduced from 
biocadmin.otago.ac.nz/fmi/xsl/bioc/learnbitslecture.xsl?-db=BIOCweb.fp7&-lay=Lectures&-
recid=5207&-find= 
If this effect is due to altered breast milk composition then potentially the altered breast milk 
composition of overweight and obese mothers may influence the metabolism of their infants. 
Consequently, if this is the case then proper delineation of exactly how breast milk from these mothers 
differs from lean mothers needs to be established. Further animal models could be employed to 
establish to what extent altered breast milk composition is able to influence infant and subsequent 
adult metabolic phenotype. 
Evidence supporting this hypothesis has been collected in human studies investigating the hormonal 
composition of breast milk and its correlation with infant growth. A number of studies have 
highlighted a negative correlation between infant growth and leptin, an anorexigenic hormone 
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(Doneray et al., 2009, Miralles et al., 2006). However, in contrast other such similar studies have not 
found this effect (Uysal et al., 2002).  
1.6.1 Animal models supporting the contribution of breast milk towards infant programming  
Animal studies have reported programming of appetite regulation due to the type of milk ingested. In 
one such study, rat pups from control dams were cross-fostered to dams with gestational diabetes. 
Cross-fostered pups where shown to have mal-programmed hypothalamic orexigenic and 
anorexigenic neural circuits, which are involved in appetite regulation (Fahrenkrog et al., 2004). 
 
Further research using rodent models have investigated the impact of maternal high fat diet during 
lactation on the neonate. Here, researchers established that dams fed a high fat diet during lactation 
predisposed their offspring to obesity in later life. Contributing towards this effect, offspring were 
shown to have impaired glucose homeostasis, associated with an impairment of the hypothalamic 
melanocortin circuitry (Vogt et al., 2014). 
In order to establish the mechanism behind this effect, the number, and neuropeptide expression of 
anorexigenic proopiomelanocortin (POMC) - appetite supressing, and orexigenic agouti-related 
peptide (AgRP) - appetite stimulating, neurons were investigated. The electrophysiological properties 
of POMC neurons and posttranslational processing of POMC were also studied. These properties all 
remained unaffected in the neonates of dams fed high fat diets. However, it was observed that the 
formation of projections from POMC and AgRP neurons to their hypothalamic target sites was 
impaired in neonates of dams fed a high fat diet (Vogt et al., 2014).  
The impaired formation of POMC projections could be prevented by abolishing the action of insulin in 
the POMC neurons, which simultaneously abolished the effect of abnormal parasympathetic 
innervation to the pancreas, and impaired glucose stimulated insulin secretion seen (Vogt et al., 2014).  
These observations demonstrate the crucial timing in programming of infant metabolism, occurring 
during the period where neuronal projections are formed, and altered insulin signalling has an 
important role in mediating this effect (Vogt et al., 2014). 
Research by Franco et al demonstrated that a maternal isocaloric high fat diet changes milk 
composition, with increased fat and protein concentrations and hyperleptinaemia. This altered milk 
composition induced obesity in the male rat offspring of the mothers fed this high fat diet (Franco et 
al., 2012). 
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Evidence from these studies suggest that if neonates are subjected to an abnormal hormonal milieu 
during development, persistent changes in the function of hypothalamic neurocircuits result, 
responsible for the regulation of energy and glucose metabolism. 
Whether these effects would be replicated in humans is unclear. This is because, in humans, it is 
thought that the development of the hypothalamic neurocircuits is more mature at birth, whist in 
rodents this process continues until several weeks post-partum, throwing into question the 
translatability of animal models in regard to these observations (Grayson et al., 2006, Koutcherov et 
al., 2003). 
Nonetheless, programming effects have been observed in primate models during the post-partum 
period, suggesting that there is still some developmental plasticity during this period. One such study 
of infant over and under nutrition in baboons tested the hypothesis pre-weaning nutrition is able to 
influence adult fat cell numbers and adiposity (Lewis et al., 1986). In this study infants were fed 
formula milk containing different caloric densities, after which they were fed the same diets. Fat cell 
number and size were then studied in ten different adipose depots. It was observed that females who 
were overfed as infants were found to have greater fat depot mass, due to fat cell hypertrophy, whilst 
males overfed as infants had greater fat mass depots in four of the ten depots studied, the different 
diets did not influence fat cell number (Lewis et al., 1986). 
Further evidence supporting the postulation that developmental differences occur for infants fed 
different diets comes from a study using NMR spectroscopy to investigate the metabolic implications 
of breast feeding and formula feeding rhesus monkeys. This study investigated urine and serum 
metabolome, recorded anthropometric measurements, and profiled the infant microbiome and 
serum cytokines. Formula fed infants were found to be larger than breast fed infants and displayed an 
altered microbiome; with breast fed infants having higher levels of Lactobacillus genus bacteria, a 
beneficial strain of bacteria. Additionally formula fed infants had increased concentrations of serum 
insulin, as well as amino acids. This study gives support to the hypothesis that different diets in early 
life can influence infant metabolism, gut microbiome and immunity (O'Sullivan et al., 2013a).  
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1.7 Maternal influences on breast milk composition 
Breast milk composition is extremely complex, varying with the time of day, maternal diet and many 
other factors, outlined below (Lawrence RA, 2005). The change in breast milk composition over 
lactation is known to reflect the infant’s needs, becoming more energy dense over lactation, with 
increasing carbohydrate and lipid concentrations to provide for the infants increased energy 
requirements. Total protein is seen to decrease, probably due to the decreasing concentration of 
factors such as immunoglobulins secreted into breast milk (Mickleson and Moriarty, 1982). This not 
only reflects the infants decreased requirement for them, as their own immune system becomes 
functional, but also reflects the increasing inability of the infant gut to absorb proteins, as gut closure 
occurs and the permeability of the gut to macromolecules decreases over the first 3 days of life 
(Vukavic, 1984).    
 
Figure 9: Variation in the content of protein, fat, lactose and total energy of breast milk from 
different mothers, analysis using a Miris milk analyser. Reproduced from Miris. (Miris, 2013). 
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1.7.1 Time since last feed 
One of the most significant predictors of milk fat concentration is the length of time since the last 
feed; the longer this interval is, the lower the concentration of fat in the milk.  In keeping with this, fat 
concentrations at the end of the previous feed, as well as the volume of milk received at the previous 
feed, have been found to be particularly important predictors of milk fat concentration (Jackson et al., 
1988). 
1.7.2 Stage of the nursing process 
The stage of the nursing process is known to result in a large change in the composition of breast milk. 
There is an increase in the fat content from the beginning, known as fore milk, to the end of a feed, 
hind milk, whilst lactose shows an inverse correlation to the change in fat content (Hytten, 1954). This 
effect is responsible for some of the biggest changes seen in the alteration of milk composition. It is a 
common misconception that there are two kinds of milk, however these distinctions correspond to a 
gradual change in the composition of milk throughout a feed as the breast milk steadily becomes 
fattier towards the end of a feed. 
 
Figure 10: Image displaying the gradual increase in milk fat concentration from the beginning far left 
(1) to the end far right (12) of a feed. Replicated from thefunnyshapedwoman.blogspot.co.uk /2011/ 
05/ foremilk-and-hindmilk-in-quest-of.html 
1.7.3 Length of Lactation 
There are considerable changes in the composition of milk over the course of lactation. Milk is 
commonly classified into colostrum, transitional milk and mature milk. Similarly to fore and hind milk, 
these are not distinct classes of milk, but refer to the gradual alteration in the content of milk 
throughout lactation (Jenness, 1979). The average content of protein in breast milk gradually 
decreases from the second month to the seventh month, after which the speed of reduction of protein 
content levels off. Lactose production is highest in the forth to seventh month, after which it 
decreases. In contrast to this, HMO production is very high during early lactation, tapering off as 
lactation proceeds, with one study finding concentrations reducing from ~21 g/L to ~13 g/L from day 
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4 to day 120 post-partum. Also there is a gradual increase in the concentration of lipid in the milk over 
lactation (Kader et al., 1972).   
1.7.4 Age of Mother 
Protein concentration is highest in breast milk of mothers aged 20-30, however, maternal age does  
not seem to influence lipid or lactose concentrations (Kader et al., 1972). Similarly, another group 
concluded maternal age did not significantly alter breast milk composition in terms of fat or 
carbohydrate concentration. This study also found protein levels decreased with increasing maternal 
age, however the authors note that the influence was very small and unlikely to be of nutritional 
relevance (Michaelsen et al., 1990). 
1.7.5 Birth weight  
Milk fat concentration increases if there is a deviation from normal birth weight i.e. there is a u-shaped 
association between fat content and infant birth weight, with a 20-30% increase observed at the 
lowest and highest infant birth weights. Concentrations of protein and carbohydrate have not been 
seen to change significantly in relation to infant birth weight (Michaelsen et al., 1990). However, this 
study did not collect information on length of gestation; therefore, this influence may simply be a 
marker of the maturity of the infant.  
1.7.6 Weight gain during pregnancy  
A correlation between maternal weight gain during pregnancy and breast milk fat content has been 
reported, however, this was only observed to be significant at four months post-partum not at two 
months post-partum. The authors hypothesise that this phenomenon may be due to the laying down 
of fat stores during pregnancy, which are used as an energy reserve during lactation and subsequently 
more quickly diminished in the low weight gain group of mothers (Michaelsen, 1997). Despite this 
finding, two further studies were unable to identify an association between maternal weight gain 
during pregnancy and breast milk fat content (Butte et al., 1984), (Dewey KG, 1986). 
1.7.7 Ethnicity 
An analysis summarising research on the composition of milk of mothers from seven countries 
suggests breast milk composition is relatively consistent from mothers across different ethnicities. Of 
the variation which was observed, fat content was seen to vary by the greatest amount. Importantly, 
the magnitude of inter-individual variation between mothers of the same ethnicity was as great as 
that observed between mothers from different ethnicities (Jenness, 1979). 
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1.7.8 Diet 
The influence of maternal diet on breast milk composition is complex. Depending on the type of 
nutrient, maternal diet can have virtually no impact on a nutrients concentration, whilst for other 
nutrients, maternal diet can result in large variations in milk composition (Innis, 2014). 
Previous research on the macronutrient content of breast milk comparing Swedish, Ethiopian 
privileged, and Ethiopian underprivileged mothers found little variation based on diet (Lonnerdal et 
al., 1976). However, this study investigated total macronutrient content, not specific metabolites 
accounting for macronutrient content, therefore, it was not sensitive enough to distinguish more 
subtle differences between groups.  
The variation in milk lipid concentration appears to be independent of maternal diet (Ballard and 
Morrow, 2013), however, fatty acids which form the lipid fraction are sensitive to maternal diet. These 
fatty acids are either endogenously synthesised in the mammary gland, or taken up from the maternal 
plasma. Both of these fatty acid sources have been observed to be influenced by maternal diet (Innis, 
1992). Because triacylglycerides consist of three fatty acids esterified to a glycerol backbone, any 
increase in one particular type of fatty acid naturally results in a concurrent decrease in concentration 
of another type of fatty acid. 
There have been numerous studies observing the fatty acid profile of breast milk can be altered by 
manipulating the maternal diet, (Innis, 1992), (Brenna et al., 2007) and (Koletzko et al., 1992), 
especially of the monounsaturated, n–6, and n–3 fatty acids. In one such study, Insull et al altered the 
diets of lactating women, providing 40% of their dietary energy from lard, corn or linseed oil. Within 
2–3 days of changing the mothers’ diet to corn oil (containing ∼52% of 18:2 n–6), the amount of the 
18:2 fatty acid increased from 8–10% to ∼42% of the fatty acid present in breast milk. Simultaneously, 
the relative contribution of arachidonic acid (20:4 n–6) and DHA to total milk composition fell from 
0.7% to 0.3%, and 0.3% to trace amounts respectively (Insull et al., 1959). Dietary fatty acids are 
therefore thought to be transferred rapidly into breast milk, and within 2 to 3 days breast milk changes 
to mimic that of dietary fat. 
The mammary gland is capable of synthesizing the medium-chain fatty acids (MCFAs) 10:0, 12:0 and 
14:0. Women receiving a high carbohydrate, low fat diet have increased MCFA synthesis, maintaining 
the quantity of triacylglycerides in breast milk (Novak and Innis, 2011). This increase in MCFA is 
accompanied by a decrease in the concentration of mono-unsaturated fatty acids (MUFA), 18:2 n–6, 
and 18:3 n–3 in the breast milk (Novak and Innis, 2011).  
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Animal studies investigating the composition of breast milk in relation to maternal diet have reported, 
in pigs, that the kind of dietary supplementation had little effect on milk composition, but the timing 
of dietary supplementation appeared to have a significant influence, especially on the percentages of 
fat and protein in the milk. It was shown that the fatty acid profile of the maternal diet during gestation 
also reflected the fatty acid profile of milk during lactation. The most dramatic differences in milk fatty 
acid profile were seen in sows that had received either sunflower oil or fish oil diets during gestation; 
with changes in milk fatty acid profile again reflecting the fatty acid composition of the diet (Laws et 
al., 2009).  
1.7.9 Diurnal variation 
There has been shown to be a typical diurnal variation of fat content in milk, with a peak fat content 
occurring at midmorning and a low during the night. This variation can be from 3g/100ml to 5g/100ml 
(Jenness, 1979). Figure 11 displays a summary diagram, indicating the findings from multiple studies 
investigating the variation fat content of breast milk throughout the day. 
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Figure 11: Circadian variation in fat content of breast-milk from previously published studies.  
(a) Thailand, demand feeding, fore and hind milk expressed samples, nineteen mothers studied for 24 
h, infants aged 1-9 months (Jackson et al., 1988). (b) The Gambia, demand feeding, fore and hind milk 
expressed samples, sixteen mothers studied for 24 h, infants aged 1-18 months (Prentice et al., 1989). 
(c) Bangladesh, demand feeding, total breast expression via breast pump, seven mothers studied for 
24 h, infants aged 1-9 months (Brown and McDonald, 1982). (d) UK, scheduled feeds, fore and hind 
milk expressed samples, one mother studied for 72 h, age of infant unspecified (Hall, 1979). (e) UK, 
scheduled feeds, total breast expression via breast pump, (1) twenty-nine mothers studied for 24 h, 
infants aged 3-8 d, (2) twenty mothers studied for 24 h, infants aged 21d-4 months, (Hytten, 1954). f) 
USA, scheduled feeds, total manual breast expression, values given for one mother, studied for 24 h 
on six occasions and 72 h on one occasion, infant aged 6-60 weeks (Nims, 1932). (g) New Zealand, 
scheduled feeds, total manual breast expression, 28 mothers studied for 24 h, infants aged 1-8 months 
(Deem, 1931). (h) Germany, scheduled feeds, total manual breast expression, two mothers studied 
for 24 h, six mothers studied for 52 h, infants aged 8-11 d (Gunther and Stanier, 1949). Reproduced 
with permission from (Jackson et al., 1988). 
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The alterations observed in breast milk lipid concentration do not obviously relate to differences in 
study design or sampling methods. As many of the studies report different findings in relation to when 
the peak of breast milk fat occurs, the authors suggest that this disparity may be due to the feeding 
behaviour of the infant, as this is significantly correlated to variations in fat content, (Jackson et al., 
1988). 
1.7.10 Colostrum 
Colostrum, the first milk produced, is significantly different from mature milk produced later on into 
lactation. Colostrum differs from mature milk in many ways, containing higher concentrations of 
protein and lower concentrations of lactose and fat (Jenness, 1979, Saint et al., 1984). As well these 
macronutrient differences, colostrum is dramatically different to mature breast milk in terms of its 
bioactive properties, containing high concentrations of secretory immunoglobulin (Castellote et al., 
2011). These qualities suggest that the primary role of colostrum is not nutritional, but immunologic, 
protecting the baby as it emerges from the relatively sterile environment of the womb to being 
exposed to many environmental pathogens.  In accordance with this, the concentration of HMO in 
colostrum is particularly high, being approximately double that of mature milk. 
As well as its immunologic and nutritional roles, colostrum appears to also act as a growth promoter. 
Colostrum contains many growth factors, again often in greater concentrations than in mature milk, 
for example, epidermal growth factor (Okada et al., 1991), transforming growth factor-beta (Saito et 
al., 1993) and colony stimulating factor-1 (Flidel-Rimon and Roth, 1997) are all found in higher 
concentrations in colostrum in comparison to breast milk.  
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1.8 Methods previously used to measure breast milk composition 
Methods previously used to measure breast milk composition have frequently focused on specific 
nutritional components such as fat or protein content, or, if a group is interested in a specific 
component, assays such as Radioimmunoassay (RIA) or Enzyme Linked Immunosorbent Assay (ELISA) 
are used (Miller et al., 2013). Methods used to measure various macronutrient and peptides are 
outlined below. 
1.8.1 Protein 
Protein content can be measured using a number of different techniques. One technique is 
colorimetric assay, using methods such as bicinchoninic acid, Lowery-Peterson or the Bradford test. 
However, it has been noted that is important to use a reference method specific for milk protein in 
order to get a reproducible result (Keller and Neville, 1986). 
Another method for determining total protein used is elemental analysis. Elemental analysis of 
carbon, hydrogen, and nitrogen is achieved by measuring the amount of nitrogen by combustion of a 
milk sample and measuring the waste NO2 produced (Power et al., 2002).  
However the gold standard of determining protein concentrations is the Kjeldahl method. This method 
determines total nitrogen content, and is used as the reference technique which other methods are 
measured against. The Kjeldahl method is extremely precise; however it requires a large (10ml) sample 
volume (Miller et al., 2013), which is often impractical. All these methods simply quantify the total 
nitrogen content present in a sample, this leads to an overestimation of actual protein content, due 
to the non-protein nitrogen found in milk, however attempts are usually made to adjust for this.  
Recent analysis, using a combination of electrophoresis and two-dimensional liquid chromatography, 
has enabled the identification of over 400 proteins present in human breast milk, many of which were 
identified for the first time (Molinari et al., 2012). 
1.8.2 Lipid  
Many methods have been established in order to measure the fat content in human milk. One 
common technique is the creamatocrit method.  Milk is first drawn into a standardised capillary tube 
and centrifuged forming a cream layer at the top of the sample. Callipers are then used to measure 
the thickness of the cream layer, the ratio of the measurement to the column length allows this to be 
converted into grams of fat per litre (Lucas et al., 1978) 
Quantification of the lipid fraction of milk using solvent extraction is a direct way of determining lipid 
content. However, specific solvents can be used to influence which species of lipid are extracted. This 
method allows for the determination of milk fat as a percentage of total weight. 
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Again more recent methods using liquid chromatography have unveiled the staggering diversity 
present in the lipid fraction of breast milk. One study, detailing the triacylglyceride content alone, 
revealed 170 different triacylglycerides (Winter et al., 1993). 
1.8.3 Carbohydrate 
The predominant carbohydrate in milk is lactose; however Human Milk Oligosaccharides, 
monosaccharides and other carbohydrates also make up a significant portion of the carbohydrate 
content in milk. Many methods developed to measure the carbohydrate content of milk only quantify 
lactose concentration, leading to an underestimation of the true carbohydrate content. Similarly to 
protein quantification, lactose concentration can also be measured using colorimetric techniques, 
with comparison to a standard (Miller et al., 2013). 
Assessment of total sugar content can be measured using a phenol-sulphuric acid method. This 
method hydrolyses the bond between sugars using sulphuric acid; sugars released then react with the 
phenol present, giving a yellow reaction product, which can be quantified using a spectrometer, 
(Dubois, 1956).  
More recent techniques used to investigate the carbohydrate content of milk have used liquid 
chromatography coupled to mass spectrometry. Using this method, the diversity of human milk 
oligosaccharide content has been investigated, with around 200 distinct oligosaccharides being 
identified (German et al., 2008). 
1.8.4 Mid Infrared transmission spectroscopy 
Mid infrared transmission spectroscopy allows for the quantification of fat, carbohydrate and protein 
content of milk samples. It has only relatively newly been applied to the analysis of breast milk. The 
primary use of this technology is for the clinical determination of nutritional content of breast milk, in 
order to establish whether fortification of breast milk is required for preterm infants nutritional intake 
(Menjo et al., 2009). This method has more recently been used in standalone research in order to 
investigate how maternal characteristics influence breast milk composition (Dizdar et al., 2013). This 
research concluded that higher concentrations of protein could be found in colostrum of mothers who 
had given birth vaginally. The authors speculate that this could arise from altered hormonal activity 
induced by labour pains and uterine contractions.  Furthermore, this study also found that an increase 
in maternal age led to a decrease in the protein concentration of breast milk. 
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1.9 An Introduction to Metabonomics 
Using metabonomics, which employs 1H NMR Spectroscopy and/or chromatographic techniques 
coupled to Mass Spectrometry (MS), it is possible to study a very large number of metabolites 
simultaneously, covering a range of metabolite classes mostly in the low molecular weight range such 
as organic acids, amino acids, sugars, phenolics, lipids and carbohydrates. These analytical techniques 
are used for metabonomic studies, analysing metabolites in a detailed manner and requiring only 
small sample volumes. Metabonomics is defined as `the quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to pathophysiological stimuli or genetic 
modification’ (Nicholson et al., 1999).  
 
 
These techniques allow for the examination of many biological processes occurring in complex 
organisms, or systems. This is because the metabolites found in a sample are present due to the cells 
which manufacture and secrete them (Lindon et al., 2000). As the composition of biofluids is 
Figure 12: This image displays a urine wheel, published in 1506 by Ullrich Pinder, describing the 
colour, smell and taste of urine, using them for the diagnosis of diseases. Reproduced with 
permission from (Nicholson and Lindon, 2008) NPG. 
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frequently altered as a result of disease or metabolic changes, metabonomics provides an excellent 
insight into the current biochemical status of an individual (Holmes et al., 1994). 
Once spectral data are collected, advanced multivariate statistical tools, commonly referred to as 
chemometrics, are used to extract the maximum amount of information possible concerning complex 
biological samples (Richards et al., 2010). These techniques provide a metabolic fingerprint of the 
individual; known as a metabolome; capable of classifying samples, and can also have a diagnostic 
value, (Lindon, 2005). This classification of samples enables investigation into the metabolic changes 
which result in the classification obtained, giving an indication of the metabolic alterations which occur 
as a consequence of a disease or condition, such as obesity.  
Since none of the analytical platforms used in metabonomics can extract all the relevant information 
from a sample, a combination of several techniques such as 1H NMR spectroscopy and 
chromatographic techniques coupled to MS are employed for a comprehensive understanding for 
components present in samples. 
1.9.1 Summary of previous studies employing metabonomics to investigate breast milk 
composition 
Very few previous studies document the use of metabonomic techniques to investigate human breast 
milk. A preliminary study using metabonomics to investigate global breast milk composition analysed 
preterm breast milk, as well as preterm formulas analysed for comparison, using 1H NMR 
spectroscopy, concluded that there was much biochemical variability between samples, but did not 
identify which metabolites accounted for these alterations. However, the authors did identify that 
lactose was present in a higher abundance in breast milk in comparison to formula, and that lactose 
concentrations increased over time (Marincola et al., 2012).  
Further research by Practico et al also used NMR based metabonomics to investigate human breast 
milk composition, suggesting it could be used for rapid characterisation of breast milk nutritional 
content. The researchers identified a total of 43 metabolites, but note the difficulty of fully 
characterising the spectra due to overlapping peaks deriving from sugars and macromolecules. By 
comparing NMR spectra, three different milk groups were identified, dependent on the pattern of 
fucosylated oligosaccharides produced (Pratico et al., 2014).  
Other studies using NMR spectroscopy or mass spectrometry to investigate human breast milk 
primarily investigate either a specific breast milk protein, or the structure of HMO. 
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A previous study using NMR Spectroscopy to investigate breast milk composition and its variation due 
to maternal phenotype and diet has been undertaken (Smilowitz et al., 2013).  Here, milk was collected 
at 90 days post-partum, from 52 healthy women, allowing for the quantification of 65 milk 
metabolites, of various biochemical classes.  
There was a wide range of biological variation between mothers, with some metabolites ranging from 
4–120%; although several metabolites displayed a low variation, less than 20%, such as lactose. The 
authors identified two groups of mothers who differentiated in their HMO profiles, these women were 
classified as either secretors or non-secretors of products of the fucosyltransferase 2 (FUT2) gene, 
which catalyses the production of oligosaccharides such as 2’-fucosyllactose, lactodifucotetraose, and 
lacto-N-fucopentaose I. Intraindividual concentrations of HMO were conserved, differing by 
approximately 18%, suggesting tight regulation of oligosaccharide production; however, 
interindividual concentrations of specific oligosaccharides varied widely from 30.4–84.3%. The 
authors concluded that the variability observed in certain milk metabolites suggested a possible role 
in infant gut microbial development (Smilowitz et al., 2013). 
This paper also investigated differences in milk metabolites from women with a different BMI, 
observing lower levels of acetone in women with a higher BMI (ρ= -0.41, P <0.01). No correlation was 
found between breast milk composition and age, blood pressure, diet or physical activity using 
multivariate statistical methods. However, using forward logistic regression the authors observed 
galactose and alanine were increased in post-prandial samples compared to fasting samples, 
(Smilowitz et al., 2013). 
Breast milk is a complex substance, containing compounds with a molecular weight ranging from tens 
of Daltons to proteins in the KDa, and contains both polar and non-polar metabolites. Breast milk has 
a unique micellar structure, allowing the transport of lipid metabolites to the infant within a non-polar 
aqueous environment. When stored outside its natural environment, and particularly post-freezing, 
breast milk separates into two phases on the basis of polarity, complicating analytical processes. The 
range of metabolites contained in breast milk mean that no single analytical technique is capable of 
resolving the entire breast milk metabolome. 
Due to a lack of information regarding human milk, a number of different methods to determine the 
best technique for preparing milk prior to metabonomic analysis were explored. Previous studies 
report that, for NMR, skimmed milk is the most suitable preparation method for analysis. This is done 
in order to remove the lipid fraction, which being less dense than water rises to the top of the sample 
and in this position it is not analysed, therefore an unrepresentative sample is analysed which does 
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not reflect the true composition of milk. Furthermore, as the lipid fraction is present in a high 
concentration, and is a very chemically heterogeneous group of molecules, the baseline is lifted 
making identifying other molecules present around the same chemical shift impossible.    
Other studies employing metabonomics to investigate breast milk composition have used solvent 
extraction to isolate the lipid and aqueous fractions (Pratico et al., 2013). The method development 
for this thesis is outlined in detail in the Method Development Section 2.10 in Chapter 2. 
In order to ensure the profiling techniques selected adequately covered polar and non-polar 
metabolites, UPLC-MS was chosen for lipidomic analysis, whilst 1H NMR analysis allowed broad 
coverage of compounds from aromatic to aliphatic compounds and was chosen for analysis of polar 
compounds. 
Separating the lipid and aqueous phases of milk is an important preparation step prior to analysis 
using mass spectrometry. This is because the columns used in mass spectrometry can become easily 
blocked with proteins or hydrophobic/hydrophilic solvents, depending on the column used, changing 
the conditions of the instrument and therefore giving unreliable results. 
As well as these considerations, many previous studies examining milk composition using 
metabonomic techniques only examine the aqueous fraction; however, as it is likely that maternal 
BMI influences the lipid fraction of breast milk, a method capable of easily and cleanly separating and 
examining the fractions is therefore important to provide a comprehensive picture. 
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1.10 Conclusion of analytical methods  
 
All of the analytical techniques outlined have their advantages and disadvantages in accurately 
quantifying the true composition of human milk. One of the main advantages in the metabonomic 
techniques described is that metabolites are measured simultaneously, within a single sample. 
Secondly, earlier techniques outlined measure only the main classes of nutrient, using metabonomics 
provides a more detailed image, detailing the specific metabolites which contribute to the groups of 
nutrients, for example, fatty acid identifications within lipids. Therefore, using a metabonomic 
approach will allow for a more detailed analysis of how maternal characteristics are able to influence 
breast milk composition. 
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1.11 Aims and objectives 
The principle objective of this thesis is to evaluate the relationship between maternal BMI and the 
nutrient and endocrine profile of her breast milk. Also the maternal and infant metabolism, assessed 
by urinary metabonomics, will be evaluated.  
The primary hypothesis to be tested is whether there is a statistically significant correlation between 
maternal BMI and key components present in breast milk. 
The secondary hypothesis to be tested is that there is a statistically significant correlation between 
maternal BMI and the maternal and the infant urinary metabolome.  
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1.12 Thesis structure 
The hypothesis explored throughout this thesis is that breast milk from overweight/obese mothers 
has alterations in its composition in comparison to breast milk from mothers of normal weight. 
Chapter 2 outlines the methods used throughout this work in order to characterise breast milk 
composition, I establish a prospective cohort study with longitudinal assessments, and describe the 
range of analytical techniques employed to characterise breast milk composition. I will discuss the 
method development phase undertaken in order to optimize sample preparation techniques for the 
metabonomic studies undertaken later. 
In Chapter 3, I report a systematic review of published literature undertaken, exploring the 
relationship between maternal BMI and concentrations of appetite regulating hormones present in 
breast milk to determine if any significant association has been observed between the two. Also, I 
employ a laboratory based in vitro analysis, using an immunological assay to explore the appetite 
regulating hormonal content of breast milk. 
In Chapter 4, I examine breast milk composition using 1H NMR spectroscopy, Ultra Performance Liquid 
Chromatography-Mass Spectrometry and mid infrared transmission spectroscopy. Here, I investigate 
whether any differences occur in the breast milk of mothers with differing BMI, and evaluate other 
factors influencing breast milk composition.  
In Chapter 5, I examine the infant and maternal urinary metabolomes using 1H NMR spectroscopy and 
explore their association with maternal BMI.  
In Chapter 6 I discuss the findings of my research and the potential scientific and societal impacts of 
the conclusions drawn. 
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Chapter 2 
Methods and Method Development 
 
In order to investigate the association between maternal BMI and appetite regulating hormone 
concentrations in breast milk, I undertook a systematic review and subsequently carried out a 
prospective cohort study to examine the effects of maternal characteristics on human breast milk 
composition and maternal/infant urinary metabolome, having first optimized the sample preparation 
techniques for metabolic profiling of milk samples using multiple spectroscopic platforms. 
Additionally, to broaden the phenotypic description I measured the concentration of appetite 
regulating hormones, and the macronutrient content of breast milk samples collected from the 
prospective cohort recruited. The experimental methods used, including sample handling, are detailed 
for each investigation at the beginning of each results chapter or respective section. 
2.1 Systematic review 
2.1.1 Systematic review of the published literature 
A literature search was conducted in PubMed (www.ncbi.nlm.nih.gov) using Medline MeSH (Medical 
Subject Heading) terms. Relevant studies were identified by evaluating the abstract or by obtaining a 
full copy of the article. Reference lists of included articles were searched for further relevant studies. 
Review articles and commentaries were excluded. 
Data extracted from each paper included date of publication, number of participants, sample type, 
sample preparation method, measurement technique, time of sample collection post-partum, mean, 
standard deviation and range of maternal BMI, hormone concentration and the correlation coefficient 
between maternal BMI and hormone concentration. A full breakdown of the methods used for the 
systematic review are detailed in Section 3.3, Chapter 3. This systematic review was published in PLOS 
ONE, December 2014, shown in Appendix 3A, (Andreas et al., 2014). 
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2.2 Prospective cohort study 
2.2.1 Research ethics 
Research Ethics Committee approval was obtained from the West London (Fulham) Research Ethics 
Committee, 20th February 2012, REC reference number 12/LO/0203, (Appendix 2A). Thanks to Dr 
Matthew Hyde for helping me set up the study.  
2.2.2 Recruitment 
Mothers were introduced to the study and the patient information sheet (Appendix 2B) on the 
postnatal ward at Chelsea & Westminster NHS Foundation Trust Hospital. Formal enrolment took 
place following informed, written maternal consent on the post-natal ward, once the mother had had 
sufficient time to consider whether to participate or not. Mothers from across the booking BMI range 
were recruited, with an attempt to recruit mothers into roughly equal numbers of BMI categories 
18.5-24.9 and >25kg/m2. 
2.2.3 Inclusion criteria 
Healthy, primiparous, breastfeeding mothers, over 18 years old and their healthy, term infants, aged 
37 weeks and above were included in the study.  
2.2.4 Exclusion criteria 
Smoking mothers, mothers who had multiple births, mothers on any prescription drugs influencing 
lactation, as well as diabetic mothers were excluded from taking part in this study. 
2.2.5 Collection of demographic data 
Detailed demographic and clinical data were collected for each participant upon enrolment, using a 
data collection form (Appendix 2C). Data collected included maternal age, race, BMI (pre-pregnancy, 
booking and current BMI), medications and diet, amongst other information. Data were also collected 
on infant characteristics including sex, mode of delivery, and gestational age at delivery. This data 
collection form was also used to collect further information at one week and three months post-
partum. 
2.2.6 Anthropometric measurements 
Mothers from across the BMI range were recruited. Maternal booking weight and height were 
obtained from medical records, and mothers were asked to recall their pre-pregnancy weight. Infant 
and maternal body weights were measured at the time of each sampling using a Seca 877 Floor Scale 
(Seca, Hamburg, Germany), with Mother/Child Weigh Function, accurate to within 0.01kg.  
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The classification of overweight and obesity used throughout this thesis are those used by the WHO; 
individuals with a BMI greater than or equal to 25kg/m2 were considered overweight, and individuals 
possessing a BMI value greater than or equal to 30kg/m2 were considered obese (WHO, 2013). 
Throughout the thesis the mothers booking appointment was used as the time point for the diagnosis 
of overweight/obesity. This point was chosen as the maternal BMI was seen to be highly variable over 
the post-partum period. The mothers booking BMI was considered to be most reflective of the 
mothers actual BMI. 
In order to measure infant length, a measuring board with a sliding footboard was used, measuring 
the crown to heel length (cm), accurate to within 1mm (Rollametre: Raven Equipment Ltd., Dunmow, 
Essex, UK). Infants’ heads were held against the headboard whilst the legs were extended and the 
sliding footboard brought into contact with the infant's heels. Head circumference was measured with 
a measuring tape; also accurate to 1mm. Measurements were taken midway between the eyebrows 
and the hairline and round the occipital prominence at the back.  
2.2.7 Breast milk collection 
Breast milk samples were collected at one week postpartum, and a further sample was collected at 3 
months post-partum, if the mother was still breast feeding. Samples were collected at the participants’ 
homes by the research midwife (Suzan Jeffries) using a Lactaline breast milk pump (Ameda, Stone, 
UK), kindly donated by Central Medical Supplies (Central Medical Supplies, Leek, UK), into breast milk 
collection bottles donated by Sterifeed (Sterifeed, Cullompton, UK). 
Mothers were asked not to feed their infants, or express breast milk, from the breast from which they 
planned to donate from for an hour before the appointment. The baby could be fed during this time 
from the opposite breast if hungry. For collection, mothers were asked to express a 15ml sample prior 
to the start of suckling which was marked as foremilk. The baby was then placed on the breast and 
after feeding, another sample of 5ml was collected at the end of suckling, marked as hind milk. The 
date and time of day of collection of each sample was noted. To control for diurnal changes in breast 
milk composition, collection was standardised to the morning, as far as possible. 
Once received at the laboratory, the expressed milk was divided into 1ml aliquots and stored in 1.5ml 
Eppendorf tubes at -80°C. To prevent the degradation of peptide hormones present in samples, a 
protease inhibitor cocktail (Sigma-Aldrich, UK) was added to a 1ml aliquot from each mother, the 
components of which are detailed in Appendix 2D. The cocktail was reconstituted as per the 
manufacturer’s instructions. Prior to samples arriving at the laboratory, a 20μl aliquot of the cocktail 
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was added to an Eppendorf tube and left to dry, after which the sample was added and inverted 
several times to mix.  
Similarly a 10μl aliquot of sodium Azide solution (Sigma-Aldrich, UK) was added to a separate 
Eppendorf tube and left to dry, ready for the addition of a sample, once added, the concentration of 
sodium azide in solution was 0.1mM. 
2.2.8 Urine collection 
Where possible, maternal and infant urine were collected on the ward before discharge and at one 
week and 3 months post-partum, if the mother was still breast feeding. Urine from infants was 
collected by placing cotton wool, (NHS supplier), in the baby’s nappy, and transferring to a sterile 
sample collection tube (STARLAB, Milton Keynes, UK), by squeezing the cotton wool into the tube. If 
there was only a small volume for a sample, the wool was kept and centrifuged later in order to collect 
any sample at the bottom of the tube. Once collected, samples were stored at -80°C. 
2.2.9 Sample collection and storage 
An important factor to consider regarding any method used to analyse biological samples is under 
which conditions samples are stored. Evidence suggests that factors such as freeze thawing, duration 
and temperature of freezing all influence breast milk composition. Previous research has suggested 
that freezing at -80°C should be considered as the gold standard for maintaining sample quality, 
(Silvestre et al., 2010). Also, research has documented considerable losses in lipid and carbohydrate 
content, due to duration of freezing in regard to the carbohydrate content, or just the process of 
freezing in respect to lipid content (Lev et al., 2014). The researchers propose that lipid adheres to 
polyethylene container walls rapidly, once all the available binding sites are occupied further drops in 
lipid content are not observed, whilst drops in carbohydrate occur more slowly over the duration of 
freezing suggesting carbohydrate has a weaker adherence to the container walls. These studies 
suggest that for analytical reproducibility, transferring samples between multiple containers is 
inadvisable; exposing samples to as few freeze thaw cycles as possible and storing samples at -80°C is 
best practice. 
Samples obtained at participants homes were stored in an insulated transport container containing 
freezer blocks frozen to -20°C whilst they were transferred to Chelsea and Westminster Hospital. Once 
samples reached the hospital they were frozen at -80°C. Once samples from all participants had been 
collected, they were transferred to the South Kensington Campus in an insulated transport container, 
with freezer blocks frozen to -80°C, to ensure they did not thaw. Also, samples were aliquoted into 
1ml volumes to ensure they underwent as few freeze/thaw cycles as possible. I would like to thank 
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Suzan Jeffries here for all her hard work both recruiting patients and collecting samples from their 
homes. 
2.2.10 Reagents  
2.2.10.1 1H NMR  
Deuterium Oxide for NMR (D, 99.9% min) was purchased from Goss Scientific Ltd (UK). All chemicals 
used for NMR analysis were purchased from Sigma-Aldrich (UK). 
2.2.10.2 CE-MS 
Methanol, ammonium hydroxide and formic acid were purchased from Sigma-Aldrich (UK). Sodium 
hydroxide solution (1.0M) was purchased from Agilent technologies (Germany), and purine and HP-
0921 were also from the Agilent Reference Mass Mixture. All buffer and standard solutions were 
prepared with deionized water purchased from Sigma-Aldrich (UK). 
2.2.10.3 UPLC-MS 
Water (Optima™ LC-MS from Fisher Chemical), acetonitrile, isopropanol, methanol were all LC-MS 
Chromasolv) formic acid, ammonium formate (LC-MS ultra), leucine enkephalin acetate salt hydrate 
and sodium formate were purchased from Sigma-Aldrich (UK), and were of analytical grade. 
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2.3 1H NMR Spectroscopy  
One and two dimensional 1H NMR spectra of urine and breast milk samples were acquired using a 
Bruker DRX-600 spectrometer (Bruker Biospin, Rheinstetten, Germany), operating at 600.13MHz, at a 
probe temperature of 300K. At the beginning of each experiment the NMR probe was tuned and 
matched to the proton transmitter resonance frequency. Samples were automatically delivered to the 
spectrometer using an automation device (SampleJet, Bruker) operated by IconNMR 4.7 (Bruker 
BioSpin). Here I would like to thank Dr Anthony Dona for his help in setting up the NMR spectrometer 
for the analysis of these samples. 
2.3.1 Basic concepts of 1H NMR spectroscopy 
NMR spectroscopy is used to detect the absorption of electromagnetic radiation in the radiofrequency 
range by specific nuclei which possess a property known as spin. The property of spin is determined 
by the number of unpaired protons and neutrons present in an atoms nucleus, if an atoms nucleus 
possesses spin, then this also means it possesses a magnetic moment.  
Due to having the property of spin, the 1H nucleus possesses a magnetic moment, once placed in an 
external magnetic field, commonly referred to as B0, this magnetic moment can either align with, or 
against, the applied external magnetic field. This orientation is either at a lower, or α, energy state; 
+½, if it is orientated with the magnetic field, or a higher energy state, β, or -½ when orientated against 
the external magnetic field. Because 1H contains one unpaired proton, its spin number, I, equals ½, as 
it aligns with or against the external magnetic field. This means it is detectable by NMR spectroscopy, 
as any nucleus with an I number greater than zero is. 
It is possible to excite nuclei from the lower energy state to the higher state using radiofrequency 
electromagnetic radiation. The frequency necessary to accomplish this is determined by the energy 
difference between the energy states, also known as the Larmor frequency, or transition energy.  
Nuclei at the lower energy level absorb radiation, which is at this specific frequency, promoting them 
to the higher energy level. Once the radiofrequency pulse ends, relaxation occurs and the spins flip as 
the nuclei revert back to the lower energy level, emitting detectable electromagnetic radiation in the 
process; this is known as the free induction decay (FID). The change in magnetisation as the protons 
relax from the higher to the lower energy state is measured by a receiver coil, this is the NMR signal. 
However, this signal is recorded in the time domain, therefore, in order to visualise the signal in the 
frequency domain (as peaks along the chemical shift axis) the signal is Fourier transformed (FT), this 
results in a set of peaks at specific frequencies, comprising the NMR spectrum. 
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As described so far, each nucleus in the magnetic field behaves in the same manner. However, due to 
the nuclear shielding phenomenon, whereby surrounding electrons shield nuclei present in different 
chemical environments to a greater or lesser extent, each nucleus experiences a slightly different 
intensity of the applied external magnetic field. This means that different nuclei resonate at slightly 
different frequencies, giving us the different chemical shifts. For standardisation, this shift is measured 
in relation to a standard compound, Trimethylsilyl-2,2,3,3-tetradeuteropropionoic acid (TSP) in 
aqueous solutions and Tetramethylsilane (TMS) in lipid solutions which are set to the frequency δ 0.0. 
The concentration of a metabolite can be determined by measuring the intensity of the NMR signal 
arising from that metabolite if a known concentration of internal standard is added to each sample. 
This is because the signal intensity is proportional to the number of protons which contribute towards 
a specific peak.  
Neighbouring nuclei are able to interact magnetically with one another via spin-spin couplings, or J-
couplings. This interaction causes splitting of peaks; this can cause a single type of nucleus to produce 
multiple peaks, with a predictable intensity and spacing. This splitting provides detail on the chemical 
environment that particular nucleus is in, providing useful structural information on the molecule. The 
combination of chemical shift, peak multiplicity and peak intensities for each metabolite provide 
complementary information allowing structural elucidation. 
2.3.2 Breast milk sample preparation for 1H NMR Spectroscopy 
Firstly, breast milk samples were defrosted in 1ml aliquots. Once fully defrosted, samples were 
vortexed to ensure samples were thoroughly mixed, after which 600µl of sample was added to 3ml 
chloroform:methanol mixture (Chloroform acquired from VWR, Poole, UK, methanol: Sigma-Aldrich, 
UK), in a 2:1 ratio. This mixture was vortexed, and 900µl of HPLC grade water (HiPerSolv, VWR) added, 
after which the mixture was vortexed again, and centrifuged at 5000×g at 4°C for 20 minutes. This 
resulted in two distinct layers, with the aqueous phase located at the top of the vial and the organic 
phase below. These different phases were split into two 1.8ml aliquots. Once separated, the aqueous 
phase was placed in a speed vacuum at room temperature until dry, (Vacufuge, Eppendorf, Hamburg, 
Germany). The aqueous phase was then reconstituted in 600µl of HPLC grade water, containing 60µl 
buffer (Appendix 2E). This mixture was then placed on a platform rocker until the precipitate was fully 
dissolved. Once dissolved, the resulting solution was transferred to a 5mm NMR capillary tube (Bruker, 
Germany), ready for analysis. This same procedure was carried out on 34 aliquots of a quality control 
(QC) sample, originating from a single large sample, which was analysed every 12 samples to ensure 
analytical reproducibility.  
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2.3.3 Urine sample preparation for 1H NMR Spectroscopy 
Approximately half of the infant urine samples had been frozen on cotton wool on which they were 
collected, therefore these samples were defrosted and centrifuged at 3000×g in order to remove the 
urine from the cotton. The other half of the infant urine samples had collected enough volume to be 
squeezed from the cotton wool directly into sample collection tubes. Occasionally samples did not 
have the minimum volume required for analysis, in this case samples were made up to the minimum 
volume using HPLC grade H2O, which was carefully noted.  All infant urine samples were defrosted at 
the same time in order to aliquot them into 1ml Eppendorf tubes, to ensure that the samples were 
treated in the same manner throughout, reducing any potential variation due to freeze thaw cycles.  
Prior to analysis, infant and maternal urine samples were defrosted in their 1ml aliquots. Once fully 
defrosted, samples were centrifuged for ten minutes at 5000×g to remove any particulate matter. 
After centrifugation, 540µl of sample was transferred to an NMR capillary tube (Bruker, Germany) and 
60µl of buffer (Appendix 2E), containing TSP was added using an Eppendorf pipette. This solution was 
then mixed thoroughly by inverting the capillary tube several times. Again, an external QC sample was 
prepared in the same manner as the study samples, also analysed every 12 samples.  
2.3.4 Standard one dimensional 1H NMR spectroscopy 
A standard one dimensional 1H NMR spectrum was acquired for each sample using a water 
presaturation pulse sequence [relaxation delay-90°-t1-90°-tm-90°-acquire free induction decay (FID)]. 
The relaxation delay was 2 seconds; with 90° relating to the 90° radio frequency pulse applied, t1, 
referring to the interpulse delay, which was set to 3µs. tm is the mixing time of 100ms. The water 
signal is reduced in intensity using the presaturation technique. This entails using a long, low power 
radio frequency pulse to selectively saturate the frequency at which water is found during the 
relaxation delay and mixing time; also known as O1. 
Thirty-two scans were collected for each sample, comprising of 32 thousand data points, giving a total 
spectral width over 20 ppm (parts per million). An acquisition time of 2.73s was used. An exponential 
weight function corresponding to a line broadening of 0.3Hz was applied to each FID (free induction 
delay) prior to Fourier transformation. This is done in order to improve the signal to noise ratio. 
The parameters used for the standard pulse sequence of the urine samples were as follows; 
P1=11.47µs, Pl1=12.8-dBW, Pl9=6.0dB and O1=2820.74Hz. 
Parameters used for the breast milk samples used were: P1=11.18µs, Pl1=13.49-dBW and 
O1=2824.40Hz. 
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The parameters for the standard pulse sequence used for method development samples were as 
follows; P1=17.1µs, Pl1=0.06-dBW, Pl9=6.0dB and O1=2027Hz. Parameters are different for the 
different matrices/extractions as they were optimised for each set of samples.  
2.3.5 Two-dimensional NMR spectroscopy  
Identifying discriminatory metabolites between different groups was achieved by comparison of 
chemical shifts, peak number and peak multiplicity using assignment tables and online databases such 
as HMDB (http://www.hmdb.ca/) and ChemSpider (http://www.chemspider.com/).  
However, if peaks remained difficult to identify using the one dimensional 1H NMR spectral 
information due to overlapping signals, then 2D J‐Resolved (JRES) and heteronuclear single-quantum 
correlation spectroscopy (HSQC) experiments also acquired were referred to, as these contain further 
structural information on metabolites detected.  
JRES spectroscopy provides information on metabolite structure by the dispersion of 1H nuclei signals 
along a second axis, generating further information on peak multiplicity and coupling constants (Aue 
et al., 1976). 
HSQC spectra allow for easier identification of metabolites by measuring the carbon spectrum in 
addition to the hydrogen spectrum, which also provides valuable structural information. Here 
correlations between the carbon and hydrogen nuclei can be visualized, if separated by one bond (Kay 
et al., 1992). 
JRES spectra were acquired using a standard JRES pulse sequence, using a spectral width of 78Hz for 
the F1 domain and 10026Hz in the F2 domain, resulting in a total of 8192 data points.  
2.3.6 NMR data pre-processing 
Spectra were automatically referenced to TSP at δ 0.0 for urine, whilst for breast milk, the ppm scale 
was automatically referenced to glucose, since TSP binds to proteins in milk causing chemical shifts. 
For lipid extracts, spectra are referenced to the resonance of the TMS signal at δ 0.0. Spectra were 
corrected for any phasing or baseline distortions. Each spectrum in the raw dataset was examined to 
ensure that it had been acquired correctly using Topspin 3.2 (Bruker Biospin). This was done by 
checking the water signal and the width of the TSP peak at half height for urine, the threshold used 
was 1Hz. For breast milk samples the glucose peak at δ 4.68 at half height was examined, the threshold 
used was 1.6Hz, if the glucose or TSP peak had a greater width than this then the sample was re-
analysed. 
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Data were then exported to Matlab 7.12 (MathWorks Inc. USA), for further processing. In Matlab the 
portion of the spectra above δ 10 and below δ -0.2 for urine, and δ -0.175 for breast milk and δ 
0.35−10.0 for method development samples, was removed. Samples which had been identified to 
have analytical artefacts were excluded in Matlab at this point. 
 The region containing the water peak was removed from each spectrum, in the urine spectra this 
region fell between δ 4.7 and 4.9, and δ 4.75 and 4.84 for breast milk spectra. Removal of the water 
peak is performed as water is present in samples in such a high concentration it can interfere with 
peaks, which fall close to this region on the spectrum, due to variability in the effectiveness of water 
suppression. Also the TSP peak was removed at this point, from δ -1 to 0.07 in urine spectra, and from 
δ -1 to 0.175 in breast milk spectra. 
2.3.7 Alignment  
Spectra were aligned using an in house script (Author, Kirill Veselkov, 2010), designed to intelligently 
align peaks from the same metabolite so that they present at the same chemical shift on the ppm axis, 
reducing effects seen of peaks shifting due to the different pH or ionic strength of the sample analysed. 
2.3.8 Normalisation 
Due to some of the samples collected not having sufficient volume, they required dilution to increase 
the sample volume up to the minimum required for NMR analysis. This was done with ultrapure 
analytical grade HPLC water. Because of this dilution, as well as the natural variation in sample 
concentration, normalisation was performed to account for this inter-sample variation.  
Normalisation allows for comparison of spectra by removing the different dilutions between biofluid 
samples. This reduces the variation observed in the data which are unrelated to differences between 
the groups studied and which would otherwise make interpretation of differences between groups 
difficult. This is especially important in urine samples due to the large differences in water content 
observed.  
Spectra were normalised using both probabilistic quotient normalisation (Dieterle et al., 2006) and 
total area normalisation (Craig et al., 2006). The most common way of normalising data is using total 
area normalisation; this is achieved by normalising each spectrum to the total spectral area, using the 
sum of the spectral intensity value. However, total area normalisation can occasionally, 
inappropriately, downscale spectra. If this is the case then probabilistic quotient normalisation is used, 
which calculates the most probable concentration of a sample based on the majority of metabolites 
observed. 
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Data were assessed to establish which was the most appropriate normalisation method; this was done 
by visualising how tightly clustered the QC samples were. Urine spectra were normalised using 
probabilistic quotient normalisation, which is less prone to the influence of high concentration 
metabolites, whilst breast milk spectra were normalised using total area normalisation. 
2.3.9 Data reduction 
In order to import data for analysis into SIMCA-P+ 13.0.2 (Umetrics, Sweden) the spectral data were 
converted into a digitized format. This was achieved by automatic data reduction using a script, 
(courtesy of Rachel Cavill), using Matlab. Once pre-processed, data were imported into SIMCA-P+ 
13.0.2 for analysis using multivariate modelling techniques. 
2.3.10 Metabolite Identification 
Multiple online reference databases of standard compounds exist including HMDB, ChemSpider and 
others, aiding in the identification of metabolites. As well as these resources, two dimensional NMR 
experiments were used to further assist in the identification of metabolites, including J-Resolved 
spectroscopy (Viant, 2003), and heteronuclear single-quantum correlation spectroscopy (HSQC) 
(Bodenhausen and Ruben, 1980). Two dimensional experiments display correlated nuclei, allowing the 
identification of which nuclei are structurally related to one another. 
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2.4 Ultra Performance Liquid Chromatography-Mass Spectrometry 
The lipid fraction of breast milk samples collected were analysed using Ultra Performance Liquid 
Chromatography-Mass Spectroscopy (UPLC-MS). An Acquity UPLC system (Waters Ltd., Elstree, U.K.) 
was used for chromatographic separation. Mass spectrometry was undertaken using a Quadrupole-
Time-of-flight (Q-TOF) Premier mass spectrometer (Waters MS Technologies, Ltd., Manchester, U.K. 
Columns, inserts and vials also from Waters). For the analysis of these samples I assisted Dr Maria 
Gomez-Romero in the operation of the UPLC-MS instrument, and I would like to thank her and Kate 
Leary for their assistance in the data processing steps.  
2.4.1 Basic concepts of UPLC-MS 
Mass spectrometry is an analytical technique that allows for the determination of the molecular 
weight, and structural information, of ionisable molecules present in a sample. It can be coupled to 
UPLC; this involves first separating out metabolites from one another using LC, and the subsequent 
detection of these metabolites using MS. The separation of the metabolites is achieved by injecting a 
small volume (typically a few µL) of sample into the instrument; the sample is mixed with a stream of 
analytical solvent, also known as the mobile phase and then pumped through an analytical column, 
(the stationary phase) consisting in a bed of packed particles of sizes below 2µm (Swartz, 2005). The 
metabolites in solution are retarded by specific competing interactions (hydrophobic, dipole–dipole 
and/or ionic) with the particles in the column. Because the metabolites analysed have different 
affinities for the column, as well as the mobile phase, they elute from the end of the column at 
different rates, separating out from one another. Coupling LC to MS reduces the complexity of the 
mass spectra due to the separation of metabolites in the time dimension, and provides an additional 
layer of information on the physico-chemical properties of the metabolites, aiding in identification.  
Depending on the analytes of interest the solvents and the columns packing material can be altered 
to better separate out metabolites, based on the analytes polarity or hydrophobicity. In order to 
efficiently separate out complex lipid mixtures the manufacturers (Waters), have published an 
optimised method to best achieve this (Isaac et al.). The parameters used are given in detail in Section 
2.4.3, Chapter 2. 
Once the metabolites elute from the UPLC column they must be converted to gas-phase ions in order 
to be detected in the mass spectrometer.  A number of interfaces are available to accomplish this; 
throughout this thesis Electrospray ionization (ESI) was used. ESI is particularly useful for the analysis 
of metabolites found in biological samples as it is a ‘soft’ ionization technique, meaning metabolites 
are less likely to fragment into smaller ions, making identification easier. In ESI, the main ions observed 
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are quasimolecular ions created by the addition (positive mode), or the removal (negative mode), of 
a proton and denoted [M+H]+ and [M-H]-, respectively. Because metabolites have different ionization 
potentials, samples are analysed in both modes of ionization in order to detect as many metabolites 
as possible.   
ESI involves dispersing the liquid eluting from the chromatograph into a fine aerosol. The mobile phase 
solvent contained in the droplets of the aerosol is evaporated using nitrogen gas at a high temperature 
and flow rate, termed desolvation gas. As the solvent evaporates from the aerosol droplets it 
eventually reaches the Rayleigh limit. Here, the electrostatic repulsion of the charges held within the 
droplet overcomes the surface tension, causing the droplet to become unstable and undergo coulomb 
fission, breaking apart. This occurs to the successive new droplets created by this process until no 
solvent remains, leaving just the charged ions behind. The ions flow into the mass spectrometer, 
induced by the combined effects of electrostatic attraction and vacuum, until they reach the mass 
analyser. 
The analyser separates out ions based on their mass to charge (m/z) ratio and outputs them to the 
detector where they are converted to a digital signal. There are a number of of different types of 
analyser, but throughout this thesis a hybrid instrument, which combines two analysers (a 
quadrupole, Q, and a Time of Flight, TOF), was employed.  
The quadrupole mass analyser can be used as a mass filter and in fragmentation experiments. It 
consists of four oppositely charged cylindrical rods parallel to one another. The quadrupole is able to 
filter ions passing through the instrument according to their m/z ratio. This is achieved by an electric 
field being applied to the rods; if a particular ion, travelling though the centre of the quadrupole, has 
a stable trajectory then it is able to pass through the quadrupole to the detector. However, depending 
on the voltage of the rods, some ions have an unstable trajectory, if so, these ions collide with the 
rods and are not detected. 
The quadrupole is orthogonally arranged with a TOF mass analyser where ions are subjected to a 
uniform electromagnetic force, at a specific time. This electrical charge accelerates ions along a flight 
tube at different speeds, according to their m/z ratio and kinetic energy. The lightest ions travel the 
fastest, arriving at the detector first. The m/z ratio is therefore determined by the time of arrival of 
the ion at the detector. TOF mass analysers are particularly useful as they allow detection of ions 
within a large mass range.  
For mass accuracy, the instrument was calibrated with a sodium formate (NaF) solution before 
commencing the run; NaF forms a series of regular clusters over the whole mass range, against which 
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the instrument is calibrated. To perform mass correction during the analysis, a lock mass solution was 
used (leucine encephalin; m/z 556.2771 in ESI+, m/z 554.2615 in ESI−) with data collected every 30 s. 
Structural elucidation of unknown compounds can be achieved using MS/MS experiments using the 
Q-TOF mass spectrometer. This process involves fragmenting the metabolites of interest and 
examining the resultant fragments. Metabolites usually fragment in a predictable manner, with the 
most labile bonds breaking first. The MS spectrum will show head groups and other groups of the 
molecule, making identification easier. The precursor ion is selected in the quadrupole, it is 
fragmented inside a collision cell, located between the quadrupole and flight tube, and the product 
ions are analysed in the TOF, which gives mass accuracy. In the collision cell, ions collide with gas 
present, using this kinetic energy to break the bonds within the molecule.  
UPLC-MS data interpretation presents many challenges  
1. Presence of isomers, which are compounds possessing the same chemical formula but 
different structures. They display an identical mass to charge ratio (m/z), making automated 
annotation difficult and structural elucidation complicated. However, some isomers are able 
to be distinguished from one another. For example, one can compare the retention times 
against a standard solution. Because different chemical structures interact with the column to 
a different extent, this results in some isomers possessing distinct retention times, if they 
interact with the column differently. If this is found not to be the case, identifications can be 
made using MS/MS data.  
2. Further complicating analysis is the fact that metabolites dimerize and can also form adducts. 
If dimerization occurs, then, in addition to detecting the molecular ion, an ion at twice the 
weight can also be detected. However, this effect can aid in identification as, if dimers are 
observed, then this gives confidence to the identity of the molecular ion. Adducts are also 
commonly observed in MS spectra, here, instead of the molecular ion being detected, 
metabolites can become associated with various salts, for example, sodium [M+Na]+ or 
ammonium [M+NH4]+ in positive ionization mode, or chlorine [M+Cl]- in negative ionization 
mode. This results in the m/z spectrum containing ions greater than the calculated molecular 
mass.  
3. In-source fragmentation. Labile molecules fragment through the MS instrument, obtaining a 
spectrum with un-desired fragments, sometimes at a higher intensity that the precursor ion, 
making interpretation more complicated.   
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2.4.2 Breast milk lipid phase sample preparation for UPLC-MS 
The lipid extracts for UPLC-MS analysis of breast milk samples were prepared using Folch extraction 
as described earlier in 1H NMR Spectroscopic analysis of breast milk samples. Once the lipid fraction 
was separated from the aqueous fraction the chloroform was left to evaporate under a fume hood, 
leaving behind a lipid residue. This was frozen at -40°C until analysis. Prior to analysis, extracts were 
defrosted and reconstituted in 200µL isopropanol/acetonitrile/water in a 2:1:1 ratio (isopropanol and 
acetonitrile were acquired from Sigma-Aldrich, UK, whilst water was from Fisher Scientific, UK). This 
suspension was centrifuged for 15 minutes at 5000×g at 4°C in order to remove any particulate matter 
which could block the column. Once centrifuged, samples were transferred to an insert placed inside 
a glass vial, ready for analysis. At the beginning of the run the column was conditioned by injecting 
ten QC samples, a pool of all the samples analysed and thus representative of the entire sample set. 
This QC sample was made by pooling 20µL of each of the samples once they had been reconstituted 
in the 200µL isopropanol/acetonitrile/water mixture. Also, for every ten samples analysed (i.e. at 
regular intervals) a QC sample was injected to ensure that analytical reproducibility was maintained, 
and to obtain structural information, using an automated MS/MS method (data-dependent 
acquisition). 
2.4.3 UPLC-MS system acquisition parameters 
Samples were analysed using an Acquity UPLC system (Waters Ltd., Elstree, U.K.) coupled to a 
quadrupole time of flight (QTOF) mass spectrometer, (QTOF Premier, Waters MS Technologies, Ltd., 
Manchester, U.K.), in positive and negative ion electrospray mode (ESI+ and ESI-). The 
chromatographic conditions used have been previously described as optimal for the separation of 
lipids by the manufacturers (Isaac et al.) 
Separation was performed using a Charged Surface Hybrid (CSH) C18 column (1.7µm, 2.1 x 100mm) 
(Waters Corporation, Milford, U.S.A.), at 55⁰C. Two mobile phases were used in different proportions 
throughout the analysis, mobile phase A consisted of 0.1% formic acid (v/v) and 10mmol/l ammonium 
formate in acetonitrile/water 60:40 (v/v). Mobile phase B consisted of 0.1% formic acid (v/v) and 
10mmol/l ammonium formate in isopropanol/acetonitrile 90:10 (v/v). The flow rate was 0.4ml/min 
and the injection volume was 5µl. 
The MS parameters were; capillary voltage, 1.5kV; sample cone voltage, 30V; source temperature 
120⁰C; desolvation temperature and gas flow, 600⁰C and 1000L/h, respectively; cone gas flow, 50l/h 
and scan range 50-1500m/z. For mass accuracy, a LockSpray interface was used with a 2ng/µl leucine 
enkephalin (555.2645 amu) solution at 10µL/min as the lock mass. Data were collected in centroid 
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mode with lock mass scans collected every 40 seconds and averaged over 3 scans to perform mass 
correction. 
2.4.4 UPLC-MS data pre-processing 
Resulting chromatograms were displayed using MassLynx, Version 4.1 (Waters). Within the MassLynx 
software, Databridge was used to convert the raw data files into NetCDF format. For the pre-
processing of UPLC-MS data XCMS was used, which is available as freeware within RStudio (Version 
0.98.953). Data were processed using an in house script written by Matthew Lewis and Paul Benton. 
An outline of this process is included below. 
2.4.5 Peak detection 
Firstly parameters were chosen to detect peaks present in the chromatograms by studying the 
chromatograms of the QC samples analysed. Parameters chosen for positive and negative mode data 
are shown in Table 2. The time range refers to the amount of time a specific mass had to elute for to 
be considered as a peak (Smith et al., 2006). 
Table 2: Parameters used for peak detection in positive and negative mode.  
Parameter Description Positive mode Negative mode 
Time range (seconds) 
Range (min, max) of 
chromatographic peak width 
1-27 4-27 
Mass accuracy of the data 
(ppm) 
Maximal tolerated m/z 
deviation in consecutive scans 
in one file of a single peak 
20 20 
Signal to noise threshold 
cutoff 
Maximum peak intensity minus 
estimated baseline value 
divided by the standard 
deviation of the local 
chromatographic noise 
3 3 
Prefilter (k,I) 
Mass traces are only retained if 
they contain at least k scans 
with intensity ≥ I. 
3, 75 3, 75 
Retention time error 
(seconds) 
Needed for proper alignment 12 18 
 
2.4.6 Retention time correction (Alignment) 
Next the retention times of eluting peaks were corrected or aligned; this is necessary as the system 
conditions change slightly over the course of the analysis, with the pressure of the column generally 
increasing as it becomes increasingly blocked with precipitate, changes in the conditions within the 
laboratory such as temperature, and the need to replenish the mobile phase solvent throughout the 
analysis. These changing conditions result in metabolites eluting at slightly different times as their 
retention times drift. To correct for this, alignment is used, enhancing the ability to compare data 
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across experiments. An example retention time deviation plot is shown in Figure 13. The alignment 
method used for the mass spectrometry data throughout this thesis is known as ordered bijective 
interpolated warping, or OBI-Warp (Prince and Marcotte, 2006). This method of alignment aligns 
matrices along a single axis using Dynamic Time Warping and a one-to-one (bijective) interpolated 
warp function. Dynamic Time Warping allows for non-linear, comprehensive alignment of datasets, 
providing natural interpolants.  
 
Figure 13: Retention time vs. retention time deviation plot. Each sample is displayed as a line 
displaying the time in seconds required to align the data to the median retention time. An upwards 
deflection indicates that that sample eluted after the median retention time, whilst a negative 
deflection indicates that the sample eluted before the median retention time, at that time point. 
Samples are coloured by run order, red relates to the first samples analysed and violet being the last 
samples analysed. Positive ionization mode data. Text adapted from 
http://metlin.scripps.edu/xcms/xcmsPreprocess.pdf 
2.4.7 Filtering of peaks 
After the peak detection step, grouping of peaks across the dataset was performed using the density 
method in XCMS; subsequently each run was checked for the presence of signal for each peak group, 
and where a peak was not detected, the signal intensity for that region was integrated to create a 
value for that region. This step is crucial to preserve normality of intensity distribution for statistical 
analyses. 
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Filtering of features from the dataset was also carried out using minimum fraction filtering; this 
involves filtration of noise before data are normalised, improving the results obtained. This process 
selects for features, or peaks, detectable in at least 50% of at least one sample class, e.g. overweight, 
and retain them, discarding the others from the dataset. Figure 14 displays the data before and after 
the filtering process.  
 
 
 
 
 
 
 
 
 
 
 
Furthermore, a coefficient of variation (CV) filter was employed. The CV filter is based on QC samples. 
The CV is calculated, dividing the standard deviation by the mean, for each peak present in the dataset, 
and any peak with a CV greater than 30% in the QC sample is discarded from the whole dataset further 
reducing the noise. 
2.4.8 Normalisation 
Data were next normalised to remove sources of systematic variation between samples due to factors 
that are not related to biological processes, such as sample dilution. As samples show differences in 
concentration, this introduces noise to the dataset by increasing the variance as a function of 
increased signal intensity, complicating information recovery. Previously, median fold change has 
been demonstrated to be the most appropriate method of normalisation for UPLC-MS urine data 
(Veselkov et al., 2011). 
A 
B 
Figure 14: (A) Raw dataset, peaks are viewed from above, plotting the retention time against m/z 
ratio. (B) Dataset after minimum fraction filtering; many fewer peaks are included for further 
multivariate analysis. Negative ionization mode data. 
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Median fold change normalisation adjusts for the median of log fold changes of peak intensities 
between samples to zero. This method of normalisation is based on the assumption that metabolite 
peaks are influenced only by dilution, and will display the same fold changes between two samples. 
This assumption is valid if peak intensities are proportional to the metabolite concentration in 
solution, any change in intensity is attributed to sample dilution and/or inconsistency of UPLC-MS 
acquisition; estimated to be equal across each peak, and therefore a fixed scaling factor is used. To 
estimate the dilution factor, the median value of fold change between a sample and target profile is 
used. This method of normalisation has been shown to be valid against at least 50% of peak intensities, 
increasing or decreasing asymmetrically in response to biological factors (Veselkov et al., 2011). 
2.4.9 Metabolite ID 
UPLC-MS metabolite identification was achieved by searching m/z values against online databases 
including METLIN, Lipidmaps and HMDB, with the mass error set to 10 ppm. In order to identify lipid 
species, MS/MS data were inspected to identify fragmentation patterns, and the presence of head 
groups, increasing confidence in the identity of the metabolite identification.   
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2.5 Capillary Electrophoresis-Mass Spectrometry 
An Agilent 7100 CE system coupled to an Agilent 6224 Accurate-Mass TOF MS system (Agilent 
Technologies, Wilmington, USA) was used to acquire CE-MS data. Ionization was accomplished using 
ESI, outlined in Section 2.4.1, Chapter 2. Method development samples (described in Section 2.10, 
Chapter 2) were analysed in a randomised run order, with a QC sample analysed at the beginning of 
the run, every six samples, and at the end of the sequence. Acquisition parameters and the data 
processing methods used are described in Appendix 2F. For the analysis of these samples, Dr Isabel 
Garcia-Perez operated the CE-MS instrument and undertook the data pre-processing, for which I am 
very grateful.  
2.5.1 Basic concepts of CE-MS 
Capillary electrophoresis-mass spectrometry (CE-MS), involves firstly separating out metabolites using 
CE, and the subsequent detection of these metabolites using MS, a description of which is given in 
Section 2.4.1, Chapter 2.  
In capillary electrophoresis, the sample is injected into a capillary possessing a small diameter. An 
electric field is then applied across the capillary, resulting in both positively and negatively charged 
ions migrating through the capillary due to the electroosmotic flow established by the electric current.  
Ions migrate through the capillary at different rates according to their electrophoretic mobility. This is 
determined by the charge of the ion, its size, and the viscosity of the solvent, with the smallest most 
highly charged ions travelling the fastest. Once metabolites pass through the capillary, they are 
introduced into the mass spectrometer. 
2.5.2 Breast milk lipid phase sample preparation for CE-MS 
Twenty one individual breast milk samples were prepared in the same manner as the aqueous fraction 
for 1H NMR analysis, as outlined in Section 2.3.2, Chapter 2. However, 200µl instead of 600µl of breast 
milk sample was used, with the volumes of the solvents adjusted accordingly. The aqueous extract 
was re-suspended in 200µl of 20mM of formic acid solution, and centrifuged to remove any particulate 
matter. The supernatant was transferred to a vial ready for injection into the CE-MS instrument. A QC 
sample was prepared by pooling 20µl of each of the samples and preparing this in the same manner 
as the method development samples.  
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2.5.3 Metabolite Identification 
In order to tentatively identify metabolites detected using CE-MS, comparison of the high mass 
accuracy data (with less than 5 ppm tolerance) was performed against standards analysed in the same 
manner.  
  
 
 
75 
 
2.6 Multiplex assay of breast milk hormone composition  
The concentrations of the hormones leptin, insulin, ghrelin and resistin were determined in a 50µL 
aliquot of the aqueous supernatant of centrifuged breast milk samples, using a Bio-Plex Pro™ human 
diabetes immunoassay (Bio-Rad, USA), as per the manufacturer’s instructions. Concentrations of milk 
hormones were calculated using a standard reference curve, constructed from standards provided 
with the kit. A Bio-Plex MAGPIX multiplex reader (Bio-Rad, USA) was used to determine the 
concentration of the hormones present. A detailed overview of the experimental design used for the 
analysis is given in Appendix 2G. Dr Bronwen Herbert was particularly helpful in the analysis of these 
samples, helping to design the workflow and operating the MAGPIX multiplex reader.  
2.6.1 An Introduction to Multiplex assays 
Multiplex assays allow for the simultaneous detection of multiple biomolecules within a single sample. 
This is achieved using fluorescently dyed beads, possessing a distinct colour code, which permits 
discrimination between the individual tests.  
The principle of the assay is essentially that of a sandwich ELISA formatted on magnetic beads. 
Antibodies against the analytes of interest are covalently bound to magnetic beads; once the sample 
is introduced the antibody binds to any analytes present in the sample, whilst unbound protein is 
washed away. A biotinylated detection antibody is then introduced, creating the sandwich complex. 
Finally streptavidin-phycoerythrin, a fluorescent indicator, is added forming a complex with the 
detection antibody.  
The fluorescent dyes are then illuminated with a red (635 nm) laser which classifies the bead, and 
therefore the assay identification. A green (532 nm) laser simultaneously excites the phycoerythrin, 
generating a reporter signal, detected by a photomultiplier tube (PMT). The concentration of the 
analytes in samples are then extrapolated from a standard calibration curve, simultaneously prepared 
using multiple dilutions of a standard mixture.  
2.6.2 Breast milk sample preparation for multiplex assay 
A multiplex assay was employed to measure concentrations of the appetite regulating hormones 
leptin, insulin, ghrelin and resistin in breast milk. Once breast milk samples had been collected they 
were aliquoted into an Eppendorf tube containing a protease inhibitor cocktail (Sigma-Aldrich, UK), 
(Appendix 2D). Breast milk samples were first defrosted in a refrigerator, 1ml aliquots were 
centrifuged at 20000×g at 4°C for 10 minutes. The lipid fraction was drawn off using a sterile pipette 
tip and 500µl of the aqueous fraction was pipetted into a separate Eppendorf tube and frozen for later 
analysis.  
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Prior to analysing samples, three trial samples were analysed in order to establish whether samples 
required dilution, or addition of Bovine Serum Albumin (BSA), (Sigma-Aldrich, UK), to block non-
specific antibody binding. Two trial samples were diluted 1:4 in sample diluent, 1:1 in sample diluent 
and one was left undiluted. In addition to these dilutions, a parallel set of dilutions were prepared, 
with the addition of BSA. The results from this trial were evaluated, suggesting addition of BSA was 
unnecessary, as it did not appear to impact the results obtained, whilst dilution meant concentrations 
would appear on the lower end of the standard curve, where quantification is less precise. 
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2.7 Mid infrared (IR) transmission spectroscopy analysis of breast milk samples 
Data on breast milk macronutrient content were collected using a Miris Human Milk Analyser, kindly 
donated by Miris, (Miris, Uppsala, Sweden). The analytical accuracy of the instrument is reported to 
be <0.1g/100ml, with a repeatability of <0.05g/100ml, (Casadio et al., 2010). 
2.7.1 An Introduction to mid IR spectroscopy 
Mid Infrared (IR) Spectroscopy measures the nutritional content of breast milk via the absorption of 
infrared energy. The sample is first drawn into a fluid film 50µm thick in a transparent cuvette and 
exposed to IR radiation, transmitted from an emitter. Any reduction in the transmission of the 
different wavelengths transmitted is quantified by a detector, and then correlated to the 
macronutrient content of the sample. Four functional groups are measured by the analyser; these 
chemical groups absorb IR radiation at specific wavelengths. The wavelengths of the IR radiation 
absorbed by chemical groups in lipid are 5.7µm and 3.5µm, absorbed by the CH2 carbon-hydrogen 
group and by the C=O carbonyl groups respectively. Also measured is the absorption at 6.5µm by 
CONH groups, found in amino acids, and 9.6µm absorbed by hydroxyl groups present in 
carbohydrates. As the hydroxyl group is also found in Human Milk Oligosaccharides (HMO) the 
analyser gives a reading for total carbohydrate, including lactose and HMO. 
The Human Milk Analyser is calibrated against a set of reference samples with different concentrations 
of macronutrients present. These samples are also measured using approved biochemical reference 
methods with the results used to fit a nonlinear calibration curve for each milk analyte. The Miris milk 
analyser gives values for both crude protein and true protein; this is due to a substantial proportion 
of nitrogen present in milk being non-protein nitrogen, mainly HMO. To account for this the ‘true’ 
protein value is derived by applying a factor of 0.8 to the crude protein values.  
Various researchers have evaluated the accuracy of the Human Milk Analyser (Silvestre et al., 2012), 
(Casadio et al., 2010), suggesting that there is a small but statistically significant difference in the 
concentrations of macronutrients measured between the Human Milk Analyser and reference 
methods. This is due to the chemical principles the assays are governed by, however, they conclude 
that with proper sample preparation the analyser is able to provide reliable measurements, as 
evaluated by Casadio et al, (Casadio et al., 2010). 
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2.7.2 Breast milk sample preparation for IR spectroscopy 
As samples were frozen prior to analysis, a number of preparation steps were undertaken to ensure 
samples analysed were as homogeneous as possible, meaning representative and reliable results were 
obtained. Approximately 3ml of sample was first thawed by heating to 40°C in a water bath, and mixed 
by inverting the aliquot multiple times. Samples were sonicated for a total of 4.5 seconds using the 
Miris sonicator (Miris, Uppsala, Sweden). This is an ultrasonic device which creates sound waves using 
clamped piezoelectric discs, causing the probes tip to oscillate in the length direction. This releases 
energy causing air bubbles to implode, breaking apart fat globules into smaller, more equally 
distributed globules, diminishing lipid separation. These steps provide a more repeatable, accurate 
and representative measurement. The ultrasound procedure used, recommended by the 
manufacturer, involves exposing each ml of milk analysed to 1.5 seconds of ultrasound at 70% 
amplitude using a micro-tip. The Human milk analyser has two settings, raw and homogenised milk, 
therefore the homogenised milk setting was used, due to the sample preparation steps used. The 
sample was then injected into the Miris Human Milk Analyser (Miris, Uppsala, Sweden) for analysis. 
For every ten samples analysed the Human Milk Analyser was cleaned and the calibration of the 
instrument was checked; recalibration was performed where necessary. 
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2.8 Statistical methods for hormonal and macronutrient analysis 
2.8.1 General statistical methods  
Data from the hormonal analysis and macronutrient analysis were analysed using IBM SPSS Statistics 
version 22 (IBM, Armonk, NY, USA), unless stated otherwise. In order to assess whether data collected 
were normally distributed, histograms and Q-Q plots of the data were visualised. If data were found 
to be normally distributed then parametric tests were used to interpret data. If data were non-
normally distributed then natural log transformation was applied to the data, histograms and Q-Q 
plots were replotted to establish normality of distribution, after which parametric tests were used to 
investigate the data collected. 
2.8.2 Sample size 
The group statistician for the section of Neonatal Medicine calculated an appropriate sample size to 
recruit. This was based on previous literature, and calculated to have sufficient power to observe a 
difference in the concentration of leptin in breast milk. Using a double sided test, a sample size of 124 
would provide 80% power to detect a correlation with an R value of 0.25, and in excess of 90% power 
for an R value of 0.3, at p=0.05, Table 3.  
Table 3: Power calculations detailing the number of participants required to have sufficient power 
to detect a difference in the concentration of leptin in breast milk. 
 
Determining an appropriate sample size for metabonomic data is complicated due to the data sets 
produced being highly dimensional, as well as the variables being highly correlated with one another. 
Because of these reasons, no accepted method currently exists to calculate sample sizes for 
metabonomic experiments (Nyamundanda et al., 2013). Therefore it was decided that the sample size 
calculation for leptin would be used, and statistical power would be checked retrospectively for any 
metabolites showing a correlation with maternal BMI, in accordance with accepted approaches in 
metabonomics.    
 Number of subjects required to detect a Pearson correlation of: 
 R=0.25 R=0.3 
Power 
Significance 
70% 80% 90% 70% 80% 90% 
0.05 98 124 136 67 86 114 
0.01 150 182 236 104 124 158 
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2.9 Multivariate data analysis methods of metabonomic data 
Metabonomic analysis produces global metabolic profiles of the samples examined. In doing this, each 
individual sample produces a large amount of raw data (e.g. an NMR spectrum or UPLC-MS 
chromatogram consisting of many data points, which correspond to the many different metabolites 
present in the samples analysed). In order to analyse datasets of this size and complexity, multivariate 
data analysis techniques are required. 
As previously outlined, 1H NMR spectroscopic data were pre-processed using Matlab, whilst UPLC-MS 
data were processed using the XCMS package within R. Once pre-processed, data were imported into 
SIMCA-P+ 13.0.2 (Umetrics, Sweden) for analysis using multivariate modelling techniques. Matlab was 
also used for multivariate modelling of some NMR data. An outline of the chemometric strategy used 
throughout this thesis is given in Figure 15. 
 
Figure 15: Chemometric strategy for sample analysis. Flow diagram descibing the analysis stategy 
used througout this thesis in order to identify biomarkers associated with overweight/obese dyads, 
and their posible biological relevence.  
2.9.1 Scaling 
Using SIMCA-P+, data are firstly scaled, as metabolites present in the biofluids analysed are present in 
vastly different concentrations, often many orders of magnitude. Because of this, the resulting data 
have substantially different numerical ranges. Because the pattern recognition techniques used 
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project the variables displaying the greatest variance, metabolites present in the highest 
concentrations dominate the models produced. Therefore, in order to be able to identify metabolites 
with an abnormal abundance, which discriminate between groups, the variables are scaled. This is so 
that the variance found in the smaller peaks are not overshadowed by the contribution of larger peaks, 
providing a more equal contribution towards the models produced, allowing for more meaningful 
interpretation of models (L. Eriksson, 2006). 
Using SIMCA-P+, data were scaled employing various different scaling methods to establish the most 
appropriate method of scaling for the data collected. The most common scaling methods used are 
unit variance (UV) scaling, Pareto and mean centering. UV scaling is carried out by dividing each 
variable by the standard deviation, giving all variables equal variance. However, UV scaling can 
introduce artefacts as it gives noise the same importance as genuine peaks.  
Mean centering is also commonly used for treating data prior to scaling; this is done by subtracting 
the average value of each variable without altering the variance. This method of scaling is useful for 
highlighting variables with the largest dynamic range.  
If neither of these scaling methods is found to be appropriate then an intermediate method can be 
used, Pareto scaling. This is achieved by giving each variable a value equal to its standard deviation, 
by scaling it using 1/√standard deviation.  
Once scaled, data are interpreted using chemometric data analysis techniques. The differently scaled 
models were visualised using Principal Component Analysis (PCA) scores plots, and the method, which 
gave the tightest clustering of QC samples was selected for further analysis. 
2.9.2 Unsupervised modelling of metabonomic data 
Because the datasets which result from metabonomic analysis contain so much information, it is not 
sufficient to merely examine the tables produced, as the data must be expressed in a way which is 
comprehensible. Data projection methods are most suited to describe and analyse this type of data. 
Unsupervised modelling first involves characterising the data collected. The data matrix produced 
consists of n, equivalent to the number of samples in rows, and K, equivalent to the number of 
variables, in this example, points along the ppm/δ axis in columns. The projection method used 
throughout this thesis is PCA. Using this technique, data are represented as a cloud of points in 
multidimensional space, corresponding to the number of variables collected, K. This is then linearly 
transformed into a lower dimensional plane, providing a representation of the observations in a 
manageable format, as a scores plot. 
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PCA is a useful visualisation tool for observing inherent grouping or clustering of samples within a 
dataset, and in order to understand the pattern of the data. The first principal component calculated 
is the direction in K dimensional space, which represents the maximum variance. The second principal 
component calculated is orthogonal to the first and describes the second largest variation found in 
the dataset. More principal components are calculated, describing less of the data as more are 
calculated.   
Interpretation of the resulting scores plots for all models was then undertaken to identify metabolic 
outliers. This involves visualising the PCA scores plot, where each spectrum is displayed as a point, 
either inside or outside of a Hotellings 95% confidence interval (CI), projected onto the scores plot. 
Spectra lying outside of this circle were investigated to determine the reason for the difference 
between them and the main body of the data. Once identified these were excluded (if a valid reason 
was ascertained, such as insufficient water suppression or poor shimming), and the models 
recalculated to improve reliability. 
Also, corresponding to the scores plots are the loadings plots. Loadings plots display the spectral 
points which are responsible for the distribution of the points seen in the scores plots and allow for 
the identification of the spectral points which are responsible for the separation of groups seen in the 
scores plots, an example loadings plot is given in Figure 16. 
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Figure 16: An example loadings plot, displaying the spectral points responsible for the separation of 
different samples in the scores plot.  
The p1 and p2 axis are vectors which display a point for each point along the ppm scale, these loadings 
allow for the visualisation of any correlation between the data in the matrix. The loadings plots display 
which data provide similar information (variables close together), if data are negatively correlated 
(variables on opposite sides of the plot), or if data are unrelated to one another (variables situated at 
90 degrees to one another).  Variables close to 0 along both the p1 and p2 axis are not able to be 
explained by the model.  
2.9.3 Supervised Orthogonal Projection to Latent Structures-Discriminant Analysis (OPLS-DA) and 
OPLS modelling of metabonomic data 
Matlab and SIMCA-P+ were employed for modelling data using Orthogonal Projection to Latent 
Structures-Discriminate Analysis (OPLS-DA) and OPLS regression.  
OPLS-DA allows the comparison of spectra/chromatograms from different classes of sample (e.g. 
obese vs. non-obese) using the class information collected over the study period.  
OPLS is a regression extension of PCA and is based on Partial Least Squares, or PLS, projection 
technique and is useful for identifying metabolites which discriminate between individuals based on 
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their class identity. It includes an internal orthogonal filter, which removes systematic variation from 
the dataset that is unrelated to the class or property used for differentiation in the model. 
The purpose of OPLS-DA is to establish if any relationship exists between the variables measured and 
class identity of the sample. Re-scaling of variables contributing towards the loadings plots is 
undertaken to maximise separation between the pre-defined classes. Because differences between 
classes may not be the most pronounced variation seen in the dataset, OPLS is used to identify and 
highlight more subtle changes in metabolic profiles. OPLS is also useful for predicting the membership 
of unknown samples to classes, for example sex.  
For NMR spectra analysed throughout this thesis an in-house Matlab code (written by Dr Olivier 
Cloarec, 2007) was used to compute OPLS-DA models. This method uses UV and mean centred scaled 
data (Cloarec et al., 2005b). A variable loadings plot is produced, displayed in a similar manner as NMR 
spectra, allowing easier identification of metabolites contributing to separation in the model. The 
standard deviation, or covariance, is multiplied onto each respective spectral point, this is then 
projected onto the spectra. The position of the peak in the loadings coefficient plot indicates whether 
that metabolite is increased or decreased in the case or control group. Figure 17 gives an example of 
an OPLS-DA model displayed in this manner. The top region of the loadings coefficient plot shows 
metabolites which are increased in case class (e.g. obesity) whilst metabolite peaks which are in the 
lower region identify metabolites which are increased in the control group (e.g. non obese). 
 
 
85 
 
Peaks are coloured by the variables which describe the correlation coefficient with the class or Y 
variable for that peak, R2, between each variable and the class membership, in order to demonstrate 
how much each peak contributes to the separation in the plot. This is displayed visually via colouring 
the peaks from blue to red, reflecting the value of the weight of each coefficient, red indicating a 
greater R2 value. The correlation value is displayed by the colour scale to the side of the loadings plot.  
For each model, the number of orthogonal components to include to reduce the influence of any non-
correlated data by using the maximum R2 and Q2 scores obtained was ascertained (Wold et al., 2001), 
but did not exceed 2 for any model. 
2.9.4 Model evaluation 
To evaluate models produced, SIMCA-P+ and Matlab calculate two metrics based on both the 
predictivity and percentage of variation explained by each model, the Q2 and R2 values. The R2 value 
relates to the percentage of variation explained by the model, describing how well the model fits the 
data. 
The Q2 value indicates how well the model is able to predict new data, with a higher Q2 indicating a 
better predictivity. If the data contain noise or have a few scattered outliers, this results in a poor Q2 
Figure 17: Example OPLS-DA loadings coefficient plot. 
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value. The Q2 value is derived from cross validation by dividing the data into 7 parts and sequentially 
removing 1/7th of the data. A model is built using the remaining 6/7th of the data and the removed 
data are predicted from this model, this is repeated 7 times so all of the data has been left out at least 
once (Wold et al., 1987). The original data are compared against the predicted data and the sum of 
squared errors is calculated.  
In order to assess the number of components required for modelling the acquired data, firstly a 
number of principal components are calculated. The point before which the ratio of the R2 value to 
the Q2 value starts to decrease is selected as the number of components to include to calculate the 
model. This ensures that the models produced are valid, and the data not ‘over fitted’.  
Further validation of multivariate models is achieved by permutation testing, which involves 
scrambling the class labels and repeating the modelling procedure, for example 100 times, in order to 
assess the chances of randomly achieving the same R2 and Q2 values. 
2.9.5 S-plots 
S-plots are useful for extracting the identification of metabolites associated with a particular group of 
participants. S-plots provide a visualisation of the OPLS-DA loadings, using a scatter plot to display the 
covariance and correlation of the modelled data, displayed in Figure 18. If there is variation in the 
data, the plot looks like an S. The two axes, p1 and p(corr)1, describe respectively the magnitude and 
reliability of each variable in the dataset.  
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Figure 18: Example S-plot, variables located within the red oval relate to peaks with a low intensity 
and have a high risk of being a spurious correlation, variables within the blue ovals possess a high 
intensity and a high reliability, and these are the metabolites of interest in regard to different 
groupings.   
2.9.6 STOCSY 
A further tool used in the metabolite identification process is Statistical TOtal Correlation 
SpectroscopY, or STOCSY, a computational approach for metabolite identification (Cloarec et al., 
2005a). STOCSY works on the assumption that peaks present in a spectrum belonging to the same 
molecule are highly correlated; STOCSY takes advantage of this by generating a pseudo-two 
dimensional NMR spectrum. The output of STOCSY is a plot which displays the correlation between 
the intensities of the different variables across the whole spectrum, highlighting peaks belonging to 
the same molecule (Cloarec et al., 2005a). An example STOSY plot is displayed in Figure 19.  
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Figure 19: Example STOCSY from the aqueous fraction of breast milk. Peaks highlighted in red 
pointing up are peaks which are highly correlated with the selected peak at δ 1.17 and belong to the 
same molecule. Peaks highlighted in red pointing down (blue arrows) belong to another molecule 
which is negatively correlated with the selected metabolite.  
2.9.7 STORM 
If metabolites were still difficult to identify using literature or STOCSY identification then SubseT 
Optimization by Reference Matching (STORM) was used, (Posma et al., 2012). This is a multivariate 
statistical approach which displays structural information from metabolites, from multiple 1H NMR 
spectra. STORM works by selecting subsets of 1H NMR spectra containing a spectroscopic signal from 
a specific metabolite. STORM uses these reduced spectral subsets to display a correlation matrix, 
containing smaller numbers of samples than the number of variables, which limits the number of false 
positive associations, making identification easier.   
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2.10 Method Development 
The studies for which these samples were collected were approved by the National Research Ethics 
Service (ref 08/H07114/3 and 10/H0713/5); research was performed with the mother’s written 
informed consent. These samples were collected separately from the prospective cohort study 
samples outlined earlier in Section 2.2 of this chapter. These studies had collected a sample volume 
surplus to requirement, and were used for method development, as outlined below. 
2.10.1 Introduction 
Analysis of breast milk composition is complicated by the changing nutritional composition of breast 
milk over the course of a single feed, throughout the day, in response to maternal diet, and over the 
course of lactation (Michaelsen et al., 1990). Additionally, the presence of large macromolecules and 
the ultrastructure of breast milk, which is micellar, mean analytical techniques must be preceded by 
sample preparation to reduce the complexity of breast milk prior to analysis. Therefore samples 
preparation techniques were optimized prior to metabonomic analysis, using 1H NMR spectroscopy 
and MS coupled with UPLC and CE. 
Very little previous research using metabonomics to analyse breast milk has been undertaken. A 
search using PubMed revealed only four studies that had used 1H NMR spectroscopy to analyse human 
breast milk (Smilowitz et al., 2013, Marincola et al., 2012, Pratico et al., 2014, O'Sullivan et al., 2013b). 
Previous MS studies on breast milk have predominantly investigated the lipid content (Lindholm et al., 
2013), or the structure of HMO present (German et al., 2008).  
Upon commencement of the method development, no study had employed a combination of 
metabonomic techniques to widen the global metabolite profile obtainable from breast milk. Since 
then we have published two articles on this (Villasenor et al., 2014), and (Andreas et al., 2015). The 
reluctance to implement a multi-platform approach in breast milk analysis may arise from the fact 
that each analytical technique normally requires different pre-processing steps, thus increasing the 
amount of sample volume and preparation time required. Therefore a simple sample preparation 
protocol for the pre-analytical preparation of breast milk for multiplatform metabonomic analysis was 
established, thus reducing the total volume of milk required to achieve comprehensive coverage of 
the milk metabolome.  
UPLC-MS and 1H NMR spectroscopy were used to characterise hydrophobic metabolites whilst polar 
metabolites were analysed using 1H NMR spectroscopy and CE-MS. To ensure reproducibility of the 
extraction protocol and analytical procedures, evaluation of analytical platforms was undertaken 
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using metabolites chosen to cover the full range of the spectral profiles for each technique, by taking 
into consideration the relative standard deviation (RSD). 
2.10.2 Samples 
Seventy human milk samples were obtained from 57 mothers, who delivered healthy term-born 
infants. Predominantly hindmilk samples were obtained between 2 to 80 days post-partum, by hand 
expression. Samples were collected into collection bottles and aliquoted into 1.5ml Eppendorf tubes. 
Samples were frozen as soon as possible after collection and stored at -80°C, until analysis. 
2.10.3 Sample pre-treatment 
No single technique is able to separate and detect the complete range of metabolites present in such 
a complex biofluid as breast milk; thus, to achieve a more comprehensive coverage of the metabolome 
the use of several analytical strategies is required. Furthermore, in the case of UPLC-MS, due to the 
proteins present in breast milk, a direct injection of a whole milk into the C18 column is not possible, 
as this would block the column; and in the case of 1H NMR, lipid peaks obscure metabolites present in 
smaller quantities, therefore different sample treatment protocols were tested in order to improve 
the number of metabolites able to be detected. In order to establish the best method to separate out 
the aqueous and lipid phases of milk, solvents were employed in liquid-liquid extraction protocols. 
Different modifications of the Folch extraction method (Folch et al., 1957) were investigated.  A total 
of 400µL of pooled whole milk was added to 2ml of a chloroform methanol mixture in different ratios 
(two ratios each of 1:2, 2:1 and 1:1 chloroform:methanol). This mixture was then vortexed and 600µL 
of demineralised water was added to one set of each of the ratios. The samples with added water 
were vortexed again; and both sets centrifuged for 10 minutes at 16000×g.  
This method produces two phases, a lipid phase at the bottom of the vial, plus an aqueous phase 
above, with metabolites splitting into the different phases according to their polarity. The phases were 
transferred to separate glass vials, and aliquoted into smaller volumes for each analytical technique, 
in order to be able to reconstitute them as needed. Both phases were evaporated to dryness using a 
speed vacuum concentrator (Eppendorf, Hamburg, Germany). Once dry, the phases were frozen at -
80°C until analysis.  
The method which produced the cleanest spectra, resolving the greatest number of metabolites was 
chosen. This was the method using a 2:1 ratio of chloroform:methanol with the addition of 600µL of 
water after the initial mix. This was the method which we therefore subsequently used to prepare the 
study samples from the cohort recruited. 
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2.10.4 Profile characterisation  
Each analytical platform generated a set of metabolites, some of which were unique to that platform 
and some of which were detected by more than one platform. Metabolites present in the profiles of 
each of these techniques were, as far as possible, identified using online databases and metabolite 
identification techniques.  
2.10.5 1H NMR Spectroscopy profile characterisation 
Analysing the aqueous fraction of breast milk using 1H NMR spectroscopy allowed the identification 
of ~52 metabolites. In the spectra of the organic extract 14 peaks were identified, however, these 
peaks do not correspond to specific molecules, but lipid classes or distinct proton environs within the 
lipid metabolites. Likewise, in the aqueous extract the HMO designations are not definitive, but 
examples of the type of HMO these peaks may originate from. This is because peaks correspond to 
proton environments, some of which are shared due to the similar structures of these compounds. 
Metabolites identified from the two dimensional NMR spectra are presented in Figures 20-22. The 
one dimensional breast milk aqueous and lipid spectra are displayed in Figure 23 A and B respectively, 
with identified metabolites defined in Table 4. The main metabolite classes identified from the 
aqueous fraction included; monosaccharaides, disaccharides, HMO, amino acids and their derivatives, 
choline containing molecules, intermediates of the tricaboxylic acid cycle, ketones and short chain 
fatty acids.  
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Table 4: Peak Assignments for 1H NMR Spectrum from the aqueous and lipid fraction of human 
breast milk. 
# Compound name 
1D 
/2D 
Group 
Assign
ment 
1H (ppm) 
13C 
(ppm) 
Multiplicit
y 
Metabolite 
class 
1 2-Oxoglutarate 2D   
  2.42,  
2.99 
33.4, 
38.6 
(t) Citrate cycle 
2 
  
2'-Fucosyllactose 
  
  
2D 
Fuc(α1-2) CH-1 5.32 102.3 
  HMO 
  CH-5 4.23 69.9 
  CH3-6 1.24 18.1 
Gal(β1-4) CH-1 4.53 103 
3 3'-Fucosyllactose 2D 
Fuc(α1-3)αGlc CH-1 5.39 101.3   
HMO   CH3-6 1.19 18.2 
Fuc(α1-3)βGlc CH-1 5.44 101.1 
4 
  
3’-Sialyllactose 
  
2D Neu5Ac(α2-3) 
CH-5 3.85 54.5 
  HMO CH-3 2.75 42.7 
CH-3' 1.78 42.6 
5 6’-Sialyllactose 2D Neu5Ac(α2-6) 
CH-3 2.73 42.9 
  HMO 
CH-3’ 1.73 42.9 
6 
Lacto-N-
neoDiFucohexaose 
 
2D Fuc(α1-3)GlcNAc 
CH-1 5.19 102.3 
  HMO 
CH-5 4.3 69.5 
7 
Lacto-N-
neofucopentaose/ 
Lacto-N-
neotetraose/ Para-
Lacto-N-
neohexaose/Lacto-N-
neooctaose/ Lacto-
N-neofucopentaose/ 
Galacto-N-
neoPentaose 
2D Gal(β1-4)GlcNAc 
CH-1 4.43 104.6 
  HMO 
CH-4 4.15 71.34 
8 
  
2D 
Fuc(α1-2) CH-1 5.29 102.3 
  HMO 
Lactodifuco-tetraose Fuc(α1-3)αGlc CH-1 5.4 101.5 
    CH3-6 1.19 18.34 
  Fuc(α1-3)βGlc CH-1 5.46 101.21 
9 
Lacto-N-
difucohesaose I 
  
Fuc(α1-2) CH-1 5.16 102.3 
  HMO   CH-5 4.35 69.1 
GlcNAc(β1-6) CH-1 4.62 106.17 
10 
    Fuc(α1-4) CH-1 5.03 100.6 
  HMO 
Lacto-N-
difucohesaose II 
  CH3-6 1.18 18.34 
  Fuc(α1-3)αGlc CH-1 5.38 101.71 
  Fuc(α1-3)βGlc CH-1 5.43 101.5 
    CH3-6 1.14 18.34 
  Gal(β1-4) CH-1 4.52 105.7 
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11 
Lacto-N-
fucopentaose II 
  Fuc(α1-4) 
CH-1 5.03 100.81 
  HMO 
CH3-6 1.18 18.34 
12 
Lacto-N-
fucopentaose III 
  
Fuc(α1-
3)GlcNAc 
CH3-6 1.19 18.34 
  HMO   CH-1 5.13 101.51 
Fuc(α1-
3)GlcNAc 
CH3-6 1.19 18.34 
13 
  
  
Fuc(α1-3)αGlc CH-1 5.39 101.51 
  HMO 
LNFP V   CH3-6 1.19 18.34 
  Fuc(α1-3)βGlc CH-1 5.44 101.22 
    CH3-6 1.19 18.34 
14 Lacto-N-neotetraose     CH-1 4.35 104.6   HMO 
15 Lacto-N-tetraose     
CH-1 4.35 104.6 
  HMO 
CH-2 3.51 71.5 
16 Acetate 1D     1.92   (s) Organic acid 
17 Acetone 1D     2.22   (s) Ketone 
18 Alanine 
1D, 
2D 
    1.48 19 (d) Amino Acid 
19 Aspartate 
1D, 
2D 
    2.71, 2.8 
39.3, 
39.4 
(dd), (dd) Amino Acid 
20 Butyrate 1D     0.89, 1.55   (t), (m) 
Short chain 
fatty acids 
21 Caprate 
1D, 
2D 
    1.27   (m) 
Short chain 
fatty acids 
22 Caprylate 1D     1.27   (m) 
Short chain 
fatty acids 
23 Carnitine 
1D, 
no 
2D 
    3.25   (s) 
Amino acid 
derivative 
24 Choline 
1D, 
2D 
    3.18 58.4 (s) Cholines 
25 Citrate 
1D, 
2D 
    2.53, 2.66 
48.7, 
48.7 
(dd) Citrate cycle 
26 Creatine 1D     3.04   (s) Organic Acid 
27 Creatine phosphate 1D         (s) Organic Acid 
28 Creatinine 1D     3.048   (s) Organic Acid 
29 Ethanolamine 
1D, 
2D 
    3.14 44.18 (t) Other 
30 Formate 1D     8.46   (s) Organic acid 
31 Fucose 
1D, 
2D 
    
1.18, 
1.23, 
3.42, 
4.15, 
4.53, 5.2 
  
(d), (d), 
(m), (m), 
(d), (d) 
Monosaccha
ride 
32 Galactose 2D     5.28 95 (d) 
Monosaccha
ride 
33 Glucose 
1D, 
2D 
  CH-1 4.65 98.82 (d) 
Monosaccha
ride 
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34 Glutamate 1D     2.13, 2.35   (m), (m) Amino Acid 
35 Glutamine 1D     2.13, 2.44   (m), (m) Amino Acid 
36 Lactate 
1D, 
2D 
    1.33 22.9 (d) Organic acid 
37 Lactose 
1D, 
2D 
    
3.3, 3.54-
3.97, 
4.46, 
4.68, 5.24 
  
(t), 
(multiple 
peaks), 
(d), (d), 
(d) 
Disaccharide 
38 Isoleucine 1D     0.92   (t) Amino Acid 
39 Leucine 1D     0.96, 1.7   (t), (m) Amino Acid 
40 Lysine 2D     3.01 42.1 (t) Amino Acid 
41 Methanol 
1D, 
2D 
    3.37 51.4 (s) Other 
42 Methionine 2D     2.1 17 (m) Amino Acid 
43 
N-Acetylneuraminic 
acid 
1D     2.06   (s) 
Monosaccha
ride 
44 N-Acetylglucosamine 1D     2.04, 5.2   (s), (d) 
Monosaccha
ride 
45 O-Acetylcarnitine 1D         (s) 
Amino acid 
derivative 
46 O-Phosphocholine 1D     3.2   (s) Cholines 
47 
sn-Glycero-3-
phosphocholine 
1D, 
2D 
    3.22 56.7 (s) Cholines 
48 Succinate 
1D, 
2D 
    2.4 3.68 (s) Citrate cycle 
49 Taurine 2D     3.41 38.3 (t) 
Amino acid 
derivative 
50 Tyrosine 2D     6.83, 7.13 
118.3, 
133.2 
(m), (m) Amino Acid 
51 Urea 1D     5.78     Other 
52 Valine 1D     0.99, 1.02   (dd) Amino Acid 
Peak Assignments for 1H NMR Spectrum from the Lipid fraction of human breast milk 
Peak number Proton Chemical shift(s) (ppm) Multiplicity 
1 Terminal -CH3 0.88 (t) 
2 Terminal -CH3 in ω3 fatty acids 0.97 (t) 
3 -CH2- 1.25 (s) 
4 -CH2-CH2-COOH 1.61 (s) 
5 -CH2-CH=CH- 2.01 (q) 
6 -CH2-COOH 2.3 (t) 
7 =CH-CH2-CH2-COOH 2.34 (t) 
8 = CH-CH2-CH= 2.77 (t) 
9 -N(CH3)3 Phosphatydylcholine 3.33 (s) 
10 Glyceryl, C1, 3, 2 4.14, 4.29, 5.26 (m), (m), (m) 
11 -CH=CH- 5.34 (m) 
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Figure 20: 1H NMR HMDB Spectrum of a pooled milk sample from 0-3 ppm. 1=Citrate, 2=Oxoglutarate, 3=Alanine, 4=Ethanolamine, 5=lactate, 6=Lysine, 
7=Methionine, 8=Succinate, 9=2’-Fucosyllactose, 10=3’-Fucosyllactose, 11=LNFPII, 12=LDFT, 13=LNFPIII, 14=LNFP V, 15=3’-sialyllactose, 16=6’-sialyllactose.  
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 Figure 21: 1H NMR HMDB Spectrum of a pooled milk sample, from 3-4.5 ppm. 1=Lactose, 2=Galactose, 3=Glycerophosphocholine, 4=2’-fucosyllactose, 5=3’-
siallactose, 6=Lacto-N-neoDiFucohexaose, 7=Lacto-N-neofucopentaose/ Lacto-N-neotetraose/ Para-Lacto-N-neohexaose/Lacto-N-neooctaose/ Lacto-N-
neofucopentaose/ Galacto-N-neoPentaose, 8=LNDFHI, 9=Lacto-N-tetraose.  
 
 
 
97 
 
 
Figure 22: 1H NMR HMDB Spectrum of a pooled milk sample from 4-5.5 ppm. 1=Lactose, 2=Fucose, 3=2’-Fucosyllactose, 4=3’-Fucosyllactose, 5=LNDFHII, 
6=LNFP V, 7=LDFT, 8=Lacto-N-neoDiFucohexaose, 9=LNDFHI and branched chain oligosaccharides, 10=Fuc(α1-3)GlcNAc, 11=LNFPII, 12=Lacto-N-tetraose, 
13=Glucose,14=Galactose.
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2.10.6 UPLC-MS lipid fraction profile characterisation 
The lipid fraction of breast milk was analysed using UPLC-MS in both positive and negative ionization 
mode, as outlined in Section 2.4, Chapter 2. The resulting chromatograms were characterised, 
allowing the tentative identification of 105 metabolites, Table 5. The base peak chromatogram (BPC) 
displaying a representative sample in both positive and negative ionization mode is presented in 
Figure 23, D and E respectively, showing the tentative identifications of metabolites with the highest 
intensities. Metabolite annotation was made using literature, and by searching m/z values against 
online databases including METLIN http://metlin.scripps.edu/, LIPID MAPS, http://lipidmaps.org/, and 
HMDB, http://hmdb.ca. In negative ionization mode, the main metabolites identified were saturated 
fatty acids, monounsaturated fatty acids and polyunsaturated fatty acids whilst in positive ionization 
mode the main classes of lipid identified were triacylglycerols and phospholipids. 
Table 5: Metabolites tentatively identified in positive and negative mode using UPLC-MS. 
Number  Common Name Formula Ion 
Experimental 
mass (Da) 
Theoretical 
mass (Da) 
Error 
(ppm) 
RT 
(min) 
ESI(-) Figure 23 D 
1 Lauric acid C12H24O2 [M-H] 199.1702 199.0698 0.4 1.21 
2 Stearidonic acid C18H28O2 [M-H] 275.2014 275.2011 0.3 1.27 
3 Eicosapentaenoic acid C20H30O2 [M-H] 301.2168 301.2168 0 1.44 
4 Linolenic Acid isomer C18H30O2 [M-H] 277.2171 277.2168 0.3 1.52 
5 Docosahexaenoic Acid C22H32O2 [M-H] 327.2325 327.2324 0.1 1.64 
6 Arachidonic acid isomer C20H32O2 [M-H] 303.2325 303.2324 0.1 1.78 
7 Docosapentaenoic acid C22H34O2 [M-H] 329.2482 329.2481 -0.1 1.85 
8 Linoleic Acid C18H32O2 [M-H] 279.233 279.2324 0.6 1.9 
9 
Docosapentaenoic acid 
isomer 
C22H34O2 [M-H] 329.2481 329.2481 0 2.05 
10 
Dihomo-gamma-
linolenic acid 
C20H34O2 [M-H] 305.248 305.2481 -0.1 2.1 
11 
Dihomo-gamma-
linolenic acid isomer 
C20H34O2 [M-H] 305.2479 305.2481 -0.2 2.3 
12 Docosatetraenoic acid C22H36O2 [M-H] 331.2636 331.2637 -0.1 2.33 
13 Palmitic acid C16H32O2 [M-H] 255.2326 255.2324 0.2 2.4 
14 Oleic acid C18H34O2 [M-H] 281.2482 281.2481 0.1 2.48 
15 Eicosadienoic acid C20H36O2 [M-H] 307.2641 307.2637 0.4 2.68 
16 Stearic  acid C18H36O2 [M-H] 283.2638 283.2637 0.1 3.21 
17 Eicosenoic acid C20H38O2 [M-H] 309.279 309.2794 -0.4 3.26 
18 Docosadienoic acid C22H40O2 [M-H] 335.2941 335.295 -0.9 3.42 
19 Erucic acid C22H42O2 [M-H] 337.3101 336.3029 -0.6 4.22 
ESI(+) Figure 23 E 
1 SM(d32:1) 
C37H75N2O6
P 
[M+H]+ 675.5451 675.5442 0.9 3.98 
2 PC(28:0) C36H72NO8P [M+H]+ 678.5083 678.5074 0.9 4.08 
3 SM(d34:2) 
C39H77N2O6
P 
[M+H]+ 701.5605 701.5598 0.7 4.13 
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4 DG(28:2) C31H56O5 [M+H]+ 509.4195 509.4206 -1.1 4.36 
5 PC(32:2) C40H76NO8P [M+H]+ 730.5397 730.5387 0.9 4.44 
6 SM(d33:1) 
C38H77N2O6
P 
[M+H]+ 689.5609 689.5599 1 4.54 
7 PC(29:0) C37H74NO8P [M+H]+ 692.5228 692.5203 -0.2 4.62 
8 PC(36:4) C44H80NO8P [M+H]+ 782.5714 782.5694 1.4 4.84 
9 SM(d34:1) 
C39H79N2O6
P 
[M+H]+ 703.5756 703.5754 0.1 5.19 
10 PC(30:0) C38H76NO8P [M+H]+ 706.5397 706.5387 1 5.28 
11 PC(32:1) C40H78NO8P [M+H]+ 732.555 732.5543 0.7 5.43 
12 PC(36:4) C44H80NO8P [M+H]+ 782.5705 782.5694 0.5 5.55 
13 DG(30:2) C33H60O5 [M+H]+ 537.4513 537.4519 -0.7 5.65 
14 PC(34:2) C42H80NO8P [M+H]+ 758.5706 758.5699 0.7 5.79 
15 PC(36:3) C44H82NO8P [M+H]+ 784.5859 784.5857 0.2 5.96 
16 PS(36:2) 
C42H78NO10
P 
[M+H]+ 788.5444 788.5442 0.2 6.04 
17 PC(36:3) C44H82NO8P [M+H]+ 784.5857 784.5857 0 6.14 
18 PC(36:3) C44H82NO8P [M+H]+ 784.5853 784.5857 -0.4 6.22 
19 PE(36:3) C41H76NO8P [M+H]+ 742.5389 742.5387 0.1 6.41 
20 PE(36:4) C41H74NO7P [M+H]+ 724.5288 724.5268 0.7 6.77 
21 SM(d36:1) 
C41H83N2O6
P 
[M+H]+ 731.6066 731.6067 -0.1 6.86 
22 PC(32:0) C40H80NO8P [M+H]+ 734.5681 734.5700 -1.7 6.93 
23 PC(34:1) C42H82NO8P [M+H]+ 760.5885 760.5856 -0.2 7.12 
24 PC(38:4) C46H84NO8P [M+H]+ 810.6007 810.6009 -0.2 7.31 
25 PC(36:2) C44H84NO8P [M+H]+ 786.6013 786.6013 0 7.37 
26 DG(32:2) C35H64O5 [M+H]+ 565.4817 565.4833 -1.6 7.43 
27 PC(36:2) C44H84NO8P [M+H]+ 786.6018 786.6013 0.5 7.64 
28 Unknown   663.454   7.82 
29 PE(36:2) C41H78NO8P [M+H]+ 744.5541 744.5543 -0.2 7.95 
30 DG(36:4) C39H68O5 [M+NH4]+ 634.542 634.5404 1.5 8.13 
31 PE(36:2) C41H78NO8P [M+H]+ 744.5541 744.5543 -0.2 8.25 
32 DG(38:6) C41H68O5 [M+NH4]+ 658.5415 658.5404 1 8.61 
33 DG(40:7) C43H70O5 [M+NH4]+ 684.5566 684.5561 0.4 8.84 
34 SM(d38:1) 
C43H87N2O6
P 
[M+H]+ 759.6379 759.6380 -0.2 9.1 
35 PC(34:0) C42H84NO8P [M+H]+ 762.6018 762.6013 0.5 9.15 
36 DG(32:1) C35H66O5 [M+H-H2O]+ 549.4875  549.4883  -0.8 9.31 
37 PC(36:1) C44H86NO8P [M+H]+ 788.6169 788.6169 0 9.43 
38 SM(d40:2) 
C45H89N2O6
P 
[M+H]+ 785.6535 785.6537 -0.2 9.52 
39 DG(34:2) C37H68O5 [M+NH4]+ 610.5410 610.5404 0.5 9.87 
40 DG(36:3) C39H70O5 [M+NH4]+ 636.5573  636.5567 0.6 10.15 
41 PE(36:1) C41H80NO8P [M+H]+ 746.5707 746.5700 0.7 10.2 
42 SM(d41:2) 
C46H91N2O6
P 
[M+H]+ 799.6691 799.6693 -0.3 10.38 
43 SM(d39:1) 
C44H89N2O6
P 
[M+H]+ 773.6523 773.6537 -1.4 10.5 
44 SM(d41:2) 
C46H91N2O6
P 
[M+H]+ 799.6678 799.6693 -1.6 10.91 
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45 SM(d42:2) 
C47H93N2O6
P 
[M+H]+ 813.6850 813.6850 0 11.84 
46 SM(d40:1) 
C45H91N2O6
P 
[M+H]+ 787.6695 787.6695 0 12.00 
47 DG(34:1) C37H70O5 [M+H-H2O]+ 577.5192 577.5196 -0.4 12.28 
48 SM(d42:2) 
C47H93N2O6
P 
[M+H]+ 813.6844 813.6850 -0.6 12.52 
49 DG(36:2) C39H72O5 [M+H-H2O]+ 603.5357  603.5352 0.5 12.62 
50 TG (34:0) C37H70O56 [M+NH4]+ 628.5519 528.5516 0.3 12.73 
51 SM(d41:1) 
C46H93N2O6
P 
[M+H]+ 801.6851 801.6850 0.1 12.90 
52 SM(d42:1) 
C47H95N2O6
P 
[M+H]+ 815.7004 815.7006 -0.2 13.19 
53 TG(36:0) C39H74O6 [M+NH4]+ 656.5832 656.5823 0.9 13.34 
54 TG(36:1) C41H76O6 [M+NH4]+ 682.5983 682.5986 -0.3 13.41 
55 TG(40:2) C43H78O6 [M+NH4]+ 708.6141 708.6136 0.4 13.48 
56 TG(42:3) C45H80O6 [M+NH4]+ 734.6298 734.6293 0.5 13.59 
57 TG(44:4) C47H82O6 [M+NH4]+ 760.6462 760.6449 1.2 13.71 
58 TG(38:0) C41H78O6 [M+NH4]+ 684.6143 684.6142 0.1 13.84 
59 TG(40:1) C43H80O6 [M+NH4]+ 710.6299 710.6299 0 13.88 
60 TG(42:2) C45H82O6 [M+NH4]+ 736.6451 736.6449 0.1 13.94 
61 TG(44:3) C47H84O6 [M+NH4]+ 762.6603 830.7238 -3.6 14.04 
62 TG(48:5) C51H88O6 [M+NH4]+ 814.6915 814.6919 -0.4 14.13 
63 TG(40:0) C43H82O6 [M+NH4]+ 712.6457 712.6455 0.2 14.27 
64 TG(42:1) C45H84O6 [M+NH4]+ 738.6609 738.6612 -0.3 14.29 
65 TG(44:2) C47H86O6 [M+NH4]+ 764.6765 790.6925 -0.8 14.35 
66 TG(46:3) C49H88O6 [M+NH4]+ 790.6917 790.6925 -0.8 14.38 
67 TG(48:4) C51H90O6 [M+NH4]+ 816.7075 842.7238 -0.5 14.42 
68 TG(50:5) C53H92O6 [M+NH4]+ 842.7233 842.7238 -0.5 14.51 
69 TG(50:5) C53H92O6 [M+NH4]+ 842.722 842.7238 -1.8 14.61 
70 TG(44:1) C47H88O6 [M+NH4]+ 766.6918 766.6925 -0.7 14.67 
71 TG(46:2) C49H90O6 [M+NH4]+ 792.707 792.7081 -1.1 14.72 
72 TG(48:3) C51H92O6 [M+NH4]+ 818.723 818.7238 -0.8 14.73 
73 TG(50:4) C53H94O6 [M+NH4]+ 844.7373 844.7394 -2.1 14.74 
74 TG(52:5) C55H96O6 [M+NH4]+ 870.7546 870.7545 0.1 14.86 
75 TG(52:5) C55H96O6 [M+NH4]+ 870.7537 870.7545 -0.8 14.96 
76 TG(46:1) C49H92O6 [M+NH4]+ 794.7239 794.7238 0.1 15.01 
77 TG(50:3) C53H96O6 [M+NH4]+ 846.7549 846.7551 -0.2 15.07 
78 TG(52:4) C55H98O6 [M+NH4]+ 872.7706 872.7707 -0.1 15.11 
79 TG(51:3) C54H98O6 [M+NH4]+ 860.7687 860.7707 -2 15.22 
80 TG(54:5) C57H100O6 [M+NH4]+ 898.7854 898.7864 -1 15.28 
81 TG(50:2) C53H98O6 [M+NH4]+ 848.7702 848.7707 -0.5 15.34 
82 TG(52:3) C55H100O6 [M+NH4]+ 874.7858 874.7864 -0.6 15.38 
83 TG(51:2) C54H100O6 [M+NH4]+ 862.7853 862.7864 -1.1 15.49 
84 TG(52:2) C55H102O6 [M+NH4]+ 876.8016 876.8020 -0.4 15.63 
85 TG(53:2) C56H104O6 [M+NH4]+ 890.8149 890.8170 -2.2 15.77 
86 TG(54:2) C57H106O6 [M+NH4]+ 904.8325 904.8333 -0.8 15.9 
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2.10.7 CE-MS profile characterisation 
CE-MS was used to analyse the aqueous fraction of breast milk, as outlined in Section 2.5, Chapter 2. 
Using CE-MS, 23 metabolites were identified from the electropherogram; Table 6. Figure 23 C displays 
an extracted ion chromatogram (EIC) of a representative sample. Metabolites were identified by 
comparing the mass accuracy and retention times against standards analysed for comparison. 
Metabolites identified were mainly amino acids and their derivatives, organic acids as well as 
nicotinamide, glycylglycine and cytosine/dine.  
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Table 6: Identification of metabolites from the aqueous fraction of human breast milk using CE-MS.  
 Metabolite Metabolite class Formula [M+H]+ 
(Da) 
Experimental  mass 
(Da) 
Mass error 
(ppm) 
Standard 
RT 
Experimental 
RT 1 Creatinine Organic Acid C4H7N3O 114.0662 114.0663 0.9 4.1 2.8 
2 Lysine Amino acid C6H14N2O2 147.1128 147.1127 -0.7 4.2 3 
3 Nicotinamide Vitamin C6H6N2O 123.0553 123.0552 -0.8 4.2 3.1 
4 Arginine Amino acid C6H14N4O2 175.119 175.119 0.0 4.1 3.1 
5 Carnitine Amino acid 
derivative 
C7H15NO3 162.1125 162.1125 0.0 4.2 3.4 
6 Acetyl-L-carnitine Amino acid 
derivative 
C9H17NO4 204.123 204.1232 1.0 5 3.7 
7 Cytosine Nucleotide C4H5N3O 112.0505 112.0504 -0.9 3.9 3.7 
8 Cytidine Nucleoside C9H13N3O5 244.0928 244.0929 0.4 4.3 3.7 
9 Creatine Organic Acid C4H9N3O2 132.0768 132.0769 0.8 5.2 4.2 
10 Alanine Amino acid C3H7NO2 90.055 90.0551 8.7 5.6 4.5 
11 5-aminovaleric acid/Valine Amino acid C5H11NO2 118.0863 118.0864 0.8 4.5 4.9 
12 n-Methyl-L-
Valine/Leucine/Isoleucine 
Amino acid C6H13NO2 132.1019 132.102 0.8 6.7 5 
13 Serine Amino acid C3H7NO3 106.0499 106.0499 0.0 6.6 5.2 
14 Tryptophan Amino acid C11H12N2O2 205.0972 205.0971 -0.5 - 5.2 
15 Threonine Amino acid C4H9NO3 120.0655 120.0654 -0.8 - 5.3 
16 Glycylglycine Dipeptide C4H8N2O3 133.0608 133.0609 0.8 5 5.2 
17 Methionine Amino acid C5H11NO2S 150.0583 150.0582 -0.7 - 5.3 
18 Citrulline Amino acid C6H13N3O3 176.103 176.1027 -1.7 6.1 5.4 
19 Phenylalanine Amino acid C9H11NO2 166.0863 166.0861 -1.2 10.8 5.4 
20 Glutamic acid Amino acid C5H9NO4 148.0604 148.0603 -0.7 6.4 5.5 
21 Tyrosine Amino acid C9H11NO3 182.0812 182.0811 -0.5 6.1 5.6 
22 Cystine Amino acid C6H12N2O4S2 241.0312 241.0311 -0.4 - 5.8 
23 Aspartic acid Amino acid C4H7NO4 134.0448 134.0445 -2.2 7.1 6.1 
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Figure 23: Profiles of breast milk analysed using;  
(A) 1H NMR spectrum of aqueous fraction of breast milk, along the X axis is thee ppm scale whilst along the Y axis is intensity. 1=Fucose, 2=Lactate, 3=Alanine, 
4=Butyrate, 5=N-acetyl glutamine, 6=Acetate, 7=N-acetyl neuraminic acid, 8=Glutamine, 9=Glutamate 10=Citrate, 11=Creatine, 12=Creatinine, 13=Choline, 
14=Phosphocholine, 15=Glycerophosphocholine, 16=Lactose, 17=Taurine, 18=Glucose, 19=Galactose  
(B) 1H NMR spectrum of lipid fraction of breast milk, 1=Cholesterol, 2=Terminal CH3, 3=Omega 3 terminal CH3, 4=Saturated CH2, 5=CH2-CH2-COOH, 
6=Unsaturated fatty acids CH2-CH=CH, 7=CH2-COOH, 8=Docosahexaenoic acid, =CH-CH2-CH2-COOH, 9=Polyunsaturated fatty acid, =CH-CH2-CH= 
10=Phosphatidylcholine,-N(CH3)3, 11=Phospholipid, 12=Glyceryl C1,3, 13=Glyceryl C2, 14=Unsaturated fatty acids, -CH=CH- 
(C) CE-MS aqueous fraction analysed using positive ionization mode 1=Creatinine, 2=Lysine, 3=Nicotinamide, 4=Arginine, 5=Carnitine, 6=Acetyl-L Carnitine, 
7=Cytosine, 8=Cytidine, 9=Creatine, 10=Alanine, 11=5-amino Valeric acid/valine, 12= N- methyl-L-Valine/leucine/isoleucine, 13=Serine, 14=Tryptophan, 
15=Threonine, 16=Glycyl-glycine, 17=Methionine, 18=Citrulline, 19=Phenylalanine, 20=Glutamic acid, 21=Tyrosine, 22=Cystine, 23=Aspartic acid 
(D) UPLC-MS; lipid fraction analysed using negative ionization mode. Identified metabolites are displayed in Table 5. 
(E) UPLC-MS; lipid fraction analysed using positive mode. Identified metabolites are displayed in Table 5. 
Figure adapted from (Andreas et al., 2014). 
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2.10.8 Analytical performance: Relative Standard Deviation   
The RSD was calculated for each of the methods, and was used to establish the reproducibility of the 
methods used, Table 7. All of the methods were found to be robust and reproducible. Of all the 
methods, 1H NMR of the aqueous breast milk fraction was found to be the most reproducible, with 
mean RSD value of 6.4%. The UPLC-MS methods also showed good reproducibility across the selected 
metabolites, with mean RSDs values of 7.95% and 13.56% for positive and negative mode data. The 
mean RSD for the CE-MS metabolites was the weakest in terms of reproducibility (24.18%), but was 
still within the accepted cut off value of 30% RSD. CE-MS has a limited reproducibility and analytical 
robustness in comparison to UPLC-MS and NMR. This is due to the migration time of metabolites in 
CE-MS being less reproducible, due to modifications in the capillary wall. This was one of the reasons 
why CE-MS was not employed to analyse the whole sample set of the cohort recruited for this work. 
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Table 7: The relative standard deviation (RSD) calculated for each of the methods used to establish the reproducibility of the methods. DG; diacylglyceride, 
PC; phosphocholine, PE; phosphoethanoamine, SM; sphingomyelin, TG; triacylglyceride. 
 
 1H NMR, RSD of Aqueous fraction metabolites, normalised to TSP  1H NMR, RSD of Lipid fraction metabolites, normalised to TMS  
Metabolite Alanine 
(δ1.48) 
Citrate (δ2.59) Choline (δ3.21) 
Lactose 
(δ4.46) 
Formate 
(δ8.46) 
CDCl3 
(δ7.26) 
Choline 
(δ3.33) 
CH2-CH3 
(δ1.63) 
CH3 of fatty 
acids (δ0.88) 
Cholesterol 
(δ0.68) 
RSD % 1.7 1.0 5.4 0.1 24.0 4.72 11.82 9.79 10.13 10.19 
 CE-MS Validation parameters for selected metabolites  
Metabolite Creatinine Lysine Nicotinamide Carnitine Arginine 
Acetyl-L-
Carnitine 
Creatine Valine Tryptophan Phenylalanine 
RSD (%) 12.7 21.2 21.0 23.5 22.8 26.4 29.1 29.1 28.3 29.8 
 Validation parameters for selected metabolites by UPLC-MS of the Folch extraction, negative mode 
Metabolite  Lauric acid 
Eicosapentaenoic 
acid 
Docosahexaenoic 
acid 
Linoleic 
acid 
Palmitic 
acid 
Oleic acid 
Stearic 
acid 
Eicosanoic 
acid 
Docosadienoic 
acid 
Erucic acid 
RSD (%) 4.4 3.8 2.7 14.6 25.7 7.8 4.2 20.3 21.1 26.6 
 Validation parameters for selected metabolites by UPLC-MS of the Folch extraction, positive mode 
Metabolite  SM (d32:1) PC(36:4) PE(36:3) PC(38:4) DG(36:4) 
SM 
(d41:2) 
TG(42:3) TG(38:0) TG(44:1) TG(54:2) 
RSD (%) 5.0 5.0 5.7 5.4 4.8 18.3 22 5 3.2 5.1 
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2.10.9 Multiplatform assessment of metabolite alterations in breast milk over time  
Metabolites were identified which altered in concentration over lactation between the three different 
groups; days 1-5 post birth (group 1), 6-10 days post birth (group 2) and >10 days post-birth (group 3). 
In general the models generated for analysis of time-related aqueous components were stronger than 
those generated for the non-polar fraction, suggesting that changes in the composition of polar 
metabolites were more systematic than the variation observed in the lipid fraction. The equivalent 
PCA models provided in Figure 24 show that the differentiation of samples over time according to 
inherent similarity in chemical composition was apparent only for 1H NMR and CE-MS analysis of the 
aqueous fraction.  
PLS-DA models comparing the three time groups against one another were computed for each of the 
analytical methods used; these models displayed a gradual change in the composition of breast milk 
in regard to the time of collection post-birth, Figures 25.   
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Figure 24: PCA scores plots, separated by time groups. White diamonds represent samples taken during days 1-5 post-partum, black squares show samples 
taken days 6-10 post-partum and white stars represent samples taken over 10 days post-partum. 
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Figure 25: PLS-DA scores plots, separated by time groups; White diamonds represent samples taken during days 1-5 post-partum, black squares show samples 
taken days 6-10 post-partum and white stars represent samples taken over 10 days post-partum. 
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None of the models based on analysis of the Folch-extracted organic layer gave valid models. These 
results indicate that time related compositional changes in lactation are evident in polar metabolites 
showing a strong systematic change in relative concentration over time. 
Pairwise analysis using OPLS-DA was used to establish which metabolites changed over time 
comparing groups 1 vs 2, 1 vs 3 and 2 vs 3. Identified metabolites are displayed in Table 8. OPLS-DA 
scores plots comparing these time groups are displayed in Figures 26-28, Appendix 2H gives the R2 and 
Q2 values for these models. Changes identified in breast milk composition over the first few days of 
lactation include an increase in the relative concentrations of di- and triacylglycerols along with a more 
sustained increase in lactose, several amino acids, and short and medium chain fatty acids. Conversely 
a time dependent decrease was observed in multiple HMO, several phosphocholines and energy 
metabolites such as citrate and pyruvate. 
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 Figure 26: OPLS-DA scores plots separated by time groups. White diamonds represent samples taken during day’s 1-5 post-partum, black squares 
show samples taken day’s 6-10 post-partum. 
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Figure 27: OPLS-DA scores plots separated by time groups. White diamonds represent samples taken during days 1-5 post-partum, white stars show samples 
taken days +10 post-partum. 
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Figure 28: OPLS-DA scores plots separated by time groups. Black squares represent samples taken during days 6-10 post-partum, white stars show samples 
taken days +10 post-partum. 
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Table 8: Metabolites identified as changing in abundance in breast milk samples collected at 
different point’s post-partum. Capitals relate to higher concentration in the later time group, whilst 
lower case letters refer to metabolites which were decreased in abundance in the later time point. 
NMR aqueous A, a; CE-MS aqueous B, b; HPLC-MS single phase C, c; NMR lipid D, d; UPLC-MS positive 
E, e; UPLC-MS negative F, f; GC-MS single phase G, g. 
Class Metabolite 1 vs 2 1 vs 3 2 vs 3 
Amino acids Alanine  A  
 Glutamine A A  
Acids 3,4 hydroxymandelic acid g   
 Butyrate A A  
 Citrate a a a 
 Taurine f   
 Pyruvic acid  g  
Ceramides GlucosylCeramide (36:2)   F 
 Ceramide (20:4) c   
 PE-Ceramide (38:2) f   
 PI-Ceramide (40:0) f   
 PE-Ceramide (38:2)    
Diacylglycerols Diacylglycerol (24:0) C   
 Diacylglycerol (26:0) C   
 Diacylglycerol (28:2) C   
 Diacylglycerol (30:2) C   
 Diacylglycerol (34:0)   E 
 Diacylglycerol (34:1) E   
 Diacylglycerol (34:3)  E E 
 Diacylglycerol (40:7) C  E 
 Diacylglycerol (44:10)  e e 
Prenol Lipids Tocopherol g g  
Pyrimidine Nucleosides N4-Acetylcytidine   B 
Amino Acids Derivatives N-acetyl glutamine a a a 
Steroids and Derivatives Cholesteryl stearate f   
 Cholesterol  d, g  
Sugar alcohols Glycerol  G  
Phthalic Acid and Derivatives Dioctyl phthalate G   
Fatty Acid Esters Methyl Stearate G   
Fatty Acids 11S-hydroxy-hexadecanoic acid  F  
 9,12-octadecadienoic acid G G  
 Arachidonic Acid  C  
 Caprylic acid F F  
 3-Hydroxycapric acid  F  
 Hexadecenoic acid  F  
 Myristic acid g   
 Oleic acid  G  
 Palmitoleic acid  G  
 Lauric acid  G  
 Linoleic acid G G  
 Polyunsaturated FA  d  
 Terminal CH
3 
on omega 3 fatty acids  d  
Saccharides Fucose (from HMO) a a, g a 
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 D-glucosaminic acid (from HMO) g g  
 N-acetyl neuraminic acid (from HMO) a a a 
 Glucose G G  
 Lactose A, G A A 
 Gluconic acid lactone G   
Glycerophosphocholines Glycerophosphocholine (18:0) e   
 Glycerophosphocholine (34:0)  e e 
 Glycerophosphocholine (32:0) e  e 
 Glycerophosphocholine (32:1) e   
 Glycerophosphocholine (30:0) e e e 
 Glycerophosphocholine (38:5)   f 
 Glycerophosphocholine (34:2) e e  
 Glycerophosphocholine (36:1)  e c 
 Glycerophosphocholine (36:2) E   
 Glycerophosphocholine (36:3)  e  
 Glycerophosphocholine (36:4)  f  
 Glycerophosphocholine (40:7)  f  
 Glycerophosphocholine A A  
Glycerophosphoethanolamines Glycerophosphoethanolamine (40:6) F   
 Glycerophosphoethanolamine (36:2) E   
 Glycerophosphoethanolamine (42:3)  f  
 Glycerophosphoethanolamine (44:2)  f  
Glycerophosphoserines Glycerophosphoserine (30:3) F   
 Glycerophosphoserine (18:1)  f  
Glycererophosphoglycerol Glycerophosphoglycerols (44:7)  f  
Glycerphosphoinositols Glycerophosphoinositol (35:2) f   
 Glycerophosphoinositol (32:0) E   
 Glycerophosphoinositol (37:4)  f  
Monoacylglycerols Monoacylglycerol (18:3)  b b 
Sphingomyelins Sphingomyelin (42:0)   F 
 Sphingomyelin (34:1) e e  
 Sphingomyelin (36:3)   c 
 Sphingomyelin (38:1) e   
Triacylglycerols Triacylglycerol (34:0) E  e 
 Triacylglycerol (36:0) E  e 
 Triacylglycerol (38:0) E  e 
 Triacylglycerol (42:1) E  e 
 Triacylglycerol (42:2) E  e 
 Triacylglycerol (44:2) E  e 
 Triacylglycerol (45:1)  F  
 Triacylglycerol (48:1) e  f 
 Triacylglycerol (48:4)   e 
 Triacylglycerol (48:5)  e  
 Triacylglycerol (50:2) e   
 Triacylglycerol (51:2)   C 
 Triacylglycerol (51:7) F   
 Triacylglycerol (52:2) e  E 
 Triacylglycerol (55:9)   f 
 Triacylglycerol (58:2)  c  
 Triacylglycerol (60:3) c c c 
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2.11 Discussion 
A comprehensive metabolic map of breast milk using different analytical platforms has been 
generated, tentatively identifying 180 metabolites; previous studies have commonly identified 
between 50-100 metabolites. Additionally, the utility of multiplatform analytical techniques to 
investigate questions of clinical and biological importance has been demonstrated, including a report 
on the changes in abundance of metabolites over the first 3 months of lactation  
Each platform contributed a set of unique metabolites to the overall global profile. There was some 
overlap in metabolites identified by the different platforms, but insofar as this allows corroboration 
of the data, this may be regarded as a strength of the multiplatform analytical approach adopted. 
Ultimately, given the complexity of breast milk composition, these results have demonstrated that 
there is no single analytical platform capable of identifying all metabolites present in milk.  
Beyond simply establishing a list of metabolites present in breast milk (although this is not 
unimportant), in order to answer questions of biological relevance, it is important that these analytical 
platforms can identify alterations in the abundance of metabolites between different milk samples. It 
is well known that there is a temporal change in breast milk composition over lactation (Prosser et al., 
1984). Based on this metabolites were identified which displayed temporal changes over the first 3 
months of lactation, these were in keeping with previous reports using established biochemical assays 
to investigate breast milk composition.  
For example, Ilcol et al demonstrated that glycerophosphocholine concentrations significantly 
increase in concentration from colostrum to mature milk (Ilcol et al., 2005), which was replicated in 
this work. One of the most prominent changes observed in the time course analysis of breast milk 
were the decreasing concentrations of HMO from the 1st time point to the third time point, also 
previously identified, (Carlson, 1985). Furthermore, this study identified increases in the abundance 
of lactose (Coppa et al., 1993), and glutamine (Carlson, 1985) in mature milk. In regard to the temporal 
change in composition of breast milk through lactation, although the data presented here are not 
novel, they do demonstrate that the analytical techniques utilised have the power to resolve these 
temporal changes. 
Over time, there appeared to be a trend the data towards increased diacylglycerol and reduced 
triacylglycerols. It is possible that this is a reflection of breast milk lipase activity breaking down the 
triacylglycerides into diacylglycerides and free fatty acids. Tocopherol was decreased over the first 
week of lactation, but then remained at constant concentrations; this is in agreement with reports 
showing lower concentrations of α-Tocopherol in early lactation (Chappell et al., 1985). However, the 
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decrease noted in citrate over lactation is in contrast to previous studies which have noted an early 
rise in citrate, causing the lowest point of milk pH at around day 21 of lactation (Morriss et al., 1986). 
1H NMR analysis of the polar breast milk fraction provided the most detailed description of the HMO 
profile, and provided the most reproducible data in terms of stability and capturing systematic 
compositional changes over time. 
Although this analysis provides a comprehensive map of breast milk composition, and shows 
systematic changes in breast milk over the course of early lactation, the composition of breast milk is 
complex and subject to the influence of many factors such as time of day, the time during the feed at 
which the sample is collected, time since the last feed and maternal diet. Ideally these factors require 
standardisation to increase confidence in results obtained from future studies, however they are often 
difficult to control.  
In summary, this analysis displays the complementarity of various analytical technologies for 
characterising breast milk composition and identifies the respective strengths and limitations of the 
different analytical techniques. 
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Chapter 3 
The effect of maternal body mass index 
on the concentration of appetite 
regulating hormones present in breast 
milk: a systematic review and in vitro 
analysis 
 
3.1 Introduction 
Early life nutrition is considered a key candidate modulator of feeding behaviour, food intake and 
energy balance throughout life (Cripps et al., 2007). Evidence from a large number of observational 
studies identifies the neonatal period as a critical time for the long-term programming of adult health 
(Lucas, 2005). Meta-analyses indicate that breastfeeding, as opposed to formula feeding, may protect 
against the development of obesity and metabolic syndrome associated conditions in later life (Owen 
et al., 2005, Harder et al., 2005, Arenz et al., 2004), though other research suggests that the association 
between formula feeding and obesity is explained by confounding (Li et al., 2012). Beneficial effects 
have been hypothesised to derive in part from the action of bioactive components in breast milk such 
as hormones (Hamosh, 2001). To date, a number of hormones involved in the regulation of energy 
homeostasis have been identified in breast milk; these include leptin, adiponectin, insulin, ghrelin, 
resistin, obestatin, peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) (Houseknecht et al., 1997, 
Martin et al., 2006, Aydin et al., 2006, Aydin et al., 2008, Savino et al., 2012c, Shehadeh et al., 2003, 
Schueler, 2013, Berseth et al., 1990). In addition to having a direct influence on infant appetite and 
weight gain, these peptides may also promote gut maturation and the development of neuronal 
circuits in the central nervous system that control metabolism. In this respect, hormones in breast 
milk may have long-term metabolic repercussions for the offspring following early life exposure 
(Agostoni, 2005). 
In adults, the circulating concentration of these hormones are linked to an individual’s body weight 
and BMI; leptin is secreted primarily by adipocytes in proportion to the total amount of body adipose 
tissue, and is therefore positively correlated with BMI (Considine et al., 1996), as is resistin (Degawa-
Yamauchi et al., 2003). The concentration of serum insulin also increases with overweight and obesity 
(Lovejoy and DiGirolamo, 1992). In contrast, adiponectin (Coppola et al., 2009), ghrelin (Cummings et 
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al., 2002), obestatin (Lippl et al., 2008) and PYY (Alvarez Bartolome et al., 2002) correlate negatively 
with adiposity and BMI, whilst the association of GLP-1 with BMI is unclear (Madsbad, 2014). Factors 
controlling breast milk hormone concentrations are also unclear. Whilst leptin, ghrelin, insulin and 
adiponectin have been speculated to pass from serum into breast milk (Doneray et al., 2009, Savino 
et al., 2010a, Weyermann et al., 2006, Whitmore et al., 2012), the mammary gland is also capable of 
synthesising various hormones (Smith-Kirwin et al., 1998, Kierson et al., 2006), potentially contributing 
to the quantity of hormone detected; the source of the other hormones investigated remains to be 
established. In this chapter a systematic review of evidence from studies examining the concentration 
of appetite regulating hormones in breast milk and their relation to maternal BMI is reported in 
combination with a laboratory based in vitro analyses of breast milk appetite regulating hormone 
content. This systematic review was published in PLOS ONE, December 2014, Appendix 3A, (Andreas 
et al., 2014), and the in vitro analysis is currently under review at PLOS ONE. 
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3.2 Aims 
 
- Systematically review the literature regarding the influence of maternal BMI on appetite 
regulating hormones present in breast milk.  
 
- Evaluate the influence of maternal BMI on appetite regulating hormones present in breast 
milk using an in vitro multiplex assay. 
 
3.2.1 Hypothesis  
I will test the following null hypothesis; the concentration of appetite regulating hormones in breast 
milk does not correlate with maternal BMI.  
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3.3 Systematic review methods  
3.3.1 Literature search 
A search in PubMed (www.ncbi.nlm.nih.gov) for studies published before 04/09/2014 in English was 
carried out using the following search terms and MEDLINE Medical Subject Headings (MeSH) terms 
(milk, human [MeSH] OR breastmilk OR "breast milk") AND (leptin OR adiponectin OR resistin OR 
insulin OR ghrelin OR adipokine OR adipokines [MeSH] OR insulin [MeSH] OR ghrelin [MeSH] OR 
obestatin OR Peptide YY [MeSH] OR Glucagon-Like Peptide 1 [MeSH]). The literature search was 
conducted by myself, assisted by Dr Matthew Hyde. For inclusion into the systematic review the study 
must have included a report of breast milk concentrations of any of the hormones; leptin, adiponectin, 
insulin, ghrelin, resistin, obestatin, PYY and GLP-1, and their relation to maternal BMI, including pre-, 
in- or post-pregnancy BMI. 
3.3.2 Data Extraction from identified papers 
Relevant studies were identified by evaluating the abstract, or by obtaining a full copy of the article if 
the abstract was not available. Review articles and commentaries were excluded. Reference lists of 
included articles were reviewed by the authors to identify further relevant studies. Data extracted 
included date of publication, number of participants, sample type, sample preparation method, 
measurement technique, time of sample collection post-partum, mean, standard deviation and range 
of maternal BMI, hormone concentration and the correlation coefficient between maternal BMI and 
hormone concentration. Data were independently verified by myself and Dr Matthew Hyde and 
checked by Dr Chris Gale. 
3.3.3 Quality of included studies 
A non-validated but pragmatic score by which to compare and measure the quality of included studies 
was devised. This involved assessing whether the study disclosed the type of sample analysed, e.g. 
fore or hind milk, whether maternal BMI was measured at the time of sample collection, if time of 
sample collection was standardised and whether adjustment was made for confounding factors, and 
if the study used appropriate statistical analysis. Sample preparation was considered appropriate if 
there was a centrifugation or sonication step prior to analysis. We considered that some kind of 
sample preparation was required to get a true reading of the hormone concentration, especially 
leptin. Previous research suggests that either leptin is associated with milk fat globules (Smith-Kirwin 
et al., 1998), meaning samples require sonication in order to liberate leptin, or milk lipids interfere 
with the assays, so centrifugation of samples is required (Lonnerdal and Havel, 2000). Whichever the 
case, sample preparation appears to be needed in order to acquire accurate and reproducible 
readings. Sample size of less than 50 participants was defined as small, 50-100 as medium, and above 
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100 as large. The score was derived by totalling the number of factors the investigators had included 
and adding half a point for whether the study was small, one point for a medium sized study, and 1.5 
points for a large study.  
3.3.4 Analysis of statistical methods used in systematic review  
As the concentration of hormones present in breast milk is non-normally distributed, non-parametric 
statistical analysis, or analysis of log transformed data was considered appropriate. Statistical 
significance was defined as a p value of below 0.05. 
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3.4  Results: Systematic Review  
3.4.1 Literature search  
The literature search is outlined in Figure 29. The search strategy identified 313 publications, with two 
further publications identified from reference lists. Abstracts were screened for suitability; 259 studies 
were unsuitable and excluded as breast milk hormone concentrations were not investigated. The full 
texts of 56 articles were reviewed; 30 studies were excluded after full-text review because they did 
not report the correlation between maternal BMI and breast milk hormone concentration, leaving 26 
articles suitable for inclusion to the systematic review. The publications identified used a range of 
different techniques for quantification of hormone concentration, and reported concentrations over 
a wide range of time throughout lactation (see Tables 9, 10, 11, 12 and 13 for further details). Table 
14 gives an overview of the quality of the studies included. Studies investigating hormone 
concentrations in both colostrum and mature breast milk are evaluated. There was not a large 
difference seen in the concentration of hormone between these samples, however infants ingest 
significantly less colostrum than mature milk, whether there is a different influence of breast milk 
hormones in colostrum compared to mature milk is not known. Infants will ingest significantly greater 
quantities of hormone in mature milk; however, it may be that hormones in colostrum are more 
bioavailable due to gut closure not having completed in colostrum fed infants (Vukavic, 1984).  
 
 
 
 
 
 
 
 
 
  
Records identified through 
database searching n=313 
Records identified through 
other sources n=2 
 
Records screened n=315 
 
Full text articles assessed 
for eligibility n=56 
 
Abstracts excluded n=259 
 
Studies included for 
systematic review n=26 
 
Full text articles excluded 
n=30 
 
Figure 29: Flowchart of the search strategy used in the systematic review. The relevant number 
of papers at each point is provided. 
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3.4.2 Individual study data 
 
3.4.2.1 Leptin 
Fifteen studies included a report of the correlation between breast milk leptin concentration and 
maternal BMI (Bielicki et al., 2004, Bronsky et al., 2006, Bronsky et al., 2011, Dundar et al., 2005b, 
Eilers et al., 2011, Miralles et al., 2006, Ucar et al., 2000, Uysal et al., 2002, Weyermann et al., 2007, 
Houseknecht et al., 1997, Fields and Demerath, 2012, Schuster et al., 2011, Savino et al., 2012c, 
Schueler, 2013, Brunner et al., 2014) (Table 9). In ten studies, a positive correlation between maternal 
BMI and breast milk leptin concentration was reported at all time points (Bronsky et al., 2006, Eilers 
et al., 2011, Fields and Demerath, 2012, Houseknecht et al., 1997, Miralles et al., 2006, Uysal et al., 
2002, Weyermann et al., 2007, Schuster et al., 2011, Schueler, 2013, Brunner et al., 2014). In an 
additional study a positive correlation at 2-3 days post-partum was found, but no correlation at six 
weeks post-partum (Bielicki et al., 2004). In four studies no correlation was found between breast milk 
leptin and maternal BMI at any time point (Bronsky et al., 2011, Dundar et al., 2005b, Ucar et al., 2000, 
Savino et al., 2012c). In one study no correlation was identified between maternal BMI and colostrum 
leptin concentration (Bronsky et al., 2011). In four studies a positive correlation was identified in the 
first two weeks of lactation between maternal BMI and breast milk leptin concentration (Bielicki et al., 
2004, Bronsky et al., 2006, Eilers et al., 2011, Schuster et al., 2011), whilst in one study there was no 
correlation at 15 days post-partum (Dundar et al., 2005b). In five studies no correlation was found at 
1-3 months post-partum (Dundar et al., 2005b, Bielicki et al., 2004, Ucar et al., 2000, Bronsky et al., 
2011, Savino et al., 2012c), whilst in six studies a positive correlation was reported over the same 
period (Eilers et al., 2011, Fields and Demerath, 2012, Miralles et al., 2006, Weyermann et al., 2007, 
Uysal et al., 2002, Schueler, 2013). In two studies a positive correlation was found up to six months 
post-partum (Schuster et al., 2011, Brunner et al., 2014), whilst in a further study leptin concentrations 
were positively correlated with maternal BMI throughout the lactation period, up to nine months post-
partum (Miralles et al., 2006). In one study no correlation was found at 12 months of lactation 
(Bronsky et al., 2011). One study did not specify at which point samples were collected post-partum, 
but identified a positive correlation (Houseknecht et al., 1997). A negative correlation between 
maternal BMI and breast milk leptin concentration was not reported by any study (Table 10).  
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Table 9: Studies examining the association between breast milk leptin concentrations and maternal BMI. AGA: Appropriate for gestational age; EDTA: 
Ethylenediaminetetraacetic acid; ELISA: Enzyme-linked immunosorbent assay; IQR: Interquartile range; LGA: Large for gestational age; N/A: Not available; 
RIA: Radioimmunoassay; SGA: Small for gestational age. Data are given as means and standard deviations unless stated otherwise. 
 
Author, 
Year 
Maternal 
n 
number 
Sample Type, 
Preparation and  
Analysis, Protease 
inhibitor used  
 
Time of day, 
fasted/fed 
Maternal BMI 
(kg/m2) 
Timing of Collection 
(day/week/month) 
Breast milk Leptin (ng/ml) Statistical Analysis 
Housekne
cht, 1997 
14 
Complete breast 
expression. Skimmed 
and sonicated whole 
milk samples 
prepared. RIA. No 
protease inhibitor. 
08:00am   
post-prandial  
Not disclosed N/A 
Whole milk       Skimmed Milk   
10.1±2.6               1.5±0.9 
Positive correlation seen with: 
Whole milk: r=0.5, p<0.06 
Skimmed Milk: r=0.66, p<0.001 
 
 
Ucar, 2000 
 
18 
Foremilk and 
hindmilk. Skimmed. 
RIA. No protease 
inhibitor. 
Not disclosed 
25.9±0.74   
Time not reported 
40 days post-partum 3.36±11.0 
No correlation between breast 
milk leptin and maternal 
adiposity. Pearson’s correlation 
using log transformed values 
Uysal, 
2002  
50 
Foremilk. Analysis of 
Skimmed milk by RIA, 
No protease 
inhibitor. 
08:00-
11:00am    
Not disclosed 
BMI at sample 
collection  
25.9±4.4 
3 months post-partum 
Mothers of:  
Obese infants          Lean infants   
0.27±0.2                0.37±0.4     
Leptin concentrations were 
correlated with maternal BMI; 
r=0.62, p<0.001 using 
Spearman correlation 
Bielicki, 
2004 
33 
Foremilk. Sonicated. 
RIA. No protease 
inhibitor. 
Not disclosed. 
Fed 
BMI at sample 
collection             
25.1±0.8 
- 
23.6±0.85 
2-3 days post-partum       
4-5 days post-partum        
6 weeks post-partum 
1.15±0.12 
0.79±0.10 
- 
Linear regression of log values. 
Correlation with maternal BMI:   
2-3 days: r2 =0.15, p=0.02.          
No correlation found at 6 weeks 
Dundar, 
2005 
AGA=22 
LGA=14 
SGA=11 
Foremilk. Sonicated, 
RIA, No protease 
inhibitor. 
10:00-
11:00am Not 
disclosed. 
23.8±0.77 
Time not reported 
 
15 days post-partum  
1 month post-partum 
2 months post-partum 
3 months post-partum 
AGA         SGA          LGA         
13.4±2.2    28.5±4.4    18.2±2.0 
17.0±3.4    15.5±4.9    19.4±1.7 
11.4±2.3    15.1±2.7    18.3±2.4 
9.1±1.8     17.4±3.4    11.8±1.8 
No relation between breast 
milk leptin and BMI.   
Pearson’s correlation 
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Table 9 
(continued) 
    
 
  
  
Bronsky, 
2006 
59 
Hindmilk, skimmed. 
ELISA, EDTA tubes 
and protease 
inhibitor 
7:00 am 
Not disclosed 
Pre-pregnancy             
21.4±(0.4)   
Time of delivery 
26.8±(0.4) 
48 hours post lactation 0.5±0.05 
Correlation with:  
Pre-pregnancy BMI: r=0.397, 
p=0.003  
BMI at delivery: r=0.498, 
p<0.0001 
Miralles, 
2006 
28 
Hindmilk. Whole 
milk. ELISA No 
protease inhibitor. 
Morning,  
Not disclosed 
Pre-pregnancy 
21.6±0.5 
Range     
   16.3-27.3 
1±3 days post-partum     
3 months post-partum    
6 months post-partum    
9 months ± 1 week 
1 month: 0.156±0.039 
Maternal BMI positively 
correlated with milk leptin 
concentration at each time 
point; r=0.387, p<0.01. Stronger 
association found when 
concentrations were log 
transformed (r=0.607).  
Pearson’s correlation 
Weyerma
nn, 2007 
651 
Foremilk. Analysis of 
skimmed milk 
samples by ELISA No 
protease inhibitor. 
Not disclosed 
Pre-pregnancy  
23.6±4.0 (16.7–
45.7) 
33-71 days post-
partum 
Median (Range):  0.175 (0-4.12) 
Leptin concentrations were 
strongly associated with pre-
pregnancy BMI 
BMI <20:                 0.122±0.129 
BMI 20-24.9:          0.234±0.264 
BMI 25-29.9:          0.388±0.335 
BMI > 30:                0.807±0.885 
Bronsky, 
2011 
72 
Hindmilk, skimmed. 
ELISA. EDTA tubes 
and protease 
inhibitor. 
Not disclosed 
Pre- pregnancy  
21.9±0.4 
0 day post lactation 0.3±0.04 
No correlation throughout the 
lactation period between pre-
pregnancy BMI and leptin using 
Spearman’s correlation 
1 month  0.2±0.03 
3 months  0.1±0.01 
6 months  0.1±0.02 
12 months  0.2±0.04 
Eilers, 
2011 
 
Term=40 
Preterm=
37 
  
Type of milk not 
specified. Skimmed 
milk. RIA. No 
protease inhibitor. 
16:00- 20:00  
‘No big meals’ 
Pre-pregnancy 
23±3.5 
 
Day 3 lactation       
Day 28 lactation 
  
          Preterm          Term                         
       0.70±0.79     0.65±0.67 
       0.50±0.40     0.50±0.40 
  
Spearman’s correlation with 
pre-pregnancy BMI: 
Term: Day 3: r=0.28, p<0.01; 
Day 28: 0.45, p<0.0001. 
Preterm: Day 3: r=0.40, 
p=0.016; 
Day 28: r=0.56, p<0.01. 
Mothers with BMI >25 had 
higher leptin concentrations 
compared to those with a BMI 
<25, p<0.01 
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Table 9 
(continued) 
  
 
  
 
      
Schuster 
2011 
23 
Sample sonicated 
and then skimmed. 
RIA. No protease 
inhibitor. 
Not disclosed 
Pre-pregnancy 
21.4±2.6 
Median (IQR)  
20.9 (19.3-22.6) 
 
1 week post-partum         
6 months post-partum 
 
 
0.21±0.19                                  
0.18±0.15 
 
Leptin concentration correlated 
with maternal BMI; r=0.298, 
p<0.001. Pre-pregnancy BMI did 
not correlate with leptin 
concentration,  Spearman’s 
correlation 
Fields, 
2012 
 
19 
Complete breast 
expression. 
Skimmed. 
Immunoassay. No 
protease inhibitor. 
8:00 -
10:00am. 
Fasted 2h 
Pre-pregnancy 
26.6±6.6 
40±4 days post-partum 0.092±0.05 
Positive Spearman’s correlation 
between pre-pregnancy BMI 
and leptin concentration; 
r=0.78, p<0.0001 
Savino, 
2012 
23 
Sample sonicated 
and then skimmed. 
RIA. No protease 
inhibitor. 
Not disclosed 
Median (IQR)  
27.4 (4.9)  
Time not reported 
87±40 days post-
partum 
   Median (IQR):                           
2.34 (5.73) 
No correlation between 
maternal anthropometric 
parameters and leptin using 
Spearman’s correlation 
Schueler, 
2013 
13 
Foremilk and 
hindmilk. Skimmed. 
RIA. No protease 
inhibitor used. 
07:00-
10:00am, 
fasted 10h 
BMI at sample 
collection  
25.9±4.23  
Range 
20.35-32.9 
4-5 weeks post-partum 
1.0±0.7                                     
Range 0.2-2.6 
 
Leptin concentrations were 
positively correlated with 
maternal BMI, r=0.82, p=0.001. 
Pearson correlation 
Brunner, 
2014 
6 weeks 
152  
 
4 months 
120 
Complete breast 
expression. 
Sonicated then 
skimmed. RIA. No 
protease inhibitor 
used. 
After 
overnight fast 
Pre- and during 
pregnancy BMI.  
Values not 
reported 
 
6 weeks post-partum 
4 months post-partum 
Median (IQR)                                              
0.11 (0.19)                                 
0.09 (0.18) 
A strong positive correlation 
was observed between milk 
leptin and maternal pre-
pregnancy BMI, 15wk and 32nd 
wk gestation BMI, r=0.49, 052 
and 0.57 respectively, p=<0.001 
for all, at both time points, (6 
week correlations shown). 
Spearman correlation 
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Table 10: Summary of findings of studies investigating leptin concentrations in breast milk. Boxes with pluses indicate the study found a positive correlation 
between breast milk leptin concentration and maternal BMI at this time point. Boxes with zeroes indicate the study found no correlation at this point. NR=Not 
reported, bold print indicates p value of <0.05. 
  ~1 day ~2 days ~1 week ~2 weeks ~3 weeks ~4 Weeks ~6 weeks ~2 months ~3 months ~6 months ~9 months ~12 months 
Ucar 
2000 
            
0  
NR 
          
Uysal 
2002 
                
+ 
r=0.62, 
p<0.001 
      
Bielicki 
2004 
  
+ 
r2 =0.15, 
p=0.02 
+ 
NR 
      
0  
NR 
          
Brunner 
2014 
      
+ 
r=0.57 
p=<0.001 
 
+ 
r=~0.57 
p=<0.001 
   
Dundar 
2005 
      
0  
NR 
  
0  
NR 
  
0  
NR 
0  
NR 
      
Bronsky 
2006 
  
+ 
r=0.498, 
p<0.0001 
                    
Miralles 
2006 
          
+ 
 r=0.387, 
p<0.01 
    
+ 
 r=0.387, 
p<0.01 
+  
r=0.387, 
p<0.01 
+  
r=0.387, 
p<0.01 
  
Weyermann 
2007 
            
+ 
NR 
          
Eilers 
2011 
  
+ 
r=0.28, 
p<0.01 
      
+ 
0.45, 
p<0.0001 
            
Bronsky 
2011 
0  
NR 
        
0  
NR 
    
0  
NR 
0  
NR 
  
0  
NR 
Schuster  
2011 
    
+ 
r=0.298, 
p<0.001 
+  
r=0.298, 
p<0.001 
+  
r=0.298, 
p<0.001 
+  
r=0.298, 
p<0.001 
  
+  
r=0.298, 
p<0.001 
+ 
r=0.298, 
p<0.001 
+  
r=0.298, 
p<0.001 
    
Fields 
2012 
          
+  
r=0.78, 
p<0.0001 
            
Savino 
2012 
                
0 
NR 
      
Schueler 
2013 
          
+ 
r = 0.82,   
 p = 0.001 
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3.4.2.2 Adiponectin 
Nine studies include a report of the concentration of adiponectin in breast milk and its association to 
maternal BMI (Dundar et al., 2010, Ley et al., 2012, Luoto et al., 2012, Luoto et al., 2011, Martin et al., 
2006, Weyermann et al., 2007, Woo et al., 2009, Bronsky et al., 2011, Brunner et al., 2014) (Table 11). 
Two studies report a positive correlation between breast milk adiponectin and maternal BMI (Martin 
et al., 2006, Woo et al., 2009). Woo et al (Woo et al., 2009) found a positive correlation between 
maternal BMI and breast milk adiponectin concentration. Samples were collected longitudinally, and 
due to a decrease in concentrations of adiponectin in samples collected later on in lactation, 
adjustment was made for post-partum month and month of the year, after which no correlation was 
observed. Martin et al (Martin et al., 2006) also reported a positive association between maternal BMI 
and breast milk adiponectin concentration. In seven studies, no correlation between maternal 
anthropometric measurements and milk adiponectin was found (Dundar et al., 2010, Luoto et al., 
2011, Weyermann et al., 2007, Luoto et al., 2012, Ley et al., 2012, Bronsky et al., 2011, Brunner et al., 
2014). Many of the studies that found no correlation analysed colostrum rather than mature breast 
milk. Of the studies in which no correlation was found, six involved the analysis of  colostrum (Bronsky 
et al., 2006, Dundar et al., 2010, Luoto et al., 2011, Luoto et al., 2012, Ley et al., 2012, Bronsky et al., 
2011); in three studies samples were collected at 1-4 months post-partum (Weyermann et al., 2007, 
Ley et al., 2012, Brunner et al., 2014), and in one study samples were collected up to 12 months post-
partum (Bronsky et al., 2011).  
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Table 11: Studies examining the association between breast milk adiponectin concentrations and maternal BMI. EDTA: Ethylenediaminetetraacetic acid; 
ELISA: Enzyme-linked immunosorbent assay; IQR: Interquartile range; RIA: radioimmunoassay, SEE: Standard Error of the Estimate. Data are given as means and 
standard deviations unless stated otherwise. 
Author, 
Year 
Materna
l n 
Number 
Sample Type, 
Preparation and  
Analysis, Protease 
inhibitor used 
Time of 
day, 
fasted/fe
d 
Maternal BMI 
(kg/m2) 
Timing of Collection 
(day/week/month) 
Breast milk Adiponectin 
(ng/ml) 
Statistical Analysis 
Martin, 
2006  
22 
Whole breast 
expression Skimmed. 
RIA. No protease 
inhibitor 
Not 
disclosed 
Taken at sample 
collection 
24.5        
(19.5–34.2) 
 
2-242 days post-partum 
Median (Range):                           
17.7 (4.2–87.9) 
 
Maternal post-pregnancy BMI was 
associated with natural log(milk 
adiponectin), β=0.08±0.02, 
P<0.0001. This equates to an 8.33% 
increase in milk adiponectin 
concentration with each unit 
increase in maternal BMI 
Weyerm
ann, 
2007 
651 
Foremilk. Analysis of 
skimmed milk 
samples by ELISA No 
protease inhibitor 
Not 
disclosed 
Pre-pregnancy 
23.6±4.0  
(16.7–45.7) 
33-71 days post-partum 
Median (Range):10.9 (0.8-
110) 
Maternal pre-pregnancy BMI 
showed no clear association with 
adiponectin concentrations 
BMI <20:              12.8±9.7 
BMI 20-24.9:       
12.8±10.4 
BMI 25-29.9:       11.8±9.1 
BMI > 30:             
14.8±12.1 
 
Woo, 
2009 
 
45 
Complete breast 
expression. Skimmed. 
RIA. No protease 
inhibitor 
10:00 
13:00 
Not 
disclosed 
1 month post-
partum 
25.4±3.5 
 
1 week post-partum      
2 weeks post-partum    
3 weeks post-partum  
Then monthly 
25.6±8.4 
Milk adiponectin was log 
transformed and positively 
associated with maternal BMI 
(0.67±0.30ng/ml increase in milk 
adiponectin per BMI unit, p=0.02), 
effect not seen after adjusting for 
month or month2 (p=0.11) 
Dundar, 
2010 
25 
Whole milk collected 
following an 
overnight fast. RIA No 
protease inhibitor. 
08:00-
10:00  
Not 
disclosed 
 
Pre-pregnancy  
23.1±0.8 1 day post-partum 
 
29.5±6.4 
Range: 1.26–77.1   
 
No association between adiponectin 
concentrations and maternal 
anthropometric measurements 
using Spearman’s correlation 
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Table 11 (cont.) 
Bronsky, 
2011 
72 
Hindmilk. Whole milk, 
ELISA, EDTA tubes and 
protease inhibitor 
Not 
disclosed 
 0 day post-lactation 22.8±0.8 
No correlation using Spearman’s 
correlation between maternal pre-
pregnancy BMI and adiponectin 
 1 month post-partum 22.0±0.6 
Pre- pregnancy  3 months post- partum 20.5±0.6 
21.9±0.4 6 months post- partum 21.4±0.8 
 12 months post- partum 25.7±1.4 
Luoto, 
2011  
 
181 
Type of sample and 
preparation not 
reported. Colostrum 
samples analysed by 
dissociation enhanced 
lanthanide fluoro-
immunoassay. No 
protease inhibitor 
Not 
disclosed 
Pre-pregnancy 
23.8±3.7 
0-3 days post-partum  
 
Median (Range):                        
18.4 (2.9–317.0) 
Pre-pregnancy BMI did not correlate 
with adiponectin concentration in 
colostrum (r=0.023, p=0.760). Log 
values 
Luoto, 
2011  
 
30 
Type of sample and 
preparation not 
reported. Colostrum 
samples analysed by 
dissociation enhanced 
lanthanide fluoro-
immunoassay. No 
protease inhibitor 
Not 
disclosed 
Pre-pregnancy 
23            
Range  (18.40–28.37) 
1-3 days post-partum 
Median (Range):                          
10.5 (3.1–98.9) 
 
Regression analysis revealed no 
correlation between colostrum 
adiponectin concentration and pre-
pregnancy maternal BMI 
Ley, 
2012 
170 
Foremilk. Skimmed. 
RIA No protease 
inhibitor 
Not 
disclosed 
 
 
 
 
Median (IQR) 
Pre-pregnancy BMI was not 
associated with adiponectin 
concentration in early or mature 
milk. General linear model, 
β±SEE=0.003±0.014, p=0.81, in first 
week post-partum 
Pre-pregnancy  2 days post-partum 50.0 (21.9/104.6) 
24.4±2.9 95 days post-partum 12.3 (9.9/17.2) 
Brunner, 
2014 
 
6 weeks 
151 
Complete breast 
expression. Sonicated 
then skimmed. RIA. 
No protease inhibitor 
After 
overnight 
fast 
Pre- and during 
pregnancy BMI. 
Values not reported 
 
6 weeks post-partum 
4 months post-partum 
 
Median, (IQR)                                
10.93, (8.34)  
10.36, (9.40) 
  
Using Spearman correlation, no 
correlation was observed between 
total milk adiponectin and maternal 
BMI, at either time point measured 
 4 month 
120 
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3.4.2.3 Insulin 
Four studies were identified in which the concentration of insulin in breast milk was measured, and 
the association with maternal BMI reported (Table 12). In two studies a positive correlation was 
reported; in two further studies no correlation was reported. Shehadeh et al (Shehadeh et al., 2003) 
found no correlation on day three or day ten post-partum. Fields et al (Fields and Demerath, 2012) 
found no correlation at one month post-partum. Ahuja et al (Ahuja S, 2011) reported a positive 
correlation at six weeks post-partum whilst Ley et al reported a positive correlation between maternal 
BMI and breast milk insulin at three months post-partum, but not during the first week post-partum 
(Ley et al., 2012). 
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Table 12: Studies examining the association between breast milk insulin concentrations and maternal BMI. ELISA: Enzyme-linked immunosorbent assay; 
post-partum: post-partum; IQR: Interquartile range; RIA: radioimmunoassay; SEE: Standard Error of the Estimate. Data are given as means and standard 
deviations unless stated otherwise. 
Author, 
Year 
Maternal 
n Number 
Sample Type, 
Preparation and  
Analysis Protease 
inhibitor used 
Time of day, 
fasted/fed 
Timing of Collection 
(day/week/month) 
Maternal BMI 
(kg/m2) 
Breast milk Insulin (µIU/ml) 
 
Statistical Analysis 
Shehadeh, 
2003 
90 
Milk type not reported. 
Skimmed. RIA. No 
protease inhibitor 
Not disclosed 3 days and 10 days 
post-partum 
  
23.7±5       
 Time not 
reported 
             Day 3           Day 10               
                50.1±34.6     41.1±28.5 
Median     41.0               34.0                            
Range       7-179            12-183                   
 
Insulin concentrations were 
not significantly influenced 
by BMI on day 3 or day 10 
post-partum. Spearman’s 
correlation  
Ahuja, 
2011 
  
32 
Complete breast 
expression, whole milk 
analysed by ELISA. No 
protease inhibitor 
09:00-11:00 
Not disclosed 
6 weeks post-partum 
Pre-pregnancy 
Non obese     
21.8±2.34  
Range  
18.5-24.7 
Obese       
  32.2±3.82  
Range  
26.4-40.2 
   Non-obese  Overweight/obese 
      4.5±7.6        30.1±56.3 
  
There was a positive 
correlation between insulin 
concentration and maternal 
pre-pregnancy BMI (r=0.57, 
p<0.001). Pearson’s 
correlation, non-logged 
values  
Fields,2012 19 
Complete breast 
expression. Skimmed. 
Immunoassay. No 
protease inhibitor 
8:00 -
10:00am. 
Fasted 2h 
40±4 days post-partum 
Pre-pregnancy 
26.6±6.6 
23.6±18.01 
Insulin concentrations were 
not correlated with 
maternal BMI. Spearman’s 
correlation. 
 
 
Ley, 2012 
 
170 
Foremilk. Skimmed.  
Electrochemilum-
inescence immunoassay. 
No protease inhibitor 
Not disclosed 
 
2 days post-partum      
3 months post-partum 
  
Pre-pregnancy 
24.4±2.9 
Median (IQR)                             
24.5 (9.2/57.9)                             
7.5 (4.9/12.5) 
Higher pre-pregnancy BMI 
was associated with higher 
[insulin] in mature milk after 
adjustment for maternal 
age, ethnicity and time post-
partum (β±SEE: 0.053 
±0.014; p=0.0003) at 3 
months, but not in the first 
week post-partum (β±SEE: -
0.002±0.02; p=0.91). 
General linear model 
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3.4.2.4 Ghrelin 
Aydin and colleagues conducted all three studies identified in which the association between maternal 
BMI and breast milk ghrelin concentration was assessed (Aydin, 2010, Aydin et al., 2007, Aydin et al., 
2006). A correlation was not reported in any of these studies (Table 13). In two studies, samples were 
collected at similar time points during the first two weeks post-partum (Aydin et al., 2006, Aydin et 
al., 2007); whilst the third neglected to state the time point post-partum in which samples were 
collected (Aydin, 2010). 
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Table 13: Studies examining the association between breast milk ghrelin concentrations and maternal BMI. ELISA: Enzyme-linked immunosorbent assay; 
GDM: Gestational Diabetes; HPLC: High Performance Liquid Chromatography; P-GDM: Pre-Gestational Diabetes; PP: post-partum; RIA: radioimmunoassay 
Data are given as means and standard deviations unless stated otherwise. 
Author, 
Year 
Maternal n 
Number 
Sample Type, 
Preparation 
and  Analysis 
Protease 
inhibitor used 
Time of 
day, 
fasted/fed 
Maternal BMI 
(kg/m2) 
Timing of Collection 
(day/week/month) 
Breast milk Ghrelin (pg/ml) Statistical Analysis 
Aydin, 
2006 
 
Total study=17 
BMI analyses, 
number not 
stated “only a few 
participants 
examined” 
Foremilk. 
Skimmed. RIA, 
no protease 
inhibitor. 
Not 
disclosed 
28.98±1.35 
Time not reported 
 
1 day post-partum  
7 days post-partum 
15 days post-partum 
 
 
Colostrum                          73±18 
Transitional milk               84±18 
Mature milk                       97±13 
 
Spearman’s 
correlation between 
milk ghrelin 
concentrations and 
BMI r=0.42, p=0.19 
Aydin,  
2007 
  
  
  
  
29 
 
Foremilk. 
Skimmed. RIA 
and HPLC 
analysis, no 
protease 
inhibitor. 
Morning, 
overnight 
fast 
 Post-partum  
29.6±1.9 
 
2 days post-partum    
15 days post-partum 
 
RIA               2 days PP      15 days PP 
No correlation 
observed between 
ghrelin 
concentrations and 
post-partum 
maternal BMI 
Control      64.1                55.5 
GDM          26.1                54.1 
P-GDM      28.5                32.1 
HPLC analysis 
     Active                           23±6 
     Non-active                  548±12 
 Total                         571±128 
Aydin,  
2010 
  
  
  
20 
Type of milk not 
reported. No 
sample 
preparation. 
ELISA. Protease 
inhibitor added 
Not 
disclosed 
36.3±3.2                    
Time not reported 
 
Colostrum and 
mature milk  
       Colostrum 
Spearman’s 
correlation between 
fasting milk ghrelin 
concentrations and 
BMI was not 
significant r=0.46, 
p=0.6 
                Active        Non-active 
     Control   39.2±2       466.1±52 
     GDM       27.7±2       338.1±49 
          Mature Milk 
                    Active            Non-active 
     Control  48.2±5.1       505.1±52 
 GDM        27.7±2         359.1±51.2 
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3.4.2.5 Resistin 
A single paper by Savino et al in 2012 examined the association between maternal BMI and breast 
milk concentration of resistin. The median time of collection was 80 days post-partum. Median breast 
milk resistin concentrations reported were 0.18ng/ml, with an interquartile range of 0.44. The author 
reported there was no correlation between breast milk resistin concentration and maternal 
anthropometric measurements (Savino et al., 2012c). 
3.4.2.6 Obestatin 
No studies were identified in which the association between maternal BMI and breast milk obestatin 
concentration was examined. 
3.4.2.7 Peptide YY 
The association between breast milk concentration of peptide YY and maternal BMI was evaluated in 
a single paper by Schueler et al (Schueler, 2013), the researchers also investigated breast milk leptin 
concentrations, and the study design is outlined in Table 9. Protease inhibitors were added to the 
aliquot used for peptide YY analysis. The researchers analysed peptide YY in both fore and hind milk, 
the average concentration in fore milk was 39.5±8.4pg/ml (mean and standard deviation), whilst the 
hind milk concentration was 38.9±9.1pg/ml at 4-5 weeks post-partum, as analysed by RIA. The authors 
reported that there was no correlation between maternal BMI and milk peptide YY. 
3.4.2.8 Glucagon-like peptide 1 
Concentrations of GLP-1 in breast milk were again investigated by Schueler et al (Schueler, 2013), in 
the only study identified to do so. The study design is outlined in Table 9; protease inhibitor was used 
to preserve samples. In fore milk, the concentration of GLP-1 was 12.7±3.1pM, whilst in hind milk it 
was 15.4±3.1pM (mean±SD). Milk GLP-1 was analysed using RIA for total GLP-1. The authors reported 
no correlation between maternal BMI and milk GLP-1. 
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Table 14: Table assessing the quality of studies included into the systematic review. The scoring system is outlined in Section 3.3.3. 
 
Leptin 
Stated 
what 
kind of 
milk 
Measured 
BMI at 
time of 
sample 
collection 
Standardised 
time post-
partum of 
sample 
collection 
Standardised 
time of 
sample 
collection 
Adjusted for 
confounders 
Appropriate 
Statistical 
analysis 
Appropriate 
sample 
preparation 
Small 
medium 
or large 
study 
Score 
Positive/ 
negative/no 
correlation 
Houseknecht, 1997   X  X X  Small  4.5 Positive 
Ucar, 2000   X  X  X Small  4.5 No correlation 
Uysal, 2002   X  X   Medium 6 Positive 
Bielicki, 2004     X   Small  6.5 Positive then none 
Dundar, 2005  Not stated   X X  Small  4.5 No correlation 
Bronsky, 2006  X   X   Medium 6 Positive 
Miralles, 2006     X   Small  6.5 Positive 
Weyermann, 2007  X X Not stated    Large 5 Positive 
Bronsky, 2011  X   X   Medium 6 No correlation 
Eilers, 2011 X X   X   Medium 5 Positive 
Schuster 2011 X   X X   Small  4.5 Positive 
Fields, 2012  X   X   Small  5.5 Positive 
Savino, 2012 X Not stated X  X   Small  3.5 No correlation 
Schueler, 2013     X X  Small  5.5 Positive 
Brunner, 2014  X   X   Large 6.5 Positive 
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Table 14 (continued)          
Adiponectin             
Martin, 2006  X  X  X   Small  4.5 Positive 
Weyermann, 2007  X X Not stated    Large 5 No correlation 
Woo, 2009        Small  7.5 
Positive, none after 
adjustment 
Dundar, 2010 X X   X  X Small  3.5 No correlation 
Bronsky, 2011  X   X   Medium 6 No correlation 
Luoto, 2011 X   Not stated X   Large 5 No correlation 
Luoto, 2011 X X  Not stated X   Small  3.5 No correlation 
Ley, 2012  X  Not stated X   Large 5 No correlation 
Brunner, 2014  X   X   Large 6.5 No correlation 
 
Insulin          
   
Shehadeh, 2003 X Not stated  Not stated X   Medium 4 No correlation 
Ahuja, 2011  X   X  X Small  4.5 Positive 
Fields, 2012  X   X   Small  5.5 No correlation 
Ley, 2012  X  Not stated X   Large 5 No correlation then 
Positive 
Ghrelin              
Aydin, 2006  Not stated   X   Small  5.5 Not significant 
Aydin, 2007  X   X Not stated  Small  4.5 No correlation 
Aydin, 2010 X Not stated Not stated Not stated X Not stated  Small  1.5 Not significant 
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3.5 Multiplex assay of hormone concentrations 
Breast milk samples, collected from participants in the prospective cohort study outlined in Section 
2.2, Chapter 2, were analysed using a multiplex assay to determine the concentration of leptin, insulin, 
ghrelin and resistin, as described in Section 2.6, Chapter 2. 
3.5.1 Results: Cohort characteristics   
Descriptive statistics of the mothers whose samples were analysed using the multiplex array are 
shown in Table 15. The average maternal age was 34, with a range from 23 to 46 years old, and an 
average height of 166cm. An attempt was made to recruit approximately equal numbers of 
participants into the high and low booking BMI groups. However, this proved difficult due to the 
relatively healthy maternity population served at Chelsea and Westminster hospital. Of the mothers 
recruited, at booking, 3% were underweight (4), 73% of normal weight (87), 19% overweight (23) and 
5% obese (6). 
Table 15: Descriptive characteristics of maternal cohort at one week and three months post-partum 
time points.  Data reported are means and standard deviations. 
 One week post-partum Three months post-partum 
Number 105 92 
Weight, kg 70.3 (12.7) 66.5 (11.3) 
BMI 25.4 (4.5) 23.9 (3.6) 
 
The majority of mothers lost weight from the seven day to three month time point, resulting in a drop 
in the average BMI value of mothers at three months post-partum. In addition to this, there was drop 
out of several mothers from the study. In total, 25 mothers withdrew from the study, the reasons of 
which are outlined in Table 16. 
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Table 16: Reasons given for mothers withdrawing from the study at the one week and three month 
post-partum time points. 
Reasons for withdrawal 
 1 Week 
Number % Reasons for 
withdrawal  
3 months 
Number % 
Stopped breastfeeding 2 17 Stopped breastfeeding 10 77 
Maternal illness 1 8 Maternal illness 1 7 
Infant illness 1 8 Infant illness 1 7 
Unable to contact 
mother 
2 17 No longer wished to 
participate 
1 7 
No longer wished to 
participate 
4 33 Total 13 100 
Research midwife illness 1 8    
Recruited in error 1 8    
Total  12 100    
 
The majority of women withdrew from the study at the one week time point due to no longer wishing 
to participate in the study, whilst at three months, the majority of women withdrew as they had 
stopped breast feeding. An analysis of the population who withdrew at three months revealed that 
these mothers were more likely to be overweight/obese than mothers who did not withdraw. Of the 
normal weight mothers 15% withdrew (74/87), whilst of the overweight mothers 25% withdrew 
(18/24) and 66% of obese mothers withdrew from the study (4/6). These findings reflect previous 
literature showing overweight/obese mothers have more difficulty initiating and maintaining 
breastfeeding (Lepe et al., 2011). 
Of the mothers who were overweight or obese, 46% of women delivered via caesarean section, whilst 
in the normal weight mothers, this figure was 27%. This puts overweight/obese women at a further 
disadvantage in successfully initiating early breastfeeding, as demonstrated by a systematic review 
and meta-analysis, where a negative association between caesarean section and early breastfeeding 
was observed (Prior et al., 2012). Mothers who withdrew were also less likely to be university 
educated, Pearson Chi-square=4.4, p value 0.03. 
3.5.2 Sample analysis 
Samples were analysed in a randomised run order, prepared into 96 well plates (Bio-Rad, USA). A total 
of 388 samples were analysed, after removal of duplications, and samples which had not analysed 
correctly, a total of 373 samples were available for further statistical analysis, as well as 3 formula milk 
samples analysed in singlicate for comparison. 
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Both fore and hind breast milk samples were collected from mothers at 7 days and 3 months post-
partum, as outlined in Section 2.2.7, Chapter 2. The number of samples analysed are given in Table 
17. 
Table 17: Number of each type of sample analysed in the hormone assay. 
 
 
 
3.5.3 Breast milk hormone concentrations 
Concentrations of ghrelin, insulin, leptin and resistin in breast milk were measured simultaneously as 
outlined in Section 2.6, Chapter 2. The median concentration of these hormones are given in Table 
18. 
Table 18: Summary statistics for breast milk hormone concentrations. P value derived using 
repeated measure ANOVA. * refers to results below the 0.05 significance level. 
Type of milk Stage of lactation: Mean (SE) [n] 
1 week 3 Months P value 
Ghrelin ng/ml 
Fore 123.0 (15.8) [96] 101.1 (11.5) [83] 0.17 
Hind 95.8 (16.9) [81] 59.34 (12.3) [66]  0.03* 
P value 0.09 0.01*  
Insulin ng/ml 
Fore 515.4 (42.4) [105] 524.8 (30.9) [92] 0.83 
Hind 439.5 (45.2) [91] 456.8 (32.9) [81] 0.70 
P value 0.08 0.13  
Leptin ng/ml 
Fore 541.7 (161.2) [105] 684.8 (117.4) [92] 0.38 
Hind 614.4 (172.1) [91] 464.3 (125.1) [81] 0.38 
P value 0.65 0.20  
Resistin ng/ml 
Fore 924.9 (295.9) [105] 792.5 (224.4) [92] 0.65 
Hind 967.4 (317.0) [91] 733.9 (238.9) [81] 0.46 
P value 0.89 0.85  
   
For ghrelin, 48 samples were below the limit of detection, whilst three, one and four samples were 
below the limit of detection for insulin, leptin and resistin, respectively. Concentrations of the 
hormones were non-normally distributed, as displayed in Figure 30. 
 One week Three months Total 
Number fore milk  105 92 197 
Number hind milk 91 81 172 
Total 196 173 369 
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Several associations between the hormone concentrations and the time samples were collected could 
be observed. There was a significant decrease in the concentration of ghrelin in the hind milk samples 
collected at three months post-partum, similarly, there appeared to be a trend in the same direction 
in samples collected at one week post-partum, but this did not reach significance. Furthermore, there 
appeared to be a decrease in concentration of ghrelin in the samples collected at three months post-
partum in comparison to samples collected at one week post-partum, but this was only significant for 
the hind milk samples collected. 
There were no significant associations observed between the insulin concentrations of breast milk in 
regard to time of sample collection. However, there did appear to be a trend towards reduced insulin 
concentration in hind milk samples in comparison to fore milk at both time points. 
There did not appear to be any relationship between time of sample collection and concentrations of 
either leptin or resistin. Due to data being non-normally distributed, data were log transformed to 
make the distribution more normal, as shown in Figure 31. Further statistical tests were performed 
on the log transformed data. 
D 
A B 
C 
Figure 30: Histograms displaying the distribution of data of breast milk hormone concentrations, at 
all time points post-partum, in ng/ml (A) ghrelin (B) insulin, (C) leptin, 6 samples lay above the range 
displayed, up to 16000 ng/ml, and were not plotted for display purposes. (D) resistin, 32 samples are 
not shown as they lay outside of the plotted range, up to 16000 ng/ml. 
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3.5.4 Correlation between breast milk hormone concentration and maternal BMI 
The log transformed data values were correlated against maternal BMI at each time point, splitting 
samples into fore and hind subgroups. Two-tailed Pearson correlations of maternal BMI against 
hormone concentration were computed, as shown in Table 19. One mother was excluded from further 
analysis as her BMI was extremely high in comparison to the rest of the cohort (52.5kg/m2), skewing 
the results obtained, Appendix 3B displays a scatter plot demonstrating this. 
 
Figure 31: Histogram (A), (B), (C) and (D) display the distribution of data of natural log transformed 
ghrelin, insulin, leptin and insulin respectively of breast milk samples, at all time points post-partum. 
D 
A B 
C 
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Table 19: Correlation between fore and hind milk samples taken at one week and 3 months post-
partum against maternal BMI. *Results below the 0.05 significance level. 
Fore milk Maternal BMI at 7 days Ln ghrelin Ln insulin Ln leptin Ln resistin 
Pearson Correlation -0.06 0.03 0.20* -0.05 
Significance (2-tailed) 0.55 0.79 0.05 0.64 
N 95 103 103 104 
Hind milk Maternal BMI at 7 days Ln ghrelin Ln insulin Ln leptin Ln resistin 
Pearson Correlation 0.02 .015 .039 -0.04 
Significance (2-tailed) 0.88 0.89 0.72 0.71 
N 81 90 90 89 
Fore milk Maternal BMI at 3 months Ln ghrelin Ln insulin Ln leptin Ln resistin 
Pearson Correlation 0.20 0.18 0.25* -0.05 
Significance (2-tailed) 0.07 0.10 0.02 0.64 
N 83 92 92 91 
Hind milk, maternal BMI at 3 months Ln ghrelin Ln insulin Ln leptin Ln resistin 
Pearson Correlation -0.09 0.01 -0.05 -0.08 
Significance (2-tailed) 0.48 0.95 0.69 0.49 
N 66 81 81 79 
 
As Table 19 shows, breast milk ghrelin, resistin and insulin were not correlated with maternal BMI, at 
any of the time points studied. However, leptin concentrations in fore milk, but not hind milk, were 
seen to correlate to maternal BMI at the one week time point, and more strongly at the three month 
time point. 
Figure 32 and 33 display scatter plots, showing the correlation between maternal BMI and the log 
breast milk leptin concentration at 7 days, and three months post-partum respectively.   
 
 
 
145 
 
 
Figure 32: Correlation between breast milk leptin concentrations at 7 days post-partum against 
maternal BMI. Pearson correlation coefficient 0.19, p=0.04 
 
Figure 33: Correlation between breast milk leptin concentrations at 3 months post-partum against 
maternal BMI. Pearson correlation coefficient 0.25, p=0.01. 
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3.5.5 Correlations between breast milk hormones 
Relationships between the different hormones were also analysed to establish if there were any 
associations. Each of the time points and the fore and hind milk were grouped for this analysis. Log 
transformed values of the hormones were compared against one another. Table 20 shows the values 
relating to this analysis and the correlations identified between these hormones.  
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Table 20: Pearson correlation coefficient values between the hormones analysed. ** Relates to 
results below 0.01 significance, *refers to results at the 0.05 significance level.  
Ln Leptin vs Ln ghrelin Ln insulin Ln resistin 
Pearson Correlation 0.11* 0.24** 0.11* 
Significance (2-tailed) 0.04 <0.00 0.04 
N 329 371 368 
Ln Insulin vs Ln ghrelin Ln resistin 
Pearson Correlation 0.01 -0.01 
Significance (2-tailed) 0.82 0.82 
N 329 367 
Ln Ghrelin vs Ln resistin 
Pearson Correlation 0.19** 
Significance (2-tailed) <0.00 
N 325 
 
There were seen to be multiple correlations between the different hormones, with leptin correlating 
with ghrelin, insulin and resistin. Also ghrelin and resistin were seen to correlate with one another.   
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3.6  Discussion 
3.6.1 Systematic review 
This systematic review, which includes 26 papers and samples from over 1000 participants, indicates 
that there is an association between the concentration of leptin in breast milk and maternal BMI. 
Evidence for an association between maternal BMI and other hormones investigated is either 
contradictory or inconclusive. Inconsistencies in the data reported originate from the quality, design 
and size of studies. In addition to heterogeneous study design, many studies identified had small 
sample sizes, and hence limited power to detect differences in the concentration of hormones 
between mothers with differing BMI.  
As BMI is not a direct measure of adiposity, the strength of the correlations between these hormones 
and BMI may not reflect the true value of this association. The increasing availability of more advanced 
techniques for evaluating body composition may facilitate such studies in the future. For example, to 
our knowledge, to date only one study has used dual X-ray absorptiometry to assess maternal 
adiposity (Schueler, 2013). A further limitation is non-standardised sampling; some studies involved 
analysis of either fore-milk or hind-milk, some a whole breast expression, and in some the sampling 
technique was not specified. This is potentially important as the concentration of hormones can 
change over an expression from a single breast, during a single feed (Schuster et al., 2011) and with 
increasing duration of lactation (Woo et al., 2009). Though this does not appear to be relevant for 
leptin (Schuster et al., 2011), it is unknown whether this is the case for other hormones. In the majority 
of studies, samples were collected at a single time point, and those studies that collected data at 
multiple time points did not attempt to evaluate or adjust for time (Weyermann et al., 2007). 
In regard to the methods of detection used to measure hormone concentrations, predominantly 
immunoassay methods, RIA or ELISA were used. These techniques resulted in similar values, so it is 
unlikely that method of detection explains variability in the results obtained. More likely, the method 
of sample preparation contributes to the different results observed between different studies. In the 
majority of studies the supernatant of centrifuged breast milk was analysed, whilst in some, whole 
milk was used without prior treatment. There are conflicting recommendations about the most 
appropriate method of sample preparation. Some suggest that milk lipid interferes with the assays 
(Lonnerdal and Havel, 2000), whist others suggest it does not (Houseknecht et al., 1997).   
Many studies measured maternal BMI at different times during lactation or pregnancy. There does 
not appear to be any consistent variation in results obtained from studies measuring BMI at different 
time points, pre or post-partum. Furthermore, the time of sample collection could have a significant 
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impact on results obtained. This is because concentrations of hormones change throughout the 
lactation period (Woo et al., 2009). The majority of studies accounted for this by collecting samples at 
a specific time point, and those that did not adjusted for this effect (Weyermann et al., 2007). 
Table 10 displays the associations observed by different studies over the study period, all but one of 
these report consistent results over the study period. This could be due to either a consistent biological 
observation, or the methods of the studies being consistent. 
Early nutrition may influence health outcomes in children and adults through metabolic programming; 
breast feeding is associated with altered adiposity in infancy (Gale et al., 2012) and reduced 
overweight or obesity in later life compared to formula feeding (Oddy, 2012), but evidence of a causal 
association is uncertain. In the PROBIT study, a cluster-randomized trial promoting breastfeeding, no 
difference was found in adiposity measures (weight, triceps and subscapular skinfold thicknesses, 
waist circumference, percent body fat, fat mass and fat-free mass measured by foot-to-foot bio-
impedance) at 11.5 years in two groups fed differing amounts of breast milk (Martin et al., 2013). 
Nonetheless, it is plausible that breast milk hormones might mediate offspring metabolism and risk of 
later obesity. This would require the presence of appetite regulating hormones in breast milk which 
retain their biological activity following ingestion, and affect infant metabolism. Supporting evidence 
comes from both human and animal models.  
Physiological doses of orally administered human leptin have been demonstrated to be absorbed into 
the bloodstream of nine day old rats (Casabiell et al., 1997). Oral doses of leptin have been shown to 
have demonstrable biological effects, affecting food preference, body weight, reducing caloric intake 
and is capable of improving insulin sensitivity (Sanchez et al., 2005, Pico et al., 2007, Sanchez et al., 
2008, Priego et al., 2010). Likewise, evidence suggests exogenous insulin is able to be absorbed from 
the gut into the systemic circulation in rat models (Hirsova and Koldovsky, 1969), retaining its 
biological activity and potentially mediating effects on infant body composition. In type 1 diabetic 
humans, all of the insulin present in the milk was artificial, also insulin in human milk is present at 
comparable concentrations to serum, suggesting there is an active transport mechanism (Whitmore 
et al., 2012). Further evidence has shown that breast milk leptin may actively influence infant appetite, 
being associated with the change in infant BMI (Doneray et al., 2009). Thus, current evidence supports 
the possibility of an association between enteral absorption of breast milk hormones with systemic 
effects, consistent with the hypothesis that breast milk hormones are an important factor in the 
programming of infant metabolism in the post-partum period (Shehadeh et al., 2006). 
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3.6.2 Leptin  
The data presented here support a correlation between increasing maternal BMI and increasing breast 
milk leptin. In the majority of studies a positive correlation between breast milk leptin and maternal 
BMI was found. In all but two of the studies fewer than 100 participants were recruited. However, a 
large study with 651 participants (Weyermann et al., 2007) demonstrated a strong association 
between maternal BMI and breast milk leptin concentration.  
Leptin is predominantly synthesised by white adipose tissue, but also by the mammary epithelium 
(Smith-Kirwin et al., 1998). It is associated with food intake and body weight, being released in 
proportion to the volume of adipose tissue (Lonnqvist et al., 1995), and displays an anorexigenic effect 
(Cowley et al., 2001). Obese individuals possess a decreased sensitivity to leptin, described as leptin 
resistance (Considine, 2011). The concentration of leptin in breast milk correlates with plasma leptin, 
but is around 5 times lower than that of the plasma (Casabiell et al., 1997, Aydin et al., 2008). 
Previously, a positive correlation has been observed between maternal BMI, weight and maternal 
serum leptin concentration (Savino et al., 2010b). This appears to be reflected in breast milk, due to 
the positive correlation observed between breast milk leptin concentration and maternal BMI. Infant 
serum leptin and maternal BMI have also been shown to correlate, lasting for at least 4 months post-
partum, suggesting infants breast fed by mothers with a high BMI are exposed to significantly higher 
quantities of leptin, which is subsequently transferred to the infant bloodstream (Savino et al., 2006). 
Infants born to obese mothers have been shown to be more likely to become obese themselves 
(Parsons et al., 2001). Potentially, the infant of the obese mother, who is ingesting an increased 
amount of leptin, becomes leptin resistant and subsequently has impaired appetite regulation, with 
an increased risk of obesity. Conversely increased leptin ingestion may enhance satiety, reducing 
intake and later obesity. However, confounding influences must be considered, such as the shared 
environment of mother and infant. Leptin present in milk may provide a link between maternal body 
composition and neonatal growth, development and energy balance. Further human studies have 
found correlations between the growth of neonates and the concentration of breast milk leptin, 
(Doneray et al., 2009, Miralles et al., 2006, Uysal et al., 2002). 
3.6.3 Adiponectin 
Similarly to leptin, maternal serum adiponectin concentrations correlate with maternal weight and 
BMI (Savino et al., 2012b), also breast milk adiponectin has been reported to be positively correlated 
with both maternal and infant serum adiponectin concentrations (Savino et al., 2012b, Woo et al., 
2009), although it is present at significantly lower concentrations (Weyermann et al., 2006). This 
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suggests either the mammary epithelial cells are capable of synthesizing adiponectin, or are able to 
transfer adiponectin from the blood.  
The quantity of adiponectin in breast milk may have biological implications for the infant; negative 
correlations between breast milk adiponectin concentration with infant and childhood adiposity have 
been found. Evidence demonstrates adiponectin in breast milk is associated with a lower weight of 
the infant in the first six months of life (Newburg et al., 2010). Furthermore, Luoto et al reported that 
adiponectin concentrations in colostrum were significantly higher in mothers whose offspring were of 
normal weight at 10 years compared to mothers whose offspring were overweight at 10 years (Luoto 
et al., 2011). Further supporting evidence is the recent identification of adiponectin receptors in the 
human intestine (Bronsky et al., 2012). The correlations observed between breast milk adiponectin 
concentrations and infant adiposity strengthens evidence suggesting there is an association between 
breastfeeding and a reduced risk of obesity in adulthood. This suggests that breast milk adiponectin is 
systemically absorbed in human infants, remains biologically active and is capable of programing 
infant metabolism. However, important confounding factors must be accounted for, as causality has 
not yet been demonstrated, this association may be a reflection of the increased adiponectin 
concentrations in normal weight mothers, who are more likely to have normal weight children. 
A correlation was not found between adiponectin concentrations in breast milk and maternal BMI. 
This is unexpected as in the serum of adults, adiponectin concentrations are known to be inversely 
proportional to adiposity (Coppola et al., 2009). Therefore, it would be logical that overweight and 
obese mothers would have less adiponectin present in their breast milk. In the study which did find 
an association between maternal BMI and the concentration of adiponectin in breast milk, a possible 
explanation is the association between adiponectin, prolactin and adiposity. Adiponectin is negatively 
correlated with prolactin (Nilsson et al., 2005), as prolactin secretion is reduced in obesity, if 
adiponectin is produced by the adipose tissue of the mammary gland, negative regulation by prolactin 
in more adipose women could increase the concentration of adiponectin produced in the mammary 
tissue, and secreted into breast milk. Although  adiponectin in breast milk must be regulated by factors 
other than maternal BMI, such as duration of breastfeeding (Woo et al., 2009) and smoking status 
(Weyermann et al., 2007). 
3.6.4 Insulin 
Evidence of a correlation between maternal BMI and breast milk insulin concentration was 
inconclusive. This is also unexpected; research investigating the breast milk of diabetic mothers found 
a direct correlation between serum and breast milk insulin concentrations (Jovanovic-Peterson et al., 
1989), and it is well documented that the concentration of insulin in serum increases with increasing 
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BMI, due to insulin resistance (Mayfield, 1998). One potential explanation is that included studies are 
underpowered to detect this association.  
3.6.5 Ghrelin 
With regard to ghrelin, conflicting results are also reported. Ghrelin can be either acylated or de-
acylated. The acylated form has caprylic acid attached to a serine residue, and is commonly denoted 
as the active form, however, de-acetylated ghrelin has also been shown to have appetite stimulating 
effects (Toshinai et al., 2006). Acylated ghrelin is known to be particularly labile, and therefore it is 
especially important to either acidify samples at collection, or use a protease inhibitor if attempting 
to measure acylated ghrelin (Stengel et al., 2009). A positive correlation might be expected as the 
serum concentration of active ghrelin is increased in obese compared to normal weight patients 
(Zhang et al., 2011), but this depends on the source of ghrelin found in breast milk. There have been 
conflicting reports in regard to this, with both maternal serum and mammary gland synthesis being 
suggested as the source of milk ghrelin (Aydin et al., 2006, Kierson et al., 2006). Correlations have 
been observed between maternal serum ghrelin concentration and breast milk ghrelin with infant 
serum concentrations, suggesting breast milk is a source of ghrelin for the infant (Savino et al., 2012a). 
3.6.6 Resistin 
Resistin concentrations increase with obesity, therefore concentrations of breast milk resistin might 
be expected to increase with maternal BMI. However, this inference is not supported by the study 
undertaken by Savino et al in which no correlation was found between maternal BMI and the 
concentration of resistin in breast milk (Savino et al., 2012c). However, the small number of women 
included means the study may be underpowered to examine this association. 
3.6.7 Peptide YY and GLP-1 
Concentrations of both Peptide YY and Glucagon-like peptide 1 and their association with maternal 
BMI were evaluated in a single study. Neither of these hormones was found to have an association 
with maternal BMI. In regard to GLP-1, no clear association between BMI and serum concentrations 
of this hormone are yet to be established, therefore it is unsurprising an association was not identified 
in milk, where the association is likely to be less pronounced. In regard to PYY, where in serum a 
negative association with maternal BMI has been identified, extrapolation to breast milk suggests that 
concentrations would be decreased in obese mothers, unless other factors with a stronger influence 
on the concentration of this hormone in breast milk are present. 
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3.6.8 Multiplex assay conclusions 
In agreement with previous work, outlined in the systematic review undertaken, leptin was seen to 
correlate with maternal BMI in fore milk samples at both time points. However, leptin was not seen 
to correlate in the hind milk samples analysed at either time point. Ghrelin, insulin and resistin were 
not found to correlate with maternal BMI at any of the time points analysed, in either the fore or hind 
milk.  
Also, exploration of associations between hormone concentrations and the time samples were 
collected was undertaken. Ghrelin was observed to decrease from fore to hind milk samples collected 
at three months post-partum, similarly, a trend in the same direction was noted for samples collected 
at one week post-partum. This association has not previously been reported in the literature. 
Furthermore, a decrease in concentration of ghrelin in the samples collected at three months post-
partum in comparison to samples collected at one week post-partum was noted, but this only reached 
significance in the hind milk samples collected.  
No significant associations between insulin concentrations in regard to time of sample collection were 
seen, although a trend towards reduced insulin concentration in hind milk samples in comparison to 
fore milk, at both time points, was observed. No relationships between time of sample collection and 
concentrations of either leptin or resistin were seen.  
There were seen to be multiple correlations between the breast milk hormone concentrations, with 
leptin positively correlating with insulin, resistin and ghrelin. Also ghrelin and resistin were seen to 
correlate with one another.  
3.6.9 Conclusions  
In summary, increasing maternal BMI is associated with an increase in the concentration of leptin in 
breast milk. No evidence of a correlation between maternal BMI and other hormones (adiponectin, 
insulin, ghrelin, resistin, obestatin PYY or GLP-1) was found, but published data are limited and 
interpretation problematic due to heterogeneity of study design, sample collection and preparation, 
and the small number of participants. Improved understanding of the potential of breast milk to 
influence offspring health requires that future studies address these important methodological issues.  
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Chapter 4 
Breast milk metabonomic and 
nutritional analysis 
 
4.1 Introduction 
 
Breast milk composition is known to be influenced by many factors, but less well understood is the 
influence of maternal phenotype.  
Many of the constituents of breast milk are taken up from maternal plasma, via transcytosis. In 
conditions such as obesity, where dysregulation of the concentration of various metabolites in the 
systemic circulation is often observed, it may be expected that this will be reflected in the composition 
of breast milk. The objective of the work described in this chapter is to investigate whether 
overweight/obesity exerts a measurable effect on breast milk composition; explored using  1H NMR 
spectroscopy, UPLC-MS and mid infra-red spectroscopy.  
In this chapter metabonomic techniques are applied to human milk in an attempt to characterise its 
composition comprehensively. There are however, many challenges in measuring the multitude of 
components of breast milk both accurately and reliably. Metabolic profiling brings its own analytical 
challenges such as overlapping resonances in spectra, and metabolites being present in dramatically 
different concentrations, often of many orders of magnitude.  
Furthermore, attempting to ascribe a certain effect on the composition of breast milk to a specific 
maternal factor, such as obesity, is complicated by the significant background variation in breast milk 
due to effects from differences in time of collection, time since last feed and maternal genotype. 
Additionally, the individuals participating in the study are free living individuals, and may have 
dramatically different diets. These factors all potentially have an unknown impact on the composition 
of breast milk. 
This chapter describes the analysis of the aqueous fraction of breast milk using 1H NMR spectroscopy. 
The aqueous fraction of breast milk contains many important and interesting metabolites, including 
lactose, human milk oligosaccharides (HMO) and other compounds important for infant health and 
development, such as amino acids. Prior to starting this work, no published literature existed 
investigating the composition of human milk using 1H NMR spectroscopy. A number of papers have 
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since been published, one preliminary study investigating the composition of breast milk of mothers 
delivering prematurely. In this study it was noted there was an increase in the abundance of lactose 
as lactation proceeded, but did not undertake a detailed analysis of sample composition (Marincola 
et al., 2012).  
Another previous paper describing a study using 1H NMR spectroscopy to investigate the aqueous 
fraction of breast milk has examined the effect of maternal obesity on breast milk composition 
(Smilowitz et al., 2013). Samples were first centrifuged and then filtered to remove lipids and protein 
and 1H NMR spectra were acquired using a standard 1D pulse sequence. In this study, it was observed 
that concentrations of acetone were lower in breast milk from women with a higher BMI (r=20.41, 
p<0.01), the authors did not note any other correlations between BMI and breast milk composition. 
The lipid fraction of breast milk is of particular interest with regard to its varied biological functions, 
being involved in neurodevelopment, immunodevelopment as well as acting as an important source 
of energy, accounting for approximately half of the calories found in breast milk. The lipid fraction of 
breast milk varies in concentration over a single feed, in relation to time of day, as well as over 
lactation, meaning it has the most variable content of the macronutrients found in breast milk (Hytten, 
1954).  
Previous research has investigated the differences in fatty acid composition of fore and hind milk, 
finding no differences in the profiles of fatty acid secreted pre- and post-feed. This suggests that it is 
simply the quantity of lipid which increases throughout a feed, rather than the species of lipid secreted 
(Insull and Ahrens, 1959, Hall, 1979).  
Indeed, it does appear that the profile of fatty acids produced is remarkably well conserved between 
mothers. Evidence for this stems from an investigation collecting samples from women at different 
times post-partum, there were large differences in the quantity of lipid present, but a remarkable 
similarity in the profiles of fatty acids was observed. Specifically, in regard to the short-chain fatty 
acids, up to α-linolenic acid, profiles were seen to be virtually identical. The variation which did occur 
was observed in the long chain fatty acid derivatives of linoleic acid and α-linolenic acid, which only 
account for around 1.5% of the total fatty acids present (Hall, 1979). 
However, the lipids present in breast milk are known to be impacted by maternal diet, especially pre- 
and during pregnancy diet, demonstrated by both animal (Laws et al., 2007), and human 
investigations. For example, when the fatty acid profile of a woman receiving dietary supplementation 
of unsaturated fats was investigated, significantly higher concentrations of linoleic acid in her milk 
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were seen, with reduced concentrations of stearic and palmitic acid, in comparison to 
unsupplemented mothers (Hall, 1979). 
In this study, the lipid fraction of breast milk was investigated using lipidomics, specifically, UPLC-MS 
analysis. The lipidome, a subset of the metabolome, refers to the complete lipid profile of a biological 
sample (Han and Gross, 2003). UPLC-MS is an extremely sensitive technique for identifying 
metabolites, capable of detecting concentrations in the picomolar range and is ideally suited to 
exploring the lipidome of individuals 
Previous research using capillary gas–liquid chromatography has examined the effect of obesity on 
breast milk fatty acid concentrations. Lindholm et al. demonstrated that the concentration of long-
chain omega 3 fatty acids were lower, and the ratio n-6/n-3 fatty acid higher, in samples of breast milk 
taken from obese mothers, in comparison to normal weight mothers (Lindholm et al., 2013). Obese 
mothers who participated in an intervention program which gave general dietary advice were found 
to have fatty acid concentrations approaching that of the normal-weight mothers. 
Further investigated was the breast milk macronutrient content, using mid IR spectroscopy. Previous 
research using this technique, associating macronutrient content with maternal BMI, has suggested 
there is a concurrent increase in protein, fat and carbohydrate as maternal BMI increases (Michaelsen 
et al., 1990). Another group has also identified increases in breast milk fat concentration in relation to 
increased maternal BMI (Barbosa et al., 1997).  
The primary objective described in this chapter is to investigate whether overweight/obesity exerts a 
measurable effect on breast milk composition. To examine the association between maternal BMI and 
breast milk metabolome and macronutrient content breast milk samples from a prospective cohort of 
mothers were acquired, as described in Chapter 2. Longitudinal measures of BMI and other clinical 
characteristics were recorded, and attempts made to describe the causes of the variability observed 
in the breast milk samples collected. 
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4.2 Aims 
- Investigate the impact of maternal BMI on maternal aqueous breast milk metabolome, using 
1H NMR spectroscopic analysis. 
 
- Investigate the impact of maternal BMI on breast milk lipidome, using UPLC-MS. 
 
- Evaluate the effects of maternal BMI on macronutrient content using mid infrared 
spectroscopy. 
 
- Examine changes in composition of breast milk samples taken at different times post-partum, 
and investigate other causes of variability. 
 
4.2.1 Hypothesis 
There will be a statistically significant difference in the metabolome/lipidome and nutritional content 
of breast milk from mothers with a high BMI compared to mothers with a low BMI. 
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4.3 Methods 
Breast milk samples were analysed using NMR spectroscopy, UPLC-MS and mid IR spectroscopy, as 
explained in detail in Sections 2.3, 2.4 and 2.7, Chapter 2. In all these techniques samples were 
analysed in a randomised run order. 
4.3.1 1H NMR spectroscopy analysis 
Breast milk samples were prepared into 96 place SampleJet racks (Bruker, Biospin). Acquired data 
were processed and analysed using Matlab 7.12 (MathWorks Inc. USA). For further analysis using 
multivariate modelling techniques, data were imported into SIMCA-P+ 13.0.2. 
4.3.2 UPLC-MS analysis 
Breast milk samples were prepared into 48 well plates. Samples were analysed in both positive and 
negative ionization mode. Once acquired, data were processed using the XCMS package within R. 
Again, data were imported into SIMCA-P+ 13.0.2 for multivariate analysis. 
4.3.3 Macronutrient analysis 
Breast milk samples were analysed according to the manufacturers’ guidelines, as described in Section 
2.7, Chapter 2. Samples which failed analysis were not available for reanalysis, as when a sample is 
injected it forces the previous sample from the instrument, resulting in the mixing of samples. Data 
acquired using the Miris macronutrient analyser were analysed by traditional statistical methods in 
SPSS, Version 22 (IBM). 
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4.4 Results 
4.4.1 Cohort Characteristics 
Descriptive characteristics for the maternal cohort studied are presented in Table 21. The average age 
of the mothers was 34 years (range from 23 to 46), and with an average height of 166cm. 
Table 21: Descriptive characteristics of the maternal cohort at one week and three months post-
partum.  Data are reported as means, standard deviations are given in brackets. 
 One week post-partum Three months post-partum 
Number 108 95 
Weight, kg 70.4 (12.7) 69 (10.7) 
BMI 25.5 (4.5) 24.9 (3.4) 
 
Maternal BMI was seen to drop from the one week time point to the three month time point, as 
displayed in Figure 34. This was in part due to the mothers losing weight between study visits, as well 
as participants dropping out of the study who were more likely to have a higher BMI, as described in 
Section 3.5.1, Chapter 3. This was an unfortunate, as it reduced the power of the study to detect 
differences in the composition of breast milk between overweight/obese and non-overweight/obese 
women. Also complicating the analysis and interpretation was the observation that several mothers 
appeared to increase the BMI over this period.  
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Figure 34: Histograms displaying the distribution of maternal BMI, measured at (A) mothers booking visit 
(B) at recruitment on the post-natal ward, (C) at 7 days post-partum (D) three months post-partum. (E) 
Histogram showing the average BMI of the cohort over the study period. 
E 
D 
A B 
C 
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4.4.2 1H NMR of aqueous fraction of breast milk  
A total of 424 samples were analysed, including 34 QC samples, originating from a single large sample, 
analysed every 12 samples, as well as three formula milks (Cow and Gate, Aptamil and SMA). Not 
including QC samples and formula, 386 maternal samples were available for analysis. Table 22 shows 
a breakdown of the number of samples collected at each time point. 
Table 22: Samples analysed using 1H NMR, (excluding QC and formula samples). 
 
 
               
 
Data were processed using Matlab and spectra were visualised for inspection, as displayed in Figure 
35. Similarly to the method development samples, spectra were dominated by extremely high 
concentrations of lactose, running from δ 3.3 to δ 5.3, with the next highest peak intensities belonging 
to the various HMO species, predominating at δ 1.2 and δ 2.0. 
 
Figure 35: All breast milk spectra overlaid. Spectra as they appear after alignment, normalisation to 
the total spectral area, and after removal of the water resonance, (n=424). 
 
 One week Three months Total 
Number fore milk  107 93 200 
Number hind milk 98 88 186 
Total 205 181 386 
 
Citrate 
Choline, 
phosphocholine
glycerophospho
choline 
Fucosylated 
HMO region 
N-acetyl-
glucosamine 
N-acetyl-
Neuraminic 
acid 
Lactose Lactose 
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Once processed, data were imported into SIMCA P+ for multivariate analysis. PCA was performed in 
order to give an overview of the data, and to establish which method of scaling would be most 
appropriate, as well as to identify any outliers; samples which were significantly different from the 
rest of the cohort.  
In order to scale the NMR dataset, Pareto scaling was selected, as this method was found to be most 
appropriate due to the tight clustering of the QC samples displayed in the scores plot. Of the 424 1H 
NMR spectra analysed to this point four were excluded, as they had been mislabelled, hence, 420 
spectra were available for multivariate analysis.  
4.4.2.1 Analysis of length of storage on milk metabolome   
In order to ensure the quality of the data, an assessment was made to identify any differences in 
sample composition based on the length of time samples were stored for at -80°C. Data were modelled 
using PCA and OPLS-DA, comparing samples stored for less than and greater than 300 days. 
Percentage of variation and predictivity values for this OPLS-DA model were R2X=0.61 and Q2Y=-0.04. 
This demonstrates that the length of time samples were frozen did not affect the metabolomic 
profiles, giving confidence that results obtained were not biased by storage time. 
4.4.2.2 Investigation of run time effects 
To further check the quality of the data aquired, an assessement was made to identify whether there 
were any run time effects due to the length of analysis, which occured over several days. This was 
done by assessing the scores plot by the number rack on which samples were analysed, to identify 
whether there was any obvious drift in the data. This was to ensure any changes seen were not due 
to analytical artifacts but genuine alterations in the composition of samples. 
To do this an OPLS-DA model was computed to investigate whether there were alterations in sample 
composition due to the sequence of analysis, using the rack number as the class variable. 
Figure 36 displays samples analysed on rack 1 against those analysed on rack 5, resulting in a highly 
predictive model, with a Q2Y value of 0.78.  
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Figure 36: OPLS-DA scores plot of samples analysed on rack 1 in dark blue, vs those analysed on rack 
5, turquoise, R2X=0.9, Q2Y=0.78. This plot indicates the presence of systematic differences relating to 
sample run order. 
 
Spectra were investigated using the loadings plot to identify the cause of this separation. This 
indicated that the abundance of lactose was decreased on the rack run later, rack 5, shown in Figure 
37.  
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Figure 37: Spectral changes observed due to run time between samples run on rack 1 and rack 5. 
Peaks highlighted in red were increased in rack 1, which correspond to signals produced by lactose, in 
blue are signals which were increased in rack 5. 
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Because lactose was decreasing in abundance inthe racks run later on in the analysis, it was decided 
to remove the lactose signals from the spectra, as displayed in Figure 38.  
 
Figure 38: Median spectra of all breast milk collected. TSP and lactose signals have been removed, 
spectra were normalised to the total area.  
Once the lactose peaks were removed, spectra were renormalised, and the resulting data used for 
subsequent data modelling and analysis, an overview PCA using this data is displayed in Figure 39.  
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Figure 39: PCA scores plot showing all breast milk samples collected with lactose signals removed. 
In black and red are fore and hind milk samples collected at one week post-partum whilst in yellow 
and turquoise are fore and hind milk samples collected at three months post-partum. Blue circles 
represent QC samples. In grey are formula samples, whilst the green circle at the top right is a 
colostrum sample. R2=0.858, Q2=0.837, indicating that the first two components accounted for the 
majority of the variation in the data set. All models are normalised to the total area and scaled using 
Pareto scaling.  
 
Individual PCA scores plots were plotted for each of the time points and for fore and hind milk, as 
displayed in Figure 40.  
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Figure 40: PCA scores plot of; A Fore milk samples collected at one week post-partum, R2=0.806, Q2=0.773. B Hind milk samples collected at one week post-
partum, R2=0.96, Q2=0.886. C Fore milk samples collected at 3 months post-partum, R2=0.926, Q2=0.817. D Hind milk samples collected at 3 months post-
partum, R2=0.901, Q2=0.775. 
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4.4.2.3 Analysis of fore and hind milk  
The median spectra of fore and hind milk at each time point were plotted against one another in order 
to identify differences between these samples. Figure 41 displays the median spectra of fore and hind 
milk, collected at one week post-partum, overlaid. This figure suggests the composition of the aqueous 
fraction of breast milk is highly regulated, as there are no obvious systematic differences between 
these spectra. Results for fore and hind milk samples collected at three months post-partum were 
similar, with no clear differences between the fore and hind milk samples.  
 
Figure 41: Median spectra of the aqueous fraction of fore and hind milk overlaid. Samples collected 
at one week post-partum, fore milk is shown in blue (behind) whilst hind milk is shown in red.  
Using PCA and OPLS-DA, models were created to compare fore and hind milk samples against one 
another to see if more subtle differences between these samples could be identified. Similarly to the 
overlaid spectra in Figure 41, there were no obvious differences between fore and hind milk identified. 
No separation was observed in either the PCA or OPLS-DA models at either time point, and both OPLS-
DA models possessed negative Q2Y values. Corresponding figures are displayed in Figure 42.  
N-acetyl-
Neuraminic 
acid 
Choline, 
PC, GPC 
Lactose 
Lactose 
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Figure 42: A PCA scores plot comparing fore milk samples (red) against hind milk samples (blue) collected at one week post-partum. R2=0.605, Q2=0.586.            
B OPLS-DA scores plot comparing fore and hind milk samples collected at one week post-partum, R2X=0.521, Q2=-0.06. C PCA scores plot comparing fore milk 
samples against hind milk samples collected at three months post-partum, R2X=0.471, Q2=0.435. D OPLS-DA scores plot comparing fore and hind milk samples 
collected at three months post-partum, R2=0.374, Q2=-0.183.  
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These models suggest the aqueous fraction of breast milk changes very little between fore and hind 
milk, as analysed using 1H NMR. Because of this finding, it was decided further analyses of the 1H NMR 
spectroscopic data from the breast milk would be carried out only on fore milk samples. This was done 
so as not to duplicate the analyses, as the fore and hind milk samples were virtually identical, and in 
order not to include multiple observations from the same participants.  
4.4.2.4 Comparison of samples taken at one week post-partum against three months post-
partum 
The median spectrum of fore milk samples collected at one week postpartum was plotted against the 
median spectrum of samples collected at three months post-partum, displayed in Figure 43. 
In this figure, clear differences are visible between the sample groups, including a major decrease in 
the signals at ~ δ 1.2 and δ 2. The decrease in these resonances corresponds to the known decrease 
in concentration of HMO as lactation proceeds, further described in Section 4.4.2.5, Chapter 4. 
Furthermore, a large drop in the abundance of certain cholines, particularly glycerophosphocholine is 
detectable in the later samples, in agreement with the method development samples and previous 
literature. Comparison between hind milk samples collected at different time points post-partum 
displayed similar results to Figure 43. 
ppm 
N-acetyl-
glucosamine 
N-acetyl-
Neuraminic 
acid 
Lactose 
Lactose 
Citrate 
Fucosylated 
HMO region 
Choline, 
PC, GPC 
Figure 43: Median spectrum of fore milk. Samples collected at one week post-partum are 
displayed in blue, sample collected at three months post-partum are displayed in red.  
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Samples were compared based on the time of collection post-partum using PCA and OPLS-DA. In both 
scores plots of these models, there was clear separation based on the time of collection post-partum, 
shown in Figure 44.  
In the loadings coefficient plot, Figure 45, there were a number of metabolites seen to alter in 
abundance in relation to the time the sample was taken post-partum. These metabolites were 
identified using the online data base HMDB and literature. At three months post-partum, the 
concentrations of lactose and glutamine were greater compared to those in samples obtained one 
week post-partum. Also a decrease in the concentration of HMO was noted at 3 months post-partum. 
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A B 
C D 
Figure 44: PCA scores plot comparing, A fore milk samples (Black) taken at one week post-partum against fore milk samples (Yellow) collected at 
three months post-partum. R2X=0.691, Q2=0.683. B OPLS-DA scores plot comparing fore milk samples taken at one week post-partum against fore 
milk samples collected at three months post-partum, R2X=0.684, R2Y=0.846, Q2 =0.842. C PCA scores plot comparing hind milk (red) samples at one 
week against hind milk samples (turquoise) collected at three months post-partum, R2X=0.698, Q2=0.687. D OPLS-DA scores plot comparing hind 
milk samples taken at one week (red) and hind milk samples collected at three months post-partum, R2 = 0.68, R2Y=0.842, Q2 =837.  
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Figure 45: OPLS-DA loadings coefficient plot. Fore milk samples collected at one week post-partum are compared to samples collected at three months 
post-partum, R2X=0.619, R2Y=0.881, Q2Y=0.871. 
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4.4.2.5 Differences in HMO profile from different mothers 
Following PCA analysis two clear groups were clearly observed in the scores plots, as shown in Figure 
39, this separation was most distinct in samples collected at one week post-partum, displayed in 
Figure 40. This difference accounted for the largest variation between samples, as the separation was 
in principal component 1. Further analysis was undertaken to determine which metabolites were 
responsible for this separation. The median spectrums of the two groups were plotted against one 
another, revealing peaks at δ 2.04, δ 2.06, as well peaks at multiple other regions in the spectra, 
discriminated between these two groups, as displayed in Figure 46.  
These discriminatory peaks were identified, and attributed to the monosaccharaides which compose 
HMO. Further identification revealed some of these resonances belonged to 2’-Fucosyllactose (2’-FL), 
and other HMO containing the 2’-FL structure. A portion of the mothers contained very high 
concentrations of 2’-FL in their milk, whilst other mothers contained none. This was attributed to some 
mothers possessing an inactive copy of the gene FUT2, encoding for the enzyme 2’-
fucosyllactotransferase, outlined in 1.2.5, Chapter 1. This was determined via the 1H NMR spectra as 
no genetic analysis was undertaken on these mothers. Mothers who possess an inactive version of 
this gene are unable to synthesize 2’-FL, and HMO containing this structure, and termed ‘non-
secretors’, in accordance with the literature. Mothers who have an active copy of this gene, are able 
to produce 2’-FL and similar HMO are termed secretors. At one week post-partum the ratio of 
secretors to non-secretors was 83/23.  
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Figure 46: Black shows the median spectrum of non-secretor mothers whilst red displays the median 
spectrum of secretor mothers. At δ 1.2 a doublet from fucose is found, whilst at δ 2.04 N-acetyl 
glucosamine is seen; the doublet at δ 1.17 is increased in non-secretor mothers, again from fucose in 
a different structure to 2’-FL. 
 
Further investigation of the region where the fucosylated oligosaccharides were found also revealed 
a group of mothers whose milk did not contain HMO with a α1,4-fucosyl linkage, according to 
previously published literature, these mothers were designated as Lewis blood group negative 
mothers.  These different spectral profiles from different groups of mothers are displayed in Figure 
47.  
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Figure 47: Spectra from four different mothers, displaying divergent HMO profiles. Blue displays a 
spectrum from a mother whose milk contains all classes of fucosylated oligosaccharides, designated 
as Secretor+/Lewis+ (Se/Le). In green, a mothers whose milk does not contain Fucose(α1-2) Galactose 
units, designated as Se-/Le+. Displayed in red is a mother whose milk does not contain α1, 4-
fucosylated oligosaccharides, (Se+/Le-) whilst in black is a mother who is Se-/Le-. 
4.4.2.6 Regression of breast milk metabolome against maternal BMI  
Analysis was undertaken to investigate whether maternal BMI had an influence on the breast milk 
metabolome in a dose dependent manner. Models were computed using data from fore milk spectra. 
OPLS was used, a regression technique, employing the values of maternal BMI at the booking visit. 
These models had negative Q2Y values, indicating maternal BMI had no systematic effect on the 
composition of the aqueous fraction of breast milk, as analysed by 1H NMR spectroscopy, Table 23.  
Table 23: OPLS models computed comparing mothers with different BMI, using booking BMI values. 
 
  
N R2X R2Y Q2Y Outliers t[1] t[2] Components Model 
105 0.633 0.163 -0.02 2 0.16 0.46 2 Week  
92 0.437 0.258 -0.14 3 0.06 0.37 2 3 Month  
3’-Fucosyllactose, etc. 
2’-Fucosyllactose, etc. 
α1, 4-fucosylated         
oligosaccharides 
ppm 
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4.4.3 UPLC-MS analysis of breast milk lipid fraction   
A total of 383 samples were analysed, as well as three formula milks; Cow and Gate, Aptamil and SMA, 
a breakdown of the samples analysed is given in Table 24. A QC sample was analysed throughout the 
run, injected every 10 samples, to ensure analytical accuracy was maintained. 
Table 24: Samples analysed using UPLC-MS (not including QC and formula samples). 
  
 
 
 
Chromatograms from the lipid fraction of the breast milk QC sample, analysed using UPLC-MS in 
positive and negative ion mode, were overlaid, Figure 48. This clearly displays how different 
metabolites are selectively ionized in different polarities. Retention times were observed to be very 
accurate at the beginning of the run, with increasing drift in retention time during the middle of the 
run, and then improving again towards the end of the run, as displayed by the width of the peaks. 
 One week Three months Total 
Number fore milk  106 93 199 
Number hind milk 98 86 184 
Total 204 179 383 
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Data were pre-processed using RStudio, as outlined in 2.1.26, Chapter 2. Pre-processing involved 
filtering of noise from the data, alignment; to reduce the retention time drift seen in the above 
chromatograms, and a further filtering step to remove peaks with a high coefficient of variation. Once 
this processing was complete, data were imported into SIMCA-P+ for multivariate analysis. For both 
positive and negative ionization mode, data were scaled using Pareto scaling, as this was found to be 
the most appropriate method of scaling the MS data. UV scaling of MS data results in too much 
importance given to background noise which may not have been filtered out.  
 
 
Time (min) 
(A) 
 
 
 
 
 
 
 
 
 
 
(B) 
lysoPC,  
lysoPE,  
FFA 
PI, PC, PG, PE, PS, SM 
SM, 
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TG PI, PC, PG, PE 
lysoPC,  
lysoPE 
Figure 48: (A) Base Peak Chromatogram (BPC) of all lipid sample QCs overlaid, analysed in positive 
ionization mode. (B) BPC of lipid sample QCs overlaid, analysed in negative ionization mode. CE, 
cholesterol esters; DG, diacylglycerols; FFA, free fatty acids; PC, phosphatidylcholines; PE, 
phosphatidylethanolamines; PG, phosphatidylglycerols; PI, phosphatidylinositols;  PS, 
phosphatidylserines; SM, sphingomyelins; TG, triacylglycerols. 
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4.4.3.1 UPLC-MS multivariate analysis 
PCA scores plots were visualized for all data in order to observe grouping of data, and exclude any 
outliers. The PCA scores plot of the positive and negative mode data are shown in Figure 49 and 50 
respectivley.
 
Figure 49: PCA scores plot showing all breast milk lipid samples analysed in positive ionization mode. 
Black and red display the one week fore and hind milk samples collected. In yellow and turquoise are 
the fore and hind milk samples collected at three months post-partum. Blue circles represent QC 
samples. R2X=0.314, Q2X=0.255. 
 
Figure 50: PCA scores plot showing all breast milk lipid samples analysed in negative ionization 
mode. Black and red display the one week fore and hind milk samples. Yellow and turquoise display 
the fore and hind milk samples collected at three months post-partum. Blue circles represent QC 
samples. R2X=0.607, Q2X=0.507. 
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For both positive and negative ionization mode, 2 samples we excluded as they were mislabelled. A 
further 6 samples were excluded in the outlier analysis, as they were distant from the Hotellings 95% 
CI.  
On investigation of the chromatograms corresponding to these samples, it was observed that, for four 
of these samples, the abundance of triacylglycerides was much reduced, with a concurrent increase 
in the concentration of diacylglycerides, potentially as the triacylglycerides had either been 
enzymatically digested, or had degraded. Another outlier also had an incredibly high abundance of 
diacylglycerides, but no decrease in triacylglycerides. One more outlier was identified as having very 
high concentrations of triacylglycerides, but not diacylglycerides. Four of these were matched fore 
and hind milk samples.  
The scores plot show the QCs clustering tightly in the middle of the scores plot, indicating that the 
data collected were of good quality. PCA scores plots for the individual time points in positive and 
negative ionization mode are shown in Appendix 4A and B respectively. Also seen in the scores plot is 
a clear separation between the two time points and differences between fore and hind milk, analysed 
in more detail in the Sections 4.4.3.4 and 4.4.3.5 below.  
4.4.3.2 Analysis of length of storage on milk lipidome 
Alterations in sample composition based on length of storage were investigated. Data were modelled 
using OPLS-DA, comparing samples stored for less than, and greater than 300 days. The Q2 value for 
the first component in this OPLS-DA model was negative in positive ionization mode, whilst for 
negative ionization mode the Q2 value was 0.04 ; suggesting length of storage did not affect milk 
lipidome. 
4.4.3.3 Investigation of run time effects 
To investigate the quality of the data acquired in terms of the length of analysis, as this occurred over 
several weeks, an OPLS model was computed, using the run order number as the Y variable. The scores 
plots for these models are shown in Figure 51 and Figure 52, for positive and negative ionization mode 
respectively. 
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Figure 51: OPLS scores plot of all breast milk lipid samples, classified and coloured by the run order, 
blue being the first samples analysed with red the last. R
2
X=0.285, R
2
Y=0.508, Q
2
=0.451, positive 
ionization mode. 
 
 
Figure 52: OPLS scores plot of all breast milk lipid samples, classified and coloured by the run order, 
blue being the first samples analysed with red the last. R
2
X=0.224, R
2
Y=0.556, Q
2
=0.499, negative 
ionization mode. 
As Figures 51 and 52 show, highly predictive models were produced; meaning the run order of samples 
produced a systematic change in sample composition over the length of the run, which occurred over 
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a week. This effect appeared to affect predominantly samples run in the last rack, in the positive mode 
data with other samples being relatively comparable to one another.  
This effect is most likely due to the changing conditions of the column, as the pressure was seen to 
increase throughout the run, effecting the time at which metabolites eluted. It was hoped that the 
data processing involving retention time correction would account for this, but some effect of length 
of analysis remained.  
4.4.3.4 Analysis of fore and hind milk  
PCA and OPLS-DA comparisons of fore and hind milk in positive and negative ionization mode are 
displayed in Figure 53 and 54 respectively. 
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  Figure 53: A PCA scores plot comparing fore milk samples (black) against hind milk samples (red) collected at one week post-partum, R
2
=0.409, Q
2
=0.283. B OPLS-DA scores plot 
comparing fore (black) and hind milk (red) samples collected at one week post-partum, R
2
X=0.257, R
2
Y=0.277, Q
2
=0.08. C PCA scores plot comparing fore milk samples (yellow) 
against hind milk samples (turquoise) collected at three months post-partum, R
2
=0.354, Q
2
=0.304. D OPLS-DA scores plot comparing fore (yellow) and hind milk (turquoise) 
samples collected at three months post-partum, R
2
X=0.332, R
2
Y=0.298, Q
2
=0.167 in positive Ionisation mode. 
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Figure 54: A PCA scores plot comparing fore milk samples (black) against hind milk samples (red) collected at one week post-partum, R
2
=0.332 Q
2
=0.293. B OPLS-DA scores 
plot comparing fore (black) and hind milk (red) samples collected at one week post-partum, R
2
X=0.269, R
2
Y=0.312, Q
2
=0.08. C PCA scores plot comparing fore milk samples 
(yellow) against hind milk samples (turquoise) collected at three months post-partum, R
2
=0.422, Q
2
=0.383. D OPLS-DA scores plot comparing fore (yellow) and hind milk 
(turquoise) samples collected at three months post-partum, R
2
X=0.31, R
2
Y=0.375, Q
2
=0.104 in negative ionisation mode. 
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There appeared to be some separation of the fore and hind milk samples in the PCA models of samples 
collected at each time point, in both positive and negative ionization mode. However, unexpectedly, 
the OPLS-DA models were not very strong in relation to their Q2Y values, typically being around 0.1, 
meaning they were not very predictive of class designation.   
4.4.3.5 Differences in breast milk lipid fraction taken 7 days post-partum compared to 3 months 
post-partum  
Scores plots of PCA and OPLS-DA models comparing samples collected at different time points post-
partum, in positive and negative mode, are displayed in Figure 55 and 56 respectively. As these models 
possess positive Q2Y values, this indicates the duration of lactation causes a systematic difference in 
milk composition. 
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  Figure 55: A PCA scores plot comparing 7 day fore milk samples (black) against fore milk samples collected at 3 months post-partum (yellow), R
2
=0.342 Q
2
=0.293. B 
OPLS-DA scores plot comparing fore milk at 7 days (black) and 3 months post-partum (yellow), R
2
X=0.324, R
2
Y=0.824, Q
2
=0.801. C PCA scores plot comparing 7 day hind 
milk samples (red) against three month hind milk samples (turquoise), R
2
=0.219, Q
2
=0.212. D OPLS-DA scores plot comparing 7 day hind milk samples (red) against three 
month hind milk samples (turquoise), R
2
X =0.277, R
2
Y=0.854, Q
2
=0.833, positive ionisation mode. 
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Figure 56:  A PCA scores plot comparing 7 day fore milk samples (black) against fore milk samples collected at 3 months post-partum (yellow), R
2
=0.342 Q
2
=0.288. B OPLS-DA scores 
plot comparing fore milk at 7 days (black) and 3 months post-partum (yellow), R
2
X=0.312, R
2
Y=0.905, Q
2
=0.894. C PCA scores plot comparing 7 day hind milk samples (red) against 
three month hind milk samples (turquoise), R
2
=0.369, Q
2
=0325. D OPLS-DA scores plot comparing 7 day hind milk samples (red) against three month hind milk samples (turquoise), 
R
2
X =0.345, R
2
Y=0.9, Q
2
=0.89 in negative ionisation mode. 
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To investigate the features or peaks responsible for differences between samples taken at different 
time points post-partum, S-plots were analysed, an example from this analysis is displayed in Figure 
57. S-plots identify variables which most highly contribute to the separation of groups, in this case, 
fore milk collected at 7 days against fore milk samples collected at 3 months post-partum. This was 
done for both the positive and negative ionization mode models, and the responsible variables 
identifications were ascertained.  
 
Figure 57: S-plot displaying data from an OPLS-DA model. Comparison of fore milk samples taken at 
one week against fore milk samples taken at three months post-partum, in negative ionization mode.  
The m/z ratio and retention times were extracted for the variables located at the end of the tails of 
the plots. These m/z values were then searched for using METLIN, using all possible adducts, removing 
peptides from the search results, using an accuracy within 5 ppm. 
Results were considered plausible if the fatty acid chain was an even number. Frequently, a large 
number of search results were returned, in order to better identify the most likely metabolite the 
original chromatogram was visualised, as well as the MS/MS chromatogram. In the MS/MS 
chromatogram the fragments of the original chromatogram are displayed, MS/MS is described in more 
detail in Section 2.4, Chapter 2. For MS/MS analysis, a greater collision energy is applied in the 
quadrupole; as the metabolites fragment in a predictable manner, the head groups of the different 
phospholipid were searched for to more confidently identify metabolites present in the 
chromatogram. Because different phospholipids possess different head groups, fragmenting from the 
remainder of the metabolite, the species of phospholipid can be inferred. For example, if a 
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phosphatidylcholine is detected, the head group fragment presents in the mass spectrum with a m/z 
value of 184.07, whereas a phosphotidylethanolamine produces a head group fragment with a mass 
of 141 atomic units.  
Due to the difficulty in identification, outlined previously in Section 4.1, the following are considered 
to be tentative identifications. In order to definitely identify a metabolite using mass spectrometry, 
the compound of interest must be compared against a standard of sufficient purity, using identical 
experimental conditions. If the retention time, m/z value and fragmentation pattern are identical, only 
then it can be considered as the same metabolite (Sumner et al., 2007). Due to the impracticality and 
expense of running thousands of standards, only tentative identification was undertaken.  
Table 25 and 26 display the identifications of metabolites altered in concentration from the 7 day time 
point to the 3 month collection.   
Table 25: Metabolites increased in fore milk samples taken at one week against fore milk samples 
taken at three months post-partum. Analysed in positive and negative ionization mode. PC; 
phosphatidylcholine, PE; phosphatidylethanolamine, PI; phosphatidylinositol, SM; sphingomyelin. 
Experimental 
m/z 
Theoretical 
m/z 
Retention 
Time (min) 
ppm Ion 
Examples of 
potential 
metabolites 
Formula 
722.513 723.5203 6.87 0 [M-H]- PE (36:4) C41H74NO7P 
778.562 733.5622 7.00 2 [M+FA-H]- PC(22:0) C40H80NO8P 
804.578 759.5778 7.20 2 [M+FA-H]- PC(24:1) C42H82NO8P 
857.678 812.6771 11.93 3 [M-H]- SM(42:2) C47H93N2O6P 
885.552 886.5571 5.60 2 [M-H]- PI (38:4) C47H83O13P 
706.541 705.5309 5.37 4 [M+H]+ PC (30:0) C38H76NO8P 
734.573 733.5622 7.04 4 [M+H]+ PC (32:0) C40H80NO8P 
758.572 757.5622 5.88 3 [M+H]+ PC (34:2) C42H80NO8P 
760.588 759.5778 7.25 3 [M+H]+ PC (34:1) C42H82NO8P 
762.605 761.5935 9.29 5 [M+H]+ PC (34:0) C42H84NO8P 
813.688 812.6771 12.03 4 [M+H]+ SM (42:2) C47H93N2O6P 
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Table 26: Metabolites which were increased in hind milk samples taken at three months against 
hind milk samples taken at one week post-partum. Analysed in positive and negative ionization 
mode. PE; phosphotidylethanolamine, SM; sphingomyelin. 
Experimental 
m/z 
Theoretical 
m/z 
Retention 
Time (min) 
ppm Ion Examples of 
potential 
metabolites 
Formula 
279.229 280.2402 1.96 14* [M-H]- Linoleic acid C18H32O2 
281.245 282.2559 2.55 12* [M-H]- Oleic acid C18H34O2 
476.276 477.2855 1.04 4 [M-H]- PE (18:2) C23H44NO7P 
478.292 479.3012 1.27 3 [M-H]- PE (18:1) C23H46NO7P 
740.524 741.5309 6.51 0 [M-H]- PE (36:3) C41H76NO8P 
742.541 743.5465 8.39 2 [M-H]- PE (36:2) C41H78NO8P 
803.629 758.6302 9.17 0 [M+FA-H]- SM (38:1) C43H87N2O6P 
831.66 786.6615 12.10 0 [M+FA-H]- SM (40:1) C45H91N2O6P 
731.608 730.5989 6.95 2 [M+H]+ SM (36:1) C41H83N2O6P 
744.556 743.5456 8.39 3 [M+H]+ PE (36:2) C41H78NO8P 
759.64 758.6302 9.24 3 [M+H]+ SM (38:1) C43H87N2O6P 
787.672 786.6615 12.21 4 [M+H]+ SM (40:1) C45H91N2O6P 
 
* Mass accuracy was compromised, possibly due to calibration of the lower m/z range. In previous analysis (Chapter 2), the 
same two features were tentatively identified as linoleic and oleic acid, with a small ppm error value. 
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4.4.3.6 Regression of breast milk lipidome of mothers with different BMI 
OPLS regression models were computed to investigate differences in the lipid fraction of breast milk 
from mothers with a different BMI. Table 27 outlines models computed using maternal BMI at the 
mothers booking visit.  
Table 27: OPLS models computed comparing mothers with different BMI using booking BMI 
values. 
 
As displayed in Table 27, all models possessed a negative Q2Y value, meaning that maternal BMI had 
no discernable influence on the lipid fraction of her breast milk composition, as measured using MS. 
Models outlined in Table 27 display results for the fore milk samples, similar results were obtained 
with hind milk. Furthermore, similar results were observed using maternal weight, and weight change. 
  
N R2X R2Y Q2Y Outliers t[1] t[2] Components 
Time 
samples 
taken 
Mode 
105 0.171 0.399 -0.07 3 0.5 0.11 2 1 Week  - 
92 0.249 0.371 -0.20 4 0.04 0.2 2 3 months  - 
105  0.25 0.332 -0.223 2 0.05 0.19 2 1 week + 
91 0.295 0.384 -0.211 5 0.04 0.24 2 3 months + 
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4.4.4 Mid IR analysis of macronutrient content 
A total of 296 samples were analysed. After removing duplications and samples which had not 
analysed correctly (due to reading zero, as air was present in the instrument), 284 samples were 
available for statistical analysis, Table 28.  
Table 28: Number of samples analysed for macronutrient content. 
 
 
 
 
The total number of samples available for analysis using mid IR was less for that of the other 
techniques as this technique required a larger sample volume (3ml). As well as this, mid IR 
spectroscopy was used after metabonomic analysis, meaning some sample volume had already been 
used for the other techniques.  
Histograms displaying the distribution of macronutrient content data in fore and hind milk samples 
collected at 7 days post-partum are displayed in Figures 58 and 59 respectively. Data corresponding 
to fore and hind milk samples collected at 3 months post-partum are shown in Appendix 4C and D 
respectively. As these figures display, the data were normally distributed. 
 
 One week Three months Total 
Number fore milk  95 90 185 
Number hind milk 40 59 99 
Total  135 149 284 
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D 
A B 
C 
Figure 58: Histograms displaying the distribution of macronutrients in fore milk samples collected at one 
week post-partum. (A) Fat, (B) crude protein, (C) carbohydrate in g/100ml and (D) energy content 
Kcal/100ml. 
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4.4.4.1 Analysis of fore and hind milk collected at different times post-partum 
Table 29 displays the mean concentration of the different macronutrients for these different samples, 
as well as whether there was a statistically significant difference between them, as established by a 
repeated measures ANOVA. 
 
 
 
Figure 59: Histograms displaying the distribution of macronutrients in hind milk samples collected at 
one week post-partum. (A) Fat, (B) crude protein, (C) carbohydrate in g/100ml and (D) energy content 
Kcal/100ml. 
D 
A B 
C 
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Table 29: Descriptions of the means, standard error of the macronutrient content of the milk 
samples collected at different times post-partum. Based on a repeated measures ANOVA. 
Type of milk Stage of lactation: mean (Standard Error) [n] 
1 week 3 Months p-value 
Fat g/100ml 
Fore 2.4 (0.2) [95] 2.4 (0.1) [90] 0.85 
Hind 3.6 (0.3) [40] 4.3 (0.2) [59] 0.01 
p-value <0.01 <0.01   
Carbohydrate g/100ml 
Fore 6.7 (0.04) [95] 7.9 (0.03) [90] <0.01 
Hind 6.5 (0.06) [40] 6.8 (0.04) [59] <0.01 
p-value <0.01 <0.01   
True Protein g/100ml 
Fore 1.4 (0.05) [95] 0.8 (0.04) [90] <0.01 
Hind 1.4 (0.07) [40] 1.0 (0.05) [59] <0.01 
p-value 0.86 <0.01   
Crude protein g/100ml 
Fore 1.8 (0.1) [95] 1.1 (0.04) [90] <0.01 
Hind 1.8 (0.1) [40] 1.3 (0.1) [59] <0.01 
p-value 0.71 <0.01   
Total solids g/100ml 
Fore 11.1 (0.2) [95] 10.6 (0.2) [90] 0.02 
Hind 12.1 (0.3) [40] 12.6 (0.2) [59] 0.09 
p-value <0.01 <0.01   
Total energy kcal/100ml 
Fore 57.3 (1.9) [95] 54.7 (1.4) [90] 0.18 
Hind 67.2 (2.7) [40] 72.8 (1.8) [59] 0.04 
p-value <0.01 <0.01   
 
As Table 29 shows, hind milk was observed to contain significantly more fat, and less carbohydrate 
than fore milk, regardless of the stage of lactation. However, protein concentration in fore and hind 
milk differed with stage of lactation: at 7 days post-partum, there was no difference between fore and 
hind milk; but at 3 months post-partum there was a statistically significant increase protein 
concentration in hind milk, p=<0.01. Between 7 days and 3 months of lactation, in fore milk, the 
concentration of fat remained stable, whilst carbohydrate content increased and protein decreased; 
in hind milk there were significant increases in fat and carbohydrate, but a significant decrease in the 
concentration of protein. 
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4.4.4.2 Macronutrient correlations 
Further investigation of the data revealed various correlations between the different macronutrients, 
as displayed in Figures 60.  
 
 
This analysis revealed a negative correlation between breast milk carbohydrate content and fat and 
protein concentration, and a positive correlation between fat and protein concentrations, at one week 
post-partum Figure 60. Similar results were obtained for samples collected at three months post-
partum. 
 
Figure 60: Scatter plots displaying correlations between breast milk macronutrient content in fore 
milk samples collected at one week post-partum. (A) True protein concentration plotted against 
carbohydrate, (B) Fat concentration against carbohydrate concentration, (C) Fat concentration against 
true protein concentration.  
A                                                                B 
 
 
 
 
 
 
C 
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4.4.4.3 Association between breast milk macronutrient content and maternal BMI  
Scatter plots were produced to investigate whether there was a correlation between maternal BMI 
and the macronutrient content of breast milk in fore milk samples collected at 7 days post-partum. 
These plots are displayed in Figure 61. 
  
These figures demonstrate that there was no correlation between maternal BMI and the 
macronutrient content of the breast milk. This lack of correlation was also observed for hind milk 
samples, and the fore and hind milk samples collected at three months post-partum. Further analysis 
also revealed there was no correlation between the macronutrient content of breast milk using other 
measures of BMI, including booking and recruitment BMI, as well as maternal weight. 
To try and control for confounding factors which were stable over time, maternal weight change was 
plotted against the change in the fat content of milk, from one week post-partum to three months 
post-partum. However, there was no relationship obeserved between these two factors, Figure 62.  
Figure 61: Macronutrient content in fore milk samples, taken at one week postpartum, plotted 
against maternal BMI at one week post-partum. Maternal BMI at sample collection plotted against 
(A) Fat, (B) Carbohydrate, (C) True protein and (D) Energy. 
concentration plotted against  
 
A                                                  B  
 
 
 
 
C                                                    D 
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Change in fat concentration (g/100ml) 
Figure 62: Scatter plot displaying the change in breast milk fat concentration from 7 days 
to 3 months post-partum plotted against the change in maternal BMI over this time, in 
kg/m2. R2 linear=0.01. 
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4.5 Discussion 
The primary aims of this chapter were to establish whether maternal BMI exerted an influence on the 
aqueous, lipid or macronutrient content of breast milk, analysed using 1H NMR spectroscopy, UPLC-
MS and mid IR spectroscopy. 
No differences were observed in the aqueous fraction of breast milk in relation to maternal BMI, 
analysed using 1H NMR spectroscopy. This finding is in contrast to the only previous study investigating 
this relationship using the same technique. This study, undertaken by Smilowitz et al., reported a 
decrease in the concentration of acetone in mothers of a higher BMI, which was not observed in this 
study, (Smilowitz et al., 2013). However, Smilowitz et al. only investigated the breast milk of 52 
women, and arguably did not have sufficient power to detect differences in the breast milk 
metabolome.  
Furthermore, samples were prepared differently in these two studies, which must be taken into 
account as sample preparation can have a large impact on the composition of resulting samples. In 
the study by Smilowitz et al., samples were first centrifuged, and the aqueous layer was removed and 
filtered through a 3000 molecular weight cut-off filter to further remove lipids and proteins. To 
prepare samples for 1H NMR spectroscopy throughout the present study, samples underwent solvent 
extraction, rather than these centrifugation and filtration steps, which may have contributed to 
differences in the findings. 
No correlation was found between maternal BMI and breast milk macronutrient content in this study 
using mid IR spectroscopy. Again, this is in contrast to previous findings. One such study, undertaken 
by Michaelsen et al., noted that each of the macronutrients, protein, fat and carbohydrate increased 
in conjunction with maternal BMI (Michaelsen et al., 1990). However, the Michaelsen et al. study 
recruited twice the number of participants than the present study, and analysing over 2000 samples, 
and therefore had more power to detect whether there was a correlation between these parameters. 
In agreement with results obtained from both 1H NMR spectroscopy and mid IR spectroscopy, the lipid 
fraction of breast milk was not seen to have any predictable relationship with maternal BMI, at any 
time point measured, as analysed by UPLC-MS. Again this suggests that breast milk composition is 
regulated independently of maternal BMI 
One issue encountered throughout this study was the withdrawal of mothers who had a higher BMI, 
reducing the power of the study to detect a difference in the breast milk composition of mothers of a 
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high BMI. This should be accounted for in future studies by ensuring the overweight/obese population 
is over sampled in order to address this issue.  
Even though no differences in breast milk composition in regard to maternal BMI were observed, the 
sample set and metadata collected allowed for the analysis of multiple other influencing factors on 
breast milk composition, revealing several interesting associations.  
In agreement with previous research, one of the largest influences on breast milk composition 
observed was the time samples were collected post-partum. Using 1H NMR spectroscopy, it was found 
that samples collected later on in lactation displayed an increase in the abundance of lactose and 
glutamine and an associated decrease in the abundance of a number of different species of HMO.  
These changes are most likely so highly conserved because they bestow a survival advantage to the 
infants receiving them, and are likely to be timed to provide key nutrients and other factors to the 
infant at specific times during development.  
Again in agreement with the NMR and macronutrient analysis, differences in the lipid profile of 
samples collected at different times post-partum were also identified, with the responsible 
metabolites tentatively identified. The most variable of the metabolites based on time of collection 
were the phospholipids, which are the constituents of the milk fat lipid globule membrane. In general, 
in fore milk samples collected at one week post-partum, there was an increase in several 
phosphocholine species, whilst in the hind milk samples, an increase in several phosphoethanoamines 
and sphingomyelins was noted, in the samples collected at three months post-partum.  
The macronutrient analysis revealed that between 7 days and 3 months of lactation, in fore milk, the 
concentration of fat remained stable, whilst carbohydrate content increased and protein decreased; 
in hind milk there were significant increases in fat and carbohydrate, but a significant decrease in the 
concentration of protein. 
Protein concentrations in fore and hind milk were observed to differ based on time of collection post-
partum, at 7 days post-partum there was no difference between the two, but at 3 months post-partum 
there a statistically significant increase protein concentration in hind milk. This may be explained by 
the infants removing more breast milk at this age, therefore having a greater impact on the 
composition of the milk (Neville et al., 1988).  
Another prominent influence on breast milk composition appeared to be maternal genetic makeup; 
this was not tested, but was extrapolated from the results obtained, based on the classes of HMO 
present in mothers breast milk. In the NMR spectroscopic analysis, the largest differences in breast 
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milk composition related to HMO content, predominantly whether the mother was a secretor or non-
secretor of 2’-FL, and other related HMO. Further investigation revealed a great deal of variation 
observed in the profiles of fucosylated HMO produced, the production of which is under genetic 
control. Large differences in the type and quantity of HMO found in breast milk were seen, known to 
be dependent on whether the mother was able to express specific fucosyltransferase enzymes.  
Previous research has investigated the relationship between the concentration of various HMO and 
the composition of infant faecal microbiota. For example, on day two, Streptococcus was observed to 
be negatively correlated with 2'-FL (r=–0.94), whilst at day ten Bacteroides was positively correlated 
with 2’-FL, (r=0.73) (Williams et al., 2013).  Similarly, Lactococcus, Leuconostoc and Weissella positively 
correlated with DSLN, (r=0.98, 0.92, and 0.93 respectively).  These observations imply that the types 
and concentrations of HMO produced by a mother impact the species and diversity of her infants 
microbiota (Williams et al., 2013).  
No differences were identified between fore and hind milk samples using 1H NMR spectroscopy. No 
published literature exists to compare this data with. A possible explanation for this observation may 
be this analysis was undertaken on the aqueous fraction of breast milk. Because the largest differences 
between fore and hind milk are due to the increase in lipids in hind milk, this is potentially not reflected 
in the aqueous fraction. Furthermore, due to the sampling technique (hind milk samples were taken 
once the infant had fed), different volumes of breast milk will have been removed, acting as a 
confounding factor as if less milk was removed then the milk will have less lipid content, this factor is 
difficult to control. However, giving confidence in the analysis techniques used, alterations in lipid 
content were able to be distinguished between fore and hind milk samples using both UPLC-MS and 
mid IR spectroscopic analysis. 
In regard to the comparison of fore and hind milk using data acquired from the UPLC-MS analysis, the 
models created did not have especially high Q2Y values, in either ionization mode. This may be 
explained by the composition of fore and hind milk being similar in terms of species of molecule 
present, but the concentrations of the macronutrients changing, i.e. the types of lipid secreted do not 
alter within a single feed, just the concentration of the lipid, meaning the models produced were not 
particularly strong. Complicating this analysis was the fact that infants fed for differing amounts of 
time, meaning that it is difficult to compare these samples.  
In regard to the macronutrient analysis, hind milk was observed to contain significantly more fat, and 
less carbohydrate than fore milk, independent of the stage of lactation. The macronutrient analysis 
also revealed a negative correlation between breast milk carbohydrate and fat and protein 
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concentration, whilst a positive correlation between fat and protein concentrations at one week post-
partum was observed.  
One difficultly experienced in the analysis of these samples was the length of time required to analyse 
the whole sample set. This introduced analytical artefacts in relation to run order, observed in both 
the 1H NMR spectroscopy and mass spectrometry analysis. This was most likely identified due to the 
extremely high sensitivity of these techniques. In the 1H NMR analysis, the abundance of lactose was 
seen to decrease from the beginning to the end of the analytical run. It is hypothesised that the lactose 
may have precipitated out of solution. In order to correct for this, the lactose peaks were removed 
from the spectra, and the resulting data were used for the multivariate analysis. However, clearly this 
is undesirable, as this treatment removes much information from the spectra, which may contribute 
towards differences between participants.  
A number of outliers in the MS analysis were excluded. The majority of the excluded samples were 
observed to have much higher abundance of diacylglycerides than the QC samples, and a 
corresponding decrease in the abundance of the triacylglycerols. This observation is potentially due 
to degradation of these samples, due to the length of the analytical run. Alternatively, these samples 
may have been enzymatically digested, releasing the component parts of the triacylglycerides. 
Likewise, for the UPLC-MS analysis run time effects were observed, it was hoped that the data pre-
processing steps would account for this, via the correction of retention time deviation, but some 
effects clearly remained. However, giving confidence to the analysis, the scores plots produced 
suggested only the samples analysed on the last rack were statistically significantly different from the 
rest of the run. As well as this, the QC samples were relatively well clustered. 
In relation to how these findings may impact the infant, each technique employed demonstrated that 
sample composition was conserved across mothers of a different BMI. Where alterations in sample 
composition did occur, it was in agreement with previous literature.  
Analysis using NMR spectroscopy revealed increasing lactose concentrations and decreasing HMO 
concentrations from one week to three months post-partum. This may reflect the primarily protective 
effect of early milk for the infant, as early milk contains large quantities of antibodies and other 
immune factors, whilst at three months the increase in lactose may reflect the increased energy 
demands at this time point.   
Tight regulation of breast milk composition has been demonstrated previously, for example, iron, zinc 
and copper concentrations in breast milk are independent of maternal mineral status (Domellof et al., 
2004). Similarly, breast milk production and composition from women possessing a low BMI is 
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comparable to that of well-nourished mothers (Nazlee et al., 2011) (Soliman et al., 2014). This tight 
regulation is most likely accounted for by evolutionary pressures, and maintained in order to provide 
the infant the best possible chance of survival through infancy, meaning optimal nourishment aiding 
in infant survival via breast milk is likely to be highly conserved, as is observed.   
4.5.1 Conclusions  
In conclusion, it was observed maternal BMI had no detectable influence on breast milk composition, 
suggesting breast milk composition is regulated independently of maternal BMI.   
There were large, but predictable, alterations in breast milk composition based on the time samples 
were collected post-partum, detected using each analytical platform.  
No detectable differences were observed between fore and hind milk analysed using 1H NMR 
spectoscopy, but differences were detected in fore and hind milk using both UPLC-MS and mid IR 
spectroscopy. 
Maternal genotype resulted in large differences in the species of HMO produced, as detected using 1H 
NMR spectroscopy.  
The length of analysis posed some analytical challenges, as sample composition was observed to be 
unstable over the analytical run.    
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Chapter 5 
Infant and maternal urinary 
metabolome 
 
5.1 Introduction  
Metabolic profiling of urine provides a unique insight into the current metabolic state of an individual. 
Overweight and obesity are conditions which are intimately linked to metabolism, and dysregulation 
of many metabolic processes occurs as a result. Consequently, metabonomics is uniquely placed in its 
ability to determine these metabolic changes, generating hypotheses about potential causal 
mechanisms, and determining the consequences of these alterations, suggesting new avenues of 
research to pursue. 
Previous research has investigated the effect of obesity on the human urinary metabolome; using 1H 
NMR spectroscopy. A study of fifteen morbidly obese patients, assessed against ten age-matched 
controls revealed metabolites differing between these two groups were predominantly metabolites 
of intestinal microbial origin. Hippuric acid, trigonelline and xanthine were decreased in the urine of 
obese individuals, whilst 2-hydroxyisobutyrate was increased in the urine of obese individuals. These 
observations suggest that gut microbial metabolism is intimately associated with obesity (Calvani et 
al., 2010). 
Much previous research using animal models to investigate the effects of obesity on the urinary 
metabolome has been undertaken. One such study, assessing Zucker rats, concluded that the different 
phenotypes of rat studied, (obese (fa/fa,), lean (fa/-), and lean (-/-)), could be easily identified from 
one another, using 1H NMR spectroscopy. It was observed that the lean individuals possessed 
relatively lower hippuric acid and creatinine concentrations, but higher levels of isoleucine, leucine 
and acetate than the obese animals studied (Waldram et al., 2009).  
The authors further concluded, via the analysis of the animal’s microbial communities, selection of 
specific microbial species in each phenotype, and that the microbiota was associated with the animals’ 
metabolic phenotype (Waldram et al., 2009).  This study again highlights the close link between 
obesity and the intestinal microbiota.  
To examine the association between maternal BMI and infant and maternal urinary metabolome, 
urine samples and longitudinal measures of BMI from a prospective cohort of mothers and their 
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infants were acquired, as described in Chapter 2. To the best of my knowledge this is the first study to 
examine the effect of maternal BMI on infant urinary metabolome. 
As discussed in the previous chapter, the maternal secretor status was capable of being determined 
analysing breast milk samples using 1H NMR spectroscopy. In order to further investigate this 
interesting observation, comparison of secretor/non secretor mother’s urine, as well as the infants of 
these mothers, was undertaken. This was done in order to establish whether secretor status could be 
determined using urine samples, a much more accessible biofluid.  
Interpretations of the results from this thesis are complicated by many confounding factors, such as 
large variations in the environments, and backgrounds, of the participants, which are difficult to 
control. For example, the different dietary habits of individuals (Walsh et al., 2006), caesarean section, 
classes and doses of drugs individuals were exposed to, and the different excretion rate of these, as 
well as any background physiological variation in individuals’ metabolism are all factors contributing 
to the variation expressed in the spectrum of an individual’s urinary metabolome. A strategy is 
developed to accommodate the confounders and to focus on the investigation of the effect of obesity 
on the metabolic profiles of the offspring. 
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5.2  Aims 
 
- Investigate the impact of maternal BMI on maternal urinary metabolome, using 1H NMR 
spectroscopic analysis 
 
- Investigate the impact of maternal BMI on infant urinary metabolome, using 1H NMR 
spectroscopic analysis 
 
 
5.2.1 Hypothesis 
The following null hypotesis will be tested; there is no significant difference in the urinary metabolome 
of mothers with a high BMI compared to a normal BMI.  
Secondly: There is no significant difference in the urinary metabolome of infants born to mothers of a 
high or normal BMI. 
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5.3  Methods 
Maternal and infant samples were analysed in a randomised run order to moderate any effects seen 
in the spectra due to order of collection. Samples were run on 96 place racks (Bruker, Biospin). A total 
of 590 samples were analysed, including 50 quality control samples, originating from an external 
control (urine collected from another adult of sufficient volume), analysed to ensure analytical 
reproducibility was maintained. This QC was analysed after every 11 study samples. Urine sample 
collection is outlined in Section 2.2.8, sample preparation in 2.3.3, data collection and processing in 
2.3.4-9, and metabolite identification procedures in 2.3.10, Chapter 2. 
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5.4 Results 
5.4.1 Cohort Characteristics 
Descriptive characteristics for the infant and maternal cohort are presented in Table 30-32.  
Table 30: Descriptive characteristics for the infant cohort at recruitment, one week and three 
months post-partum. Data are reported as means, standard deviations are shown in brackets. 
   Recruitment  One week post-partum Three months post-partum 
Number 47 82 91 
Post-partum age, days 1.3 (0.7) 7.3 (0.7) 87 
Weight, kg 3.45 (0.5) 3.37 (0.5) 6 (0.85) 
Length, cm 52.5 (3.1) 51 (2.3) 61 (2.6) 
Head Circumference, cm 34.9 (1.3) 35.3 (1.3) 40.4 (1.2) 
 
The mean gestational age of these infants was 40.5 weeks, with a standard deviation of 1.2 weeks. 
The mean weights, weight for age percentile and ponderal index for this cohort of infants is shown in 
Table 31.  
Table 31: Average weights and weight for age percentiles of male and female infants. Calculated 
using www.infantchart.com, which employs WHO charts. 
 Weight in kg (percentile) [ponderal index]* 
 Recruitment One week post-partum Three months post-partum 
Male 3.48 (60.6) [24] 3.42 (45.4) [25.3] 6.18 (41.1) [26.3] 
Female 3.32 (57.5) [24] 3.3 (45.8) [25.7] 5.62 (39.5) [25.2] 
*Ponderal index calculated using (Mass in kg)/(Height in m)³ 
Table 32: Descriptive characteristics of the maternal cohort at recruitment, one week and three 
months post-partum.  Data are reported as means, standard deviations are given in brackets. 
 Recruitment  One week post-partum Three months post-partum 
Number 107 103 97 
Weight, kg 73.8 (12) 70.3 (12.4) 66.5 (11.2) 
BMI 26 (4.5) 25.3 (4.4) 23.9 (3.6) 
Height, cm 166 (6)   
 
The median age of the mothers was 34 years old, with a range from 23, to 46 years old. More samples 
were available for the maternal cohort due to the difficultly of collecting infant urine samples, 
especially at recruitment before participants were discharged home from hospital.  
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5.4.2 1H NMR spectroscopy data processing and analysis 
1H NMR data were acquired for samples collected from participants outlined in Table 36 and 38, as 
described in Section 2.3, Chapter 2. Acquired spectra were visualised and samples which had not run 
correctly were excluded, with a total of thirteen samples excluded. Twelve samples were excluded of 
which eight were maternal samples, and four were infant samples as the water peak had not been 
supressed properly due to highly diluted samples, therefore influencing the region of the spectrum 
around it. An additional infant sample was excluded, as it had been contaminated with stool.  
Signals arising from TSP δ 0.0, water, δ ~4.7, and urea, δ 5.4-6.1 were excluded. Spectra were aligned 
to correct for peak shifting, and normalised using probabilistic quotient normalisation, as this has been 
demonstrated to be a robust and accurate method of normalisation for metabonomic studies (Dieterle 
et al., 2006). The median maternal and infant urine spectra, after these processing steps, at each of 
the time points collected, are displayed in Figure 63 and 64 respectively.  
 
Figure 63: Median maternal urine spectra overlaid after normalisation and alignment. In red, black 
and blue are maternal urine samples collected at recruitment, one week post-partum and 3 months 
post-partum respectively. 1, Paracetamol/sulfate/glucuronide; 2; Citrate; 3, Creatinine; 4, 
Trimethylamine-N-oxide; 5, Glycine; 6, Creatine; 7, Glucose; 8, Hippuric acid. 
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Figure 64: Median infant urine spectra overlaid after normalisation and alignment. Samples at 
recruitment (red), one week post-partum (black) and 3 months post-partum (blue).  
1, 3-D-Hydroxybutyrate; 2, lactate, 3, unknown; 4, acetate; 5, N-acetyl groups; 6, acetone; 7, succinate; 
8, beta-Hydroxybutyrate; 9, citrate; 10, trimethylamine; 11, creatine; 12, creatinine; 13, betaine; 14, 
glycine; 15, glucose; 16, phenacetylglutamine; 17, hippuric acid; 18, formic acid. 
Once processed, data were then imported into SIMCA-P+ 13.0.2 (Umetrics, Sweden), and PCA 
performed in order to give an overview of the data. At this point data were also scaled, the most 
suitable method of scaling for this dataset was Pareto scaling as the QC samples were most tightly 
clustered using this method.  
Following PCA outlier analysis, described in Section 2.9.2, Chapter 2, a further six spectra (three 
maternal and three infant samples) were excluded. The three infant spectra were excluded due to two 
being very dilute, and one having extremely high concentrations of propylene glycol (thought to be a 
chemical contaminant). The maternal samples were excluded as two had extremely high 
concentrations of paracetamol, and one had an extremely high concentration of hippuric acid. 
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An overview PCA containing maternal samples is displayed below in Figure 65, and infant samples in 
Figure 66. PCA was also performed separately for all six groups of urine sample, grouped by time point 
(recruitment, one week and three moths post-partum), and by whether the sample was maternal or 
infant urine, displayed in Appendix 5A. This was done in order to assess general reproducibility and 
stability of the data and to identify outliers. 
 
Figure 65: PCA scores plot of maternal urine samples, coloured by time of collection. Maternal urine 
samples collected at recruitment (yellow), one week post-partum (turquoise) and 3 months post-
partum (purple). R2X=0.143, Q2X=0.122 (UV scaling). 
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Figure 66: PCA scores plot of infant urine samples, coloured by time of collection. Infant urine 
samples collected at recruitment (yellow), one week (turquoise) and three months post-partum 
(purple). R2X=0.205, Q2X=0.182 (UV scaling). 
5.4.3 Investigation of run time effects 
To ensure the quality of data collected, data were assessed to establish whether there were any run 
time effects, due to the length of analysis, as this occurred over several days. Samples in the PCA 
scores plot were coloured by the number rack on which samples were analysed, to identify any drift 
in the data, displayed in Figure 67. This plot did not show any obvious differences in sample 
composition due to the time of analysis.  
 
 
 
213 
 
 
Figure 67: OPLS scores plot of urine NMR spectra classified by run number. Blue to red relate to 
samples analysed early on in the run to samples run later on, R2X=0.234, Q2Y=-0.06. 
As the OPLS model shown in Figure 67 has a negative Q2Y value, it was concluded that length of analysis 
did not affect sample composition, and therefore variability seen should be due to biological variation, 
rather than analytical variability. 
  
Experiment number 
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5.4.4 Regression of maternal urinary metabolome against maternal BMI 
OPLS analysis was undertaken to investigate whether maternal BMI had an influence on the maternal 
urinary metabolome when a continuous measure of BMI was used. Here, values of maternal BMI were 
used instead of classifying mothers as obese/non-obese; using maternal BMI at booking visit. Values 
for these models are displayed in Table 33. A progressive increase in the predictive capability of the 
models was found, as shown by the Q2Y values. 
Table 33: OPLS models computed for maternal urinary metabolome, comparing mothers of a 
different BMI using booking BMI values. 
 
N R2X R2Y Q2Y Outliers t[1] t[2] Components Sample type 
102 0.238 0.574 -0.329 2 0.02 0.21 2 Recruitment 
98 0.273 0.324 0.05 5 0.06 0.20 2 One week 
91 0.205 0.484 0.05* 5 0.08 0.12 2 3 months 
*1st component of this model had a Q2 value of 0.15. 
As the final model in Table 33 appeared to have a small predictive capacity in the first component, 
scores and loadings plots were plotted to investigate the discriminatory metabolites, Figure 68.  
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Figure 68: OPLS scores plot of maternal urine collected at three months post-partum against 
maternal booking BMI value. R2X=0.205, R2Y=0.485, Q2Y=0.05, (1st component had a Q2Y value of 
0.15).  
In order to assess whether this was a valid model, as the Q2Y value was not very high, permutation 
testing was undertaken. Here, in order to ensure that there is not a spurious correlation between the 
X and Y matrices, the Y matrix is randomly permuted and new models produced. In Figure 69, the 
result of this testing is displayed; the original models values are shown on the right, whist the values 
from the permuted values are shown on the left.  
 
BMI (Kg/m2) 
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Figure 69: Permutation test of the model displayed in Figure 67, using 100 permutations on the first 
component. 
Figure 69 indicates that this model is valid as all the Q2 values are below the original (far right), and 
the blue regression line meets the Y axis below zero.  
The loadings plot corresponding to this model was investigated in order to establish the metabolites 
responsible for this separation. This analysis revealed that the abundance of creatine (singlet at δ 3.02 
and 3.92), creatinine (singlet at δ 3.03 and 4.05) and trimethylamine-N-oxide (TMAO) (singlet at δ 
3.27) were increased in mothers possessing a higher BMI, whilst mothers possessing a lower BMI had 
an increased abundance of hippuric acid (triplet at δ 7.55), the corresponding loadings plot is displayed 
in Appendix 5B. 
5.4.5 Comparison of NMR spectra from infants fed formula and breast milk 
To establish whether any there were systematic differences in infant urinary metabolome for infants 
fed different kinds of milk, i.e. formula vs breast milk, OPLS-DA was used, by classifying infants as to 
whether they had ever been fed formula or not. The scores plot corresponding to this model is 
displayed in in Figure 70. 
R2/Q2 value 
Correlation between Y-original and Y-permuted 
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Figure 70: OPLS-DA scores plot comparing spectra from infant urine samples from formula fed 
infants to infants solely fed breast milk, at 3 months post-partum. Red circles are infants exclusively 
fed breast milk; blue circles indicate infants fed any amount of formula. R2X=0.178, R2Y=0.561 
Q2Y=0.276. 
The separation of formula fed/breast fed infants was not seen in infant urine samples collected at one 
week post-partum, (R2X=0.15, Q2Y=-0.24). This is potentially due to the infants being fed less formula 
at this point, and/or the formula had not yet been administered for long enough to have an effect on 
the infant urinary metabolome.   
The model displayed in Figure 70 possesses a relatively good Q2Y value, meaning it has a positive 
predictive ability, demonstrating that formula feeding impacts infant metabolism, and systematic 
differences exist in the urine of breast fed and formula fed infants.   
Therefore, when modelling infant urine samples, models were computed both including and excluding 
formula fed infants to assess whether there were any differences in the models produced, as formula 
feeding is potentially a confounding factor.  
OPLS-DA was used to identify peaks systematically changed in these two groups, Figure 71.
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Figure 71: OPLS-DA loadings plot comparing infants exclusively fed breast milk (upper section) against infants fed formula (lower section) at three 
months post-partum. Peaks coloured red and pointing either up or down are metabolites which are significantly associated with that group of infants, UV 
scaling. 
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An attempt was made to identify the metabolite at δ 7.37, a discriminatory peak in the OPLS-DA model 
shown in Figure 71, using STOCSY, outlined in Section 2.9.6, Chapter 2. However, as there were several 
overlapping signals this was difficult. Therefore STORM analysis was used in order to identify this 
metabolite, (method outlined in Section 2.9.7, Chapter 2). 
This method is useful for identification as it reduces the incidence of false positive results. In this case, 
using STOCSY displayed many correlations with unrelated metabolites in the loadings plot due to the 
overlapping signals in the spectra; this effect is reduced in STORM analysis.  
STORM analysis revealed the main metabolite contributing to the separation of the formula fed, 
versus breast fed infants, was phenylacetylglutamine, or PAG, displayed in Figure 72. 
Also increased in the breast fed infants was 3-Aminoisobutyrate, as confirmed by STOCSY. Peaks 
identified included a doublet at δ 1.2, a multiplet at δ ~2.61 and two doublet of doublets at δ 3.00 and 
δ 3.10. 
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Figure 72: STORM analysis identifying PAG as a discriminatory metabolite between FF and BF infants. Peaks coloured red/orange are significantly associated 
with the peak presenting at 7.37, and agree with database assignments of the other peaks belonging to the PAG molecule. The peaks present in both the 
spectra and spectral database include a multiplet at 1.93, 2.12, 2.27, 3.67, 4.19 and triplets at 7.36 and 7. 43. Inset displays a standard spectrum of PAG (kindly 
given by Joram Posma). Arrow shows position of peak used for correlation. 
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5.4.6 Regression of infant urinary metabolome against maternal BMI 
A regression of maternal BMI using the maternal booking BMI values was performed against the infant 
urinary metabolome. Values for these models are shown in Table 34. 
Table 34: OPLS models computed for infant urinary metabolome from infants born to mothers of a 
different BMI. 
N R2X R2Y Q2Y Outliers t[1] t[2] Components Model 
44 0.203 0.773 -0.04 1 0.05 0.15 2 Recruitment 
81 0.15 0.479 -0.26 3 0.03 0.11 2 Week 
91 0.149 0.419 -0.28 7 0.03 0.11 2 3 month 
 
These models all possess a negative Q2 value suggesting maternal BMI has no detectable influence on 
the infant urinary metabolome immediately post-partum, at one week or at three months post-
partum.  
5.4.7 Investigation of gestational effects on infant urinary metabolome - Regression of infant 
urinary metabolome against gestational age 
The impact of infant gestational age on the infant urinary metabolome was also investigated. This was 
achieved by decimalising infant gestational age and computing OPLS models, using gestational age as 
a continuous variable. The OPLS models produced are outlined in Table 35. All the infants recruited 
were born at term, with a range from 37 weeks postpartum to 42 weeks post-partum.  
Table 35: OPLS models computed for infant urinary metabolomes comparing infant born with 
different gestational ages. 
N R2X R2Y Q2Y Outliers t[1] t[2] Components Model 
45 0.142 0.818 0.29* 2 0.04 0.09 2 Recruitment 
81 0.114 0.616 -0.02 3 0.03 0.07 2 Week 
91 0.172 0.207 -0.16 7 0.04 0.12 2 3 month 
*The Q2 value for the first component in this model was 0.01. 
As can be seen from the models in Table 35, the model of the infant urine collected at recruitment 
against gestational age had a positive predictive value suggesting there are systematic differences in 
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urine from infants born at different gestational ages. The model validation using permutation testing 
is shown in Appendix 5C. 
These alterations were identified by visualising the loadings and scores plot for this model, shown in 
Figures 73 and 74. 
 
Figure 73: OPLS loading plot of infant urine collected at recruitment against infant gestational age. 
Points on the right of the plot indicate metabolites which are increased in infants with a later 
gestational age, whilst points to the left indicate those metabolites increased in infants with a lower 
gestational age. R2X=0.142, R2Y=0.818, Q2Y=0. 292. 
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Figure 74: OPLS scores plot of infant urine collected at recruitment against infant gestational age. 
R2X=0.142, R2Y=0.818, Q2Y=0.292. 
The metabolites contributing towards this separation in the scores plots were identified using the 
loadings plot. Increased in abundance in infants born later term was creatinine, whilst metabolites 
increased in abundance in infants born in early term were acetate (singlet at δ 1.92), trimethylamine-
N-oxide (singlet at δ 3.27) and glycine (singlet at δ 3.56). The chemical shift of the unknown signal was 
δ 4.00 (singlet). 
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5.4.8 Comparison of maternal urine samples comparing secretor mothers against non- secretors 
of 2’-FL and related HMO 
Also investigated was the influence of maternal secretor status on the maternal urinary metabolome. 
This was achieved by classifying mothers as either secretors or non-secretors based on the profile of 
HMO she produced, as determined by the NMR spectroscopic analysis of breast milk. OPLS-DA models 
were then produced in order to determine whether mothers could be discriminated into these two 
groups based on their urinary metabolome. Using Pareto scaling, the OPLS-DA models produced had 
negative Q2Y values, however when rescaled using UV scaling, giving greater importance to low 
abundance metabolites, a good model was produced, shown in Figure 75. The difference in the model 
validity is a function of the HMO being present at relatively low concentrations compared to 
metabolites such as lactose, and are largely either present or absent, therefore they are down 
weighted by Pareto scaling which is expressed relative to the median spectrum. 
 
Figure 75: OPLS-DA scores plot of maternal urine samples collected at all time points, classified as 
either secretors (black circles) or non-secretors (blue circles), based on breast milk samples. 
R2X=0.09, R2Y=0.674, Q2=0.383. 
As seen in Figure 75, two groups are observed in the maternal urine samples, in high agreement with 
maternal secretor status, the classification of which was based on the mothers’ breast milk samples. 
This model shows a good predictivity score, as displayed by the Q2Y value.  
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In order to identify the metabolites which altered in abundance between these two groups, an OPLS-
DA loadings correlation coefficients plot was created to highlight the regions which differed between 
these two groups, as shown in Figure 76. 
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 Figure 76: OPLS-DA loadings coefficients plot comparing all maternal urine samples classified as secretor (up) or non-secretor (down) based on breast 
milk samples R2X = 0.09 R2Y = 0.80 Q2Y = 0.24. Model calculated with one orthogonal component. 
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As Figure 76 displays, the most discriminatory peaks in the secretor mothers’ urine included a doublet 
at δ 5.29, and a multiplet at δ 5.32. In order to identify this metabolite, STOCSY was used, displayed 
in Figure 77.  
 
Figure 77: STOCSY of discriminatory peak between secretor and non-secretor mothers at δ 5.32. 
Highly correlated peaks included those at δ 1.24, 4.25, 4.53 and 5.29. 
One potential identification of the metabolite highlighted in Figure 77 is 2’-Fucosylactose, as it 
contained many of the same peaks as a standard analysed for comparison (kindly donated by 
Jennewein Biotechnologie GmbH, Rheinbreitbach, Germany), displayed in Figure 78.  
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Figure 78: Standard 1H NMR spectrum of 2’-fucosylactose.  
 
5.4.9 Comparison of infant urine of infants born to secretor mothers against non-secretor 
mothers 
Similarly to the maternal urinary samples, infant urine samples were classified by whether their 
mother was a secretor or non-secretor, again based on the HMO profile of the mother’s breast milk. 
The maternal secretor status was therefore used as the class variable, and an OPLS-DA model 
produced, displayed in Figure 79. 
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Figure 79: OPLS-DA scores plot of infant urine samples collected at all time points months post-
partum, classified as either secretors (black circles) vs non-secretors (blue circles), based on 
maternal breast milk samples. R2X=0.151, R2Y=0.456, Q2Y=0.214. 
This figure demonstrates that there are systematic changes in the urinary metabolomes of infants of 
secretor/non-secretor mothers, as the Q2Y score has a positive predictive value. To identify the 
metabolites responsible for this separation the OPLS-DA loadings coefficients were plotted, displayed 
in Figure 80.  
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 Figure 80: OPLS-DA loadings coefficients plot comparing all infant urine samples classified as infant of secretor (up) or non-secretor mothers (down) from 
breast milk samples. R2X=0.152, R2Y=0.576, Q2 Y=0.261. Model calculated with one orthogonal component.  
 
 
 
232 
 
In order to aid identification of these metabolites, STOCSY was used to detect correlated peaks. A 
STOCSY of the peak at δ 1.24 is shown in Figure 81. Peaks which were highlighted correlated were 
input to HMDB in order to identify metabolites possessing similar chemical shifts; with realistic hits 
investigated further.  
 
Figure 81: STOCSY correlation and covariance plot displaying peaks associated with the doublet at 
1.24 ppm. 
Again it appeared as if 2’-fucosyllactose was the discriminatory metabolite between the infants of 
secretor mothers and non-secretor mothers, displaying many of the same peaks as a standard 
analysed for comparison, displayed in Figure 78. Shared peaks included those at δ 1.23, 3.31, 3.59, 
3.83, 3.91, 4.25, 4.53, 5.24 and 5.32. 
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5.5  Discussion 
The principal aim of this chapter was to investigate whether maternal BMI influenced either the 
maternal or infant urinary metabolome, assessed by 1H NMR spectroscopic analysis.  
In regard to the influence of maternal BMI on maternal urinary metabolome, the only model 
possessing a Q2Y value high enough to warrant further investigation was an OPLS model of samples 
collected at three months post-partum, using maternal booking BMI values. A potential reason for no 
strong correlation being identified between maternal BMI and urinary metabolome at the recruitment 
and week time points may be that effects due to maternal BMI were masked by the confounding 
effects of large metabolic changes immediately post-pregnancy, masking the effects of BMI on the 
urinary metabolome. 
The corresponding loadings plot of this model indicated that the abundance of creatinine and TMAO 
was increased in the mothers possessing a higher BMI, whilst hippuric acid was increased in mothers 
possessing a lower BMI. However, no such observation was seen in samples collected at either the 
recruitment or one week time point. 
The observation of a decreased abundance of hippuric acid in individuals of a higher BMI, has been 
recorded before, (Calvani et al., 2010). Hippuric acid is produced as a result of the co-metabolism of 
humans with their intestinal microbiota. Benzoic acid is firstly produced by several different strains of 
microbe, from various aromatic compounds in the diet; and then conjugated with glycine in the 
mammalian mitochondria (Nicholson et al., 2005). 
Animal studies have identified hippuric acid as a metabolite which alters between calorie restricted 
rats, and those fed a normal diet. Calorie restriction is associated with multiple positive metabolic 
regulating effects and increased lifespan (Zhang et al., 2012). Further animal studies of obesity have 
identified hippuric acid as differing between obese and non-obese rodents (Waldram et al., 2009). 
This study also reports a difference in the microbial communities’ between the obese and lean rats 
studied, with obese animals containing significantly lower numbers of total bacteria, as well as an 
altered microbial profile. This finding again highlights the importance of the microbiota in relation to 
the obese phenotype.  
Hippuric acid has also been identified as a biomarker distinguishing north and south Chinese 
populations, who possess differing risks of cardiovascular disease (Yap et al., 2010). Furthermore, an 
inverse relationship between hippuric acid excretion in urine and individuals blood pressure has 
previously been reported, potentially identifying the protective mechanism (Holmes et al., 2008).  
 
 
234 
 
Higher concentrations of TMAO were associated with maternal BMI. Urinary TMAO occurs as a result 
of the interaction of both the individuals’ diet, and microbial communities, particularly microbial 
metabolism of choline (Waldram et al., 2009).  
Also increased in mothers of a higher BMI was creatinine. Previous research has indicated, in rats, that 
this metabolite is decreased in obese individuals (Waldram et al., 2009), not replicated in this work. 
Similarly, the effects of dietary restriction on the urinary metabolome of control, and diet restricted 
dogs have been evaluated using 1H NMR spectroscopy. Here, it was found that diet restricted dogs 
had consistently elevated urinary excretion of creatinine, again not observed in this work (Wang et al., 
2007). 
However, in agreement with this work, obese individuals have been observed to have an increased 
amount of muscle mass in comparison to lean individuals (Mueller, 1988), and as creatinine positively 
correlates with muscle mass (Rikimaru et al., 1989), this finding is compatible with this research.  
In regard to the results obtained from the infant urinary metabolome analysis, and the influence of 
maternal BMI on this, OPLS models produced comparing infants born to mothers of a high and normal 
BMI all possessed negative Q2Y values. As these models have a negative predictive value, this suggests 
that there are no systematic differences between infants urinary metabolome born to mothers of 
differing BMI.  
A possible explanation of why maternal BMI was not seen to influence infant urinary metabolome is 
by incorporating the results obtained in Chapter 4. Here, no differences were detected in the breast 
milk composition of overweight/obese compared to non-overweight/obese mothers. Therefore, as 
the composition of breast milk infants received from mothers with different BMI was similar, it may 
not be expected for differences to be detected in the infants’ urinary metabolome. 
One hypothetical reason to expect differences in the urinary metabolomes of infants born to mothers 
of a high, verses normal BMI may be detected, was the exposure of infants in utero to maternal 
obesity. However, this obviously did not have a detectable effect on the infants’ urinary metabolome 
measured up to three months post-partum, as the models possessed negative Q2Y values.  
One limitation of this study was due to participants withdrawing from the study, particularly 
overweight and obese individuals. This resulted in a reduced power to detect differences in the urinary 
metabolomes of this group of mothers, as well as their infants, based on maternal BMI. This may be 
able to be determined with a larger cohort. Future studies should be designed to recruit greater 
number of overweight/obese mothers due to these mothers being more likely to stop breastfeeding, 
and therefore withdraw from study. However, overweight/obese mothers who are able to continue 
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breastfeeding may be different from mothers who stop breastfeeding, but this speculation would be 
difficult to test.  
To investigate whether there were any run time effects, due to the analysis taking place over several 
days, an OPLS model was produced. This indicated that the analysis was reproducible and reliable over 
the course of the run, giving confidence in the results obtained, agreeing with previous literature 
indicating that urine is a relatively stable biofluid.  
Although no identifiable differences in the infant urinary metabolomes were able to be detected in 
regard to maternal BMI, a number of other interesting influences on the urinary metabolomes of these 
individuals were able to be investigated. 
One such influence, on the infant urinary metabolome, was whether the infant was mixed formula 
fed, or exclusively breast fed. On investigation of the urinary metabolomes, PAG was revealed to be 
increased in abundance in exclusively breast fed infants, in comparison to mixed formula fed infants.  
The PAG metabolite occurs in urine as a consequence of microbial-mammalian co-metabolism (Yap et 
al., 2010). The intestinal microbiota putrefy dietary phenylalanine in the colon, converting it to 
phenylacetate, this is then transported to the liver where it is conjugated with glutamine (Swann et 
al., 2013). This demonstrates the early relationship between the intestinal microbiota and human 
metabolism. PAG has been associated with beneficial effects on cardiovascular health in later life (Yap 
et al., 2010). This finding suggests there are differences in the species or function, or both, of the 
microbiota in mixed formula fed infants in comparison to breast fed infants. It is well established that 
formula fed infants harbour a different microbiota compared to breast fed infants, (Harmsen et al., 
2000). 
PAG has also been described to be associated with age in American and Taiwanese individuals. In this 
study PAG was seen to positively associate with age, which the authors attributed to the influence of 
age on the host-microbiome metabolism (Swann et al., 2013).   
Another interesting observation was the influence of gestational age on the infant urinary 
metabolome. Here, creatinine was found to be increased in infants born late term, whilst metabolites 
increased in abundance in infants born early term were acetate, TMAO and glycine. Previous research 
investigating the urinary metabolome of preterm infants against term born infants also observed an 
increase in TMAO in preterm infants urine and an increase of creatinine in term born infants, similar 
to the results presented here (Foxall et al., 1995). Creatinine has been shown to correlate to muscle 
mass, therefore this association of an increased concentration of creatinine in the infants of a higher 
gestational age, and therefore larger, makes sense physiologically (Rikimaru et al., 1989). 
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The authors of this study hypothesised the increased excretion of creatinine and lower excretion rates 
of amino, and organic acids could be ascribed to the maturation of the infants glomerular filtration 
and tubular function (Foxall et al., 1995).  
Furthermore, analysis of the maternal urinary metabolome revealed that there were systematic 
alterations in the metabolomes of secretor verses non-secretor mothers (of 2’-FL and related HMO) 
This ability to distinguish maternal secretor status using maternal urine samples has been observed 
previously. The authors of one such study attributed this discriminatory potential to retrograde 
‘leakage’ of HMO into maternal circulation, and its subsequent elimination in urine (Hallgren and 
Lundblad, 1977a) (Hallgren and Lundblad, 1977b). Whether HMO exerts any positive effects on 
maternal health is yet to be elucidated. It has however been hypothesised that, similarly to the 
protective effects HMO confer to neonates, HMO may protect the mammary gland from mastitis 
(Bode, 2012). For example, Staphylococcus has been shown to bind to 2’-FL in vitro, which may prevent 
it from binding to the mammary epithelium, initiating infection (Lane et al., 2011). 
Likewise, investigation of the infant urinary metabolome revealed there were also systematic 
alterations in infants’ urine born to secretor mothers, in comparison to non-secretor mothers. A 
potential discriminatory metabolite, seen to be increased in infants of secretor mothers, was 2’-FL. 
This is reasonable to expect as 2’-FL is one of the HMO present in the highest abundance and 
discriminate between secretor and non-secretor mothers.  
The increased abundance of 2’-FL in the urine of infants of secretor mothers must be due to infant 
absorption of this HMO from the gastrointestinal tract. Previously, it has been thought that HMO are 
completely indigestible, but it has been demonstrated that certain HMO are able to be absorbed, and 
may be found in infant circulation (Goehring et al., 2014). 
Excretion of HMO into infant urine was first described by Rudloff et al, who showed that intact HMO 
were present in the urine of breast fed, but not formula fed, infants (Rudloff et al., 1996). Rudloff et 
al further investigated their results using 13C-labeling studies, administering labelled galactose and 
studying its metabolic fate. This research demonstrated approximately 1% of the HMO was excreted 
in the infant urine. The researchers hypothesise that these HMO, as well as having multiple important 
functions in the gastrointestinal tract, may also protect infants against urinary tract infections by 
acting as analogous receptors for pathogenic adhesion molecules (Obermeier et al., 1999) (Rudloff et 
al., 2006) (Rudloff et al., 2012).   
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5.5.1 Conclusions 
There is some evidence to suggest there are alterations in the maternal urinary metabolome of 
mothers with a high BMI compared to a normal BMI, at three months post-partum, but not at delivery 
or one week post-partum. 
No discernable differences were detected in the urinary metabolome of infants born to mothers with 
a high or normal BMI, at any of the three time points measured. 
The data presented here suggest formula fed infants show a significantly different urinary 
metabolome compared to breast fed infants, likely driven by the differences in diet between these 
two groups of infant, at three months post-partum. One identified metabolite seen to be altered 
between these two groups of infant was phenylacetylglutamine, which had an increased abundance 
in breast fed infants. This metabolite is a product of bacterial co-metabolism, highlighting that 
differences in diet have the potential to impact infant intestinal microbiota. 
One novel finding, to my knowledge, was the effect of gestational age on the infant urinary 
metabolome, in a group of term infants. Previously differences have been displayed in the urinary 
metabolomes of preterm vs term infants (Atzori et al., 2011). 
A further finding was the impact of maternal secretor status on both the maternal and infant urinary 
metabolome.  
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Chapter 6  
Discussion 
 
Key conclusions 
 A positive correlation between maternal BMI and breast milk leptin was identified using 
systematic review and an in vitro multiplex assay.   
 No correlation between breast milk ghrelin, insulin, adiponectin, resistin, Peptide YY or GLP-1 
and maternal BMI was detected, by either systematic review or in vitro analysis. 
 Breast milk composition is conserved in relation to maternal BMI, identified using 1H NMR 
spectroscopy, UPLC-MS and mid IR spectroscopy, investigating the aqueous, lipid and 
macronutrient content of breast milk. 
 Changes in breast milk composition which were observed related to the well described 
differences in time of collection post-partum which samples are taken, as well as the 
differences between fore and hind milk. 
 Maternal Secretor status can be readily identified using breast milk samples. 
 Maternal BMI did not influence the infant urinary metabolome, at any time point measured.  
 Maternal Secretor status influences both the maternal and infant urinary metabolome. 
 Formula feeding was observed to influence the infant urinary metabolome. 
 Maternal BMI influences the maternal urinary metabolome, with microbial co-
metabolites implicated as differing between high and low BMI individuals.  
6.1 Introduction 
The objective of this thesis was to evaluate the hypothesis that maternal phenotype, specifically 
maternal BMI, has a discernable impact on breast milk composition. In order to investigate this, 
analytical techniques including metabonomics (1H NMR spectroscopy and UPLC-MS), mid IR 
spectroscopy (in the form of a clinically utilised breast milk analyser), and a multiplex assay were 
employed to explore the metabolomic, nutrient and endocrine profile of breast milk.  
Additionally, the sample set collected allowed for the analysis of multiple factors associated with 
alterations in breast milk composition, as well as differences in the urinary metabolomes, to be 
explored. 
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Evaluation of appropriate techniques for analysing breast milk composition, as well as the 
optimization of sample preparation methods prior to employing these analytical platforms are 
described in detail in the method development in Section 2.10, Chapter 2. Two peer reviewed 
publications have been produced from this method development work, together detailing the most 
comprehensive characterisation of breast milk to date (Villasenor et al., 2014), and (Andreas et al., 
2015). 
The impact of maternal BMI on various appetite regulating hormones present in breast milk was also 
determined, by both systematically reviewing the published literature, and performing an in vitro 
multiplex assay. The systematic review and in vitro studies both confirmed that breast milk leptin 
consistently correlated with maternal BMI. However, evidence for the other hormones analysed 
showed no clear association with maternal BMI. This systematic review was published in PLOS ONE 
(Andreas et al., 2014) and the in vitro analysis is currently under review, also at PLOS ONE.  
Previous studies have reported a positive correlation between maternal BMI and breast fed infants’ 
serum leptin from birth to 12 months. The authors of one such study propose that ingested leptin in 
breast milk is absorbed into the infants circulation, but this is yet to be confirmed (Savino et al., 2006). 
An alternative explanation could be that the leptin in infant circulation is synthesized by the infant, 
and correlates with maternal BMI due to the positive relationship between infant and maternal 
adiposity (Modi et al., 2011).  
The majority of studies agree that with increasing maternal BMI there is a simultaneous increase in 
maternal plasma leptin, and an increase in breast milk leptin (Andreas et al., 2014). It is suggested that 
individuals who have a greater BMI become desensitised to leptins actions, resulting in its 
overproduction, i.e. leptin resistance. The quantity of leptin supplied to an infant through breast milk 
appears to be partially dependent on maternal adiposity. The leptin present in breast milk may reduce 
the appetite of infants, causing less weight gain in infants receiving higher concentrations of leptin. 
This has been suggested to be a mechanism to protect the infant against the impact of maternal 
obesity, protecting the infant against subsequent obesity and other metabolic disorders (Savino et al., 
2009).  
Doneray et al. found that the increase in breast milk leptin concentration over the first month of 
lactation is negatively correlated with the change in infant BMI over the same time period (Doneray 
et al., 2009). Likewise, Miralles et al. found a negative correlation between infant BMI at 18 and 24 
months and breast milk leptin concentrations (Miralles et al., 2006). These studies suggest that milk 
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leptin concentrations are negatively correlated with infant BMI; however, results from these studies 
are correlations, and therefore not indicative of causality. 
As described in Chapter 4, the composition of breast milk appears to be extremely well conserved in 
relation to maternal BMI. The analytical platforms used (1H NMR spectroscopy, UPLC-MS and mid IR 
spectroscopy), analysing the aqueous, lipid and macronutrient content of breast milk respectively, 
found no association between maternal BMI and alterations in breast milk composition, in the sample 
set collected during this study.  
It might be expected that breast milk composition is tightly regulated. Demonstrating this tight 
regulation, one study found the concentration of iron, zinc and copper in breast milk was independent 
of the maternal mineral status. (Domellof et al., 2004). Furthermore, another study investigating 
breast milk production from well-nourished and under nourished women found that, even in women 
possessing a low BMI, milk volume was comparable to that of the well-nourished mothers (Nazlee et 
al., 2011). Another study, investigating the composition of breast milk from under-nourished and well-
nourished mothers, demonstrated that in under-nourished women, the milk composition remained 
comparable to that of well-nourished mothers (Soliman et al., 2014). Similarly, milk quality and 
quantity are found to be maintained in women with common illnesses, such as infection, when 
compared to healthy women (Zavaleta et al., 1995) (Lonnerdal et al., 1996).  
From an evolutionary point of view, this conservation of milk composition and volume may also be 
expected. In terms of natural selection, the principle factor in selection is the successful rearing of 
infants to reproductive maturity. Advantageous traits, promoting the survival of infants through 
lactation, are therefore likely to be highly conserved. New-born mammalian infants, especially 
humans, are particularly dependant on their mothers for nourishment. The lactation period is a critical 
time in determining the survival of neonates, meaning milk composition is likely to be optimised for 
this purpose, in order to ensure the survival of the neonate.  
Of the differences which were observed in the composition of breast milk, these could be ascribed to 
previously well documented factors affecting breast milk composition, such as time of collection post-
partum, as described in Section 2.10, Chapter 2. Also exerting a large influence on the concentration 
of macronutrients present in breast milk was whether fore or hind milk was analysed, outlined in 
Section 4.4.4, Chapter 4. This demonstrates the importance of standardised collection of fore and hind 
milk, or of an entire feed, when conducting studies of milk composition. 
In the aqueous fraction of breast milk, assessed using 1H NMR spectroscopy, the largest variation 
observed was accounted for by the different profiles of HMO individual mothers produced, known to 
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be genetically determined (Thurl et al., 1997). HMO are postulated to have multiple protective and 
beneficial effects for the infants ingesting them. HMO act as prebiotics, selectively encouraging the 
growth of beneficial bacteria, especially Bifidobacterium longum subsp. longum, B. longum subsp. 
infantis, and Bifidobacterium breve, (Pacheco et al., 2014). As well as this, they act as anti-adhesive 
antimicrobials (Simon et al., 1997), exhibit immunomodulatory effects (Eiwegger et al., 2004), and 
have been proposed to play a role in brain development (Bode, 2012). 
The intestinal microbiota outnumber mammalian cells ten to one, additionally, the gene set of the 
microbiota is approximately 150 times larger than that of the human genome (Qin et al., 2010). This 
microbiome is crucial for both the immune and metabolic development of the infant, executing many 
important functions (German et al., 2002). Therefore, due to the importance of the intestinal 
microbiome to human health, one would expect factors regulating the growth of the microbiota to be 
highly conserved, as is observed with the very high concentrations of HMO found in colostrum, 
produced during the period when the infant is colonised with microbiota.   
Also investigated was the impact of maternal factors on the maternal and infant urinary metabolome, 
explored using 1H NMR spectroscopy. Here, it was established that maternal BMI did not influence the 
infant urinary metabolome, at any of the time points measured.  
This could be expected, because, as demonstrated in Chapter 4, maternal BMI was not seen to 
influence breast milk composition, meaning maternal BMI would be unlikely to be able to influence 
the infant urinary metabolome, unless this occurred through some other mechanism.  
A possible mechanism hypothesised to suggest why there may be a difference in the urinary 
metabolome of infants born to obese mothers include the fact that obese and overweight mothers 
are more likely to formula feed, an observation noted in this cohort. Formula feeding was observed 
to influence the urinary metabolome, as outlined in Chapter 4. However, when models were 
reanalysed using only exclusively breast fed infants against maternal BMI, the Q2 values were still 
negative, suggesting maternal BMI exerted no influence on infant urinary metabolome. 
Another possible factor which could have led to differences in the infant urinary metabolomes from 
infants born to obese mothers could be due to alterations in the microbiota profile. Infants are known 
to be colonised by their exposure to the maternal microbiota (in vaginally delivered infants) (Biasucci 
et al., 2008), and as obese individuals have an altered microbiota, this could be expected to be passed 
on to the infants. However, no alterations in infant urinary metabolome were observed, potentially 
due to the early period in which samples were collected, as the microbiota are unlikely to have been 
established at this point. 
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Maternal BMI did appear to influence the maternal urinary metabolome. This effect has been 
observed in previous studies, where changes in metabolite abundances related to the gut microbiome 
were particularly pronounced, also highlighted in this study (Calvani et al., 2010). 
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6.2 Implications of findings for clinical practice 
From this research it appears that maternal BMI exerts little influence on breast milk composition, 
other than leptin concentration. Due to the well documented, broad benefits of receiving breast milk, 
the current advice of ‘breast is best’ is a good recommendation to all mothers who are able to breast 
feed. These benefits are not just isolated to the neonate, but also extend to the mother, as breast 
feeding is associated with a reduced risk of type 2 diabetes, breast and ovarian cancer and maternal 
post-partum depression (Ip et al., 2007). As maternal BMI has such a small effect on the composition 
of milk, obese women should be encouraged to breast feed wherever possible, in order to provide 
their infants with all the nutritional and protective benefits breast milk contains. 
However, in relation to the effects of maternal overweight/obesity on breastfeeding itself, obese 
mothers have been shown to have difficulty in initiating, and maintaining, breastfeeding (Donath and 
Amir, 2008, Oddy et al., 2006).  A meta-analysis indicated that obese women have significantly 
reduced ability to initiate lactation, but once initiated, there is no difference from women of normal 
weight in lactation duration, meaning supporting of lactation initiation is key (Prior et al., 2012). It has 
also been reported that mothers who are overweight produce a smaller volume of breast milk 
(Barbosa et al., 1997). The authors of this study proposed that the reduced intake of breast milk of 
infants of obese mothers is balanced by an increase in the calorific density of breast milk from obese 
mothers (Barbosa et al., 1997). However, this increase in calorific density was not seen in the cohort 
of mothers recruited for this study.  
In agreement with this observation, previous studies have also demonstrated infants of 
overweight/obese mothers have decelerated early growth, gaining less weight and less fat mass, with 
these results remaining unaltered after adjustment for breastfeeding status (Ode et al., 2012). 
However, studies on the effect of maternal BMI on early infant growth have produced varied results, 
with some studies concluding that maternal BMI has no effect on early infant growth (Regnault et al., 
2010), whilst others showing increased maternal BMI increases early infant growth (Ong et al., 2008), 
and others showing reduced infant growth for infants of overweight obese mothers (Ode et al., 2012). 
This discrepancy in findings may be accounted for by studies solely measuring infant weight rather 
than body composition. Further reasons for this discrepancy may be due to bottle feeding versus self-
regulated suckling, or the infant either being formula or breast fed. 
The results from my study may help to explain the effect of reduced growth rates in infants of obese 
mothers.  shown that milk from obese mothers appears to be of the same nutritional quality as that 
of lean mothers; if obese mother’s infants have a lower milk intake, they  may receive less energy than 
infants of lean mothers, explaining the poorer growth rates seen in obese women’s infants. 
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Alternatively the slower growth rate of infants born to obese mothers may reflect physiological “catch-
down” growth following a period of intrauterine over-nutrition. 
The data presented here should encourage doctors, lactation consultants and overweight/obese 
mothers to support breast feeding, given that the composition of overweight/obese mother’s milk is 
comparable to that of normal weight mothers.  
In this work, a mid-IR human milk analyser was used to investigate the macronutrient content of 
breast milk. This instrument is intended for use in neonatal units to aid clinical decision making, to 
assess whether breast milk intended for premature infant requires nutritional fortifying. As results 
obtained from this instrument will be heavily influenced by the time of sample collection post-partum, 
and whether the sample was collected at the beginning or end of a feed, potentially limiting its clinical 
usefulness. A clinical research group in the Netherlands has employed mid IR analysis in order to 
combine milk samples with a high protein content to feed premature infants (Michaelsen et al., 1990). 
However, the utility of this approach has not yet been demonstrated, and furthermore the optimal 
growth velocity from preterm babies is not known.  
In conclusion, breast milk composition is well conserved across the maternal BMI range, with the 
exception of leptin concentration. The functional relevance of increased breast milk leptin content to 
the offspring is unclear. Overweight and obese women have difficulty in initiating lactation and hence 
added efforts are recommended to support them.   
  
 
 
245 
 
6.3 Strengths and limitations 
My thesis has a number of strengths and limitations. One limitation was the use of BMI as a proxy 
marker, as previously this has been shown to have a poor correlation with body composition, 
highlighted by methods such as whole body MRI (Thomas et al., 2012). Thomas et al describe a number 
of metabolic phenotypes, where an individual may have a healthy BMI, but possesses excess intra-
abdominal adiposity (associated with an adverse metabolic profile). Also described are individuals 
with a high BMI, but low quantities of intra-abdominal fat, who are metabolically normal.  
Furthermore, the time at which these mothers were investigated meant their BMI values were 
particularly unstable, displayed by the increase and subsequent decrease in the average maternal BMI 
over the study period. These differences in BMI values are unlikely to be wholly accounted for by 
increased maternal adipose tissue, but influenced by other factors such as maternal fluid balance. 
Alterations in adipose tissue quantity and distribution may have been better classified by magnetic 
resonance imaging (MRI), as this technique is able to delineate individual adipose tissue depots. MRI 
was not carried out due to the associated increased costs and time required, as well as difficulty in 
recruiting patients when requesting multiple MRI scans. In order to account for this the mothers 
booking BMI values were used. 
Another limitation faced was the relatively small number of samples originating from mothers with a 
higher BMI included in some of the analyses. This was due to the rapid post-partum weight loss many 
mothers experienced, meaning they were classified as having a BMI >25-30kg/m2 at recruitment, but 
not at the subsequent study visits. Analyses were carried out using maternal booking BMI values in 
order to account for this; however the same issue was apparent here as there were not equal numbers 
of individuals in the overweight/obese group against the lean group at the booking time point. This 
meant there were significantly fewer participants with a BMI over 25-30kg/m2 than expected at the 
time one week and three month time points.  
Additionally, another point to highlight is the specific population investigated throughout this thesis. 
All the mothers were recruited from a single hospital in west London and can be classified as ‘WEIRD’ 
(Western, Educated, Industrialized, Rich, and Democratic). This raises the question of how 
generalizable the results are to other cohorts of women, as the recruitment procedure used may have 
resulted in a non-representative population being sampled. However, if we make the assumption that 
the techniques used here are investigating the basic biology and metabolism of the mothers and 
infants, then this presumably means the results can be extrapolated to different groups of mother. 
However, in order to confirm this, further studies must be undertaken, recruiting mothers in different 
environments to the group here. An important consideration in these studies would be the different 
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diets of the mothers, which is known to have a particularly large influence on the fatty acid profiles of 
breast milk.  
A major strength of this work was the standardisation of breast milk sample collection. All samples 
were collected mid-morning to control for variation in breast milk composition over the course of the 
day, as fat concentrations in breast milk are known to peak mid-morning. Furthermore, the vast 
majority of samples were collected on day seven for the one week sample collection, reducing the 
variability in breast milk composition with regard to time of collection post-partum. Additionally, a 
distinction between fore and hind milk was made, allowing further influencing factors to be 
investigated, and introducing further control of sample composition.    
Strengths of this work include the assessment of each breast milk sample by both 1H NMR 
spectroscopy, in order to characterise the aqueous phase, and UPLC-MS, for the characterisation of 
the lipid phase, allowing greater coverage of the breast milk metabolome. 
Furthermore, like any piece of work requiring an analytical platform, there are various limitations 
imposed by the limitations of the instruments themselves. For example, NMR spectroscopy has a 
relatively high limit of detection in terms of the concentration of metabolites present, in relation to 
MS, meaning, in order to characterise metabolites present in lower concentrations, MS must be used.  
Likewise, the sample preparation methods employed are also able to introduce analytical artefacts, 
for example, contaminants present in solvents and collection tubes used. One problem encountered, 
introduced by the sample preparation method, was the binding of TSP to the remnants of protein 
which remained in the sample. This resulted in the TSP precipitating out of solution and therefore not 
being measured, meaning for the breast milk samples analysed by NMR, quantification of metabolite 
concentrations across samples was not possible, as there was no valid comparator. These factors limit 
the ability to compare across different studies, if different sample preparation protocols were 
employed.  
It was expected that the solvent extraction process would remove the protein from samples, however 
a proportion must have remained, which was unfortunately missed during the method development 
period. A possible approach to address this issue would be to use a greater volume of solvent, if the 
solution was saturated with protein. However, using a greater volume of solvents accrues greater 
costs, as well as increasing issues of disposal and the health implications of handling these solvents. 
Solely investigating breast milk composition reduces the complexity of the relationship between the 
mother and infant communicated via breast milk. For example, factors present in breast milk are 
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altered during digestion, and can take on new properties, such as peptides produced from the 
digestion of proteins capable of acting as antimicrobial agents.  
Additionally, breast milk contains a number of enzymes, which not only aid the digestion of milk, but 
also play important roles in gut development. The gut of the human infant has little lipase activity, 
relying on the presence of maternally derived lipoprotein lipase and bile salt stimulated lipase for 
digestion of the tri- and diacylglycerols present in breast milk (Blackberg and Hernell, 1981). The 
relative changes in lipase concentrations in the breast milk over the course of lactation, is a possible 
cause of altered lipid profile. This means, depending on the lipase activity, nutrition may be provided 
to the infant, but remain unavailable were it to go undigested.  
Furthermore, breast milk composition also influences the intestinal microbiota, meaning the quantity 
and profile of HMO produced will influence the abundance and classes of commensal bacteria present 
in the gut. As different microbes are able to carry out different functions, it is likely that this will affect 
infant physiology, which was not investigated in the present study.   
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6.4 Future Directions 
In relation to the investigation of how maternal overweight/obesity may influence breast milk 
composition I was unable to reject my null hypothesis, suggesting breast milk composition is extremely 
tightly regulated, even in conditions such as obesity. Furthermore, where breast milk composition 
does vary, such as in relation to fore or hind milk, or over lactation, this occurs in a predictable manner. 
If infants fail to grow properly, as milk composition is so tightly regulated, this suggests that it may not 
be the quality of milk, but the supply which determines failure to grow adequately. This finding should 
encourage further investment into the provision of lactation consultants for new mothers, who are 
able to support breast feeding. This will ensure the proper growth of infants, and that both infants 
and their mothers receive all the health benefits of breast feeding.   
As breast milk composition is so well conserved, determining its composition would have little value 
in a healthy term pregnancy. One situation in which screening of breast milk may be worthwhile is as 
a stratifying variable in neonatal clinical trials. Trials investigating the efficacy of antibiotics may want 
to assess the HMO profile of mothers, as HMO have been shown to influence the incidence of various 
infections, they may act as a confounding factor, obscuring the true efficacy of investigational 
treatments.  
Furthermore, for mothers of premature infants, and those at risk of necrotising enterocolitis (NEC), 
there may, in the future, be a benefit of screening mother’s breast milk for the presence of specific 
protective factors.  
For example, previous research has demonstrated that, in neonatal rats, the HMO disialyllacto-N-
tetraose can prevent NEC (Jantscher-Krenn et al., 2012). This protective effect has also been observed 
for human infants (Van Niekerk et al., 2014), meaning there may be a case for screening mothers 
breast milk for the presence of this oligosaccharide, and supplementing breast milk with this HMO in 
infant populations who experience a high incidence of NEC.  
Likewise, HIV is less likely to be transmitted to breastfeeding infants if the mother’s breast milk 
contains a higher HMO concentration, specifically lacto-N-neotetraose (Bode et al., 2012). Again, this 
poses the possibility of supplementing HIV infected mothers breast milk with this HMO to prevent the 
transmission of HIV to her infant.  
There are multiple instances where it may be feasible to screen breast milk for different protective 
factors, and supplement with appropriate factors in order to reduce the burden of disease resulting 
from vertical transmission of infections from mother to infant.  
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This work has highlighted the importance of sample preparation methods prior to metabolomic 
analysis, and attempted to optimise these, resulting in a publications in Analytical Chemistry 
(Villasenor et al., 2014), and Electrophoresis (Andreas et al., 2015). 
Future studies must ensure that sample collection is, as far as possible, standardised, especially in 
regard to time of collection post-partum, as there is a large amount of variation in breast milk 
composition in regard to this. In addition, this work provides data to ensure future experiments 
investigating these factors are adequately powered. One factor which potentially has an impact on 
breast milk composition is maternal diet. This was not explored in this work, but is an interesting 
avenue of future research. 
Likewise, this work has drawn attention to the influence of diet on infant metabolism, this was clearly 
demonstrated by the separation in the urinary metabolomes of the formula fed, and breast fed 
infants, and the subsequent identification of phenylacetylglutamine (PAG) as a metabolite 
discriminating between these groups, being increased in the breast fed infants. This indicates a clear 
relationship between infant diet and urinary metabolome. 
This work may also aid in the development of better formula compositions, improving the health and 
development of formula fed infants, as there are clearly many improvements to be made. I believe 
the formula industry must prioritise research into the manufacturing of HMO in large quantities, and 
the addition of these to formula milk, due to the clear benefits these compounds have for infants.  
However, even if the formula industry is capable of more closely reflecting the composition of breast 
milk, there are still advantages for both mother and infant from the act of breastfeeding itself. For 
example, not breastfeeding is associated with an increased risk of post-partum depression (Warner et 
al., 1996). In terms of benefits for the infant, previous research has indicated that regardless of 
whether fed breast or formula milk, bottle feeding is associated with increased infant weight gain, as 
infants are less able to regulate their own intake (Li et al., 2012).  
This work highlights the importance of breast milk not only as a source of nutrition, but for the 
multitude of other factors present, essential for the proper development of the infant, of which we 
are just starting to learn. Future studies could also investigate the alterations of various metabolites 
present in partially digested/digested breast milk, and attempt to ascribe functions to them, as they 
may take on new properties.  
For example, greater understanding of multifunctional metabolites, such as HMO, will mean more 
importance will be given to breast feeding as the optimal way to feed infants. Future work should 
focus on the specific interactions of HMO with the microbiota, as well as the functions of the 
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microbiota themselves. It would be of interest to investigate how different profiles of HMO may 
selectively stimulate specific species of microbiota. 
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Appendix 1A: Table outlining the metabolites present in breast milk. 
Metabolite Concentration Notes References 
  
g/litre                         
  
Lactose 72.0±2.5   (1985) 
Oligosaccharides 20.9±5, 12.9±3.30 Day 4, Day 120 Coppa et al 
Protein 10.5±2.0   (1985) 
Fat 39.0±4.0   (1985) 
  
mg/litre 
 
 
 
Calcium 280±26  (1985) 
Phosphorous 140±22  (1985) 
Magnesium 35±2  (1985) 
Sodium 180±40  (1985) 
Potassium 525±35  (1985) 
Chloride 420±60  (1985) 
Iron 0.3±0.1  (1985) 
Zinc 1.2±0.2  (1985) 
Copper 0.25±0.03  (1985) 
Vitamin E 2.3±1.0  (1985) 
Vitamin C 40±10  (1985) 
Thiamine 0.210±0.035  (1985) 
Riboflavin 0.350±0.025  (1985) 
Niacin 1.5±0.2  (1985) 
Vitamin B6 93±8  (Styslinger 
and Kirksey, 
1985) 
Pantothenic acid 1.8±0.2  (1985) 
  
µgrams/litre 
  
Vitamin A  670±200  (1985) 
Vitamin D 0.55±0.10  (1985) 
Vitamin K 2.1±0.1  (1985) 
Folate 85±37  (Brown et 
al., 1986) 
Vitamin B12 0.97  (Sandberg 
et al., 1981) 
Biotin 4±1  (1985) 
Iodine 110±40  (1985) 
Selenium 20±5  (1985) 
Manganese 6±2  (1985) 
Fluoride 16±5  (1985) 
Chromium 50±5  (1985) 
Molybdenum Not reported  (1985) 
 
Amino acids 
 
µmol/dl 
Colostrum, 
Transitional, Mature 
 (Carlson, 
1985) 
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Glutamic acid 36-68, 88-127, 101-
180 
  
Glutamine 2-9, 9-20, 13-58   
Taurine 41-45, 34-50, 27-67   
Alanine 9-11, 13-20, 17-26   
Threonine 5-12, 7-8, 6-13   
Serine 12, 6-11, 6-14   
Glycine  5-8, 5-10, 3-13   
Aspartic acid 5-6, 3-4, 3-5   
Leucine 3-5, 2-6, 2-4   
Cysteine 1-3, 2-5, 3-6   
Valine 3-4, 3-6, 4-6   
Lysine 5, 1-11, 2-5   
Histidine 2, 2-3, 0.4-3   
Phenylalanine 1-2, 1, 0.6-2   
Tyrosine 2, 1-2, 1-2   
Arginine 3-7, 1-5, 1-2   
Isoleucine 2, 1-2, 1   
Ornithine 1-4, 1, 0.5-0.9   
Methionine 0.8, 0.3-3, 0.3-0.8   
Phosphoserine 8, 5, 4   
Phosphoethanoamine 4, 8, 10   
𝝰-aminobutyrate 1, 0.4-1.4, 0.4-1   
Tryptophan 5, 1, 1   
Proline -, 6, 2-3   
Citrulline    
 
Protein nitrogen 
 
g/l 
 (Forsum and 
Lonnerdal, 
1980) 
Casein nitrogen 2.5   
Whey protein nitrogen 6.4   
𝝰-Lactalbumin 2.6   
Lactoferrin 1.7   
Β-Lactoglobulin -   
Lysozyme 0.5   
Serum albumin 0.5   
IgA 1   
IgG 0.03   
IgM 0.02   
Proteins                                415 identified 
 
Non-protein nitrogen 
 
g/l 
Urea nitrogen 0.25  (Forsum and 
Lonnerdal, 
1980) 
Creatine nitrogen 0.037   
Creatinine nitrogen 0.035   
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Uric acid nitrogen 0.005   
Glucosamine nitrogen 0.047   
𝝰-Amino  nitrogen 0.13   
Ammonia nitrogen 0.002   
 
Amino sugars 
N-Acetylglucosamine  230mg N/L N/L=nitrogen/litre  
N-Acetylneuraminic 
acid 
63 mg N/L   
 
Peptides  
Epidermal growth 
factor 
88 ng/ml   
Somatomedin-
C/insulin-like growth 
factor 
18 ng/ml   
Delta sleep-inducing 
peptide 
30ng/ml   
Carnitine   62.9 nmol/ml Mean over 50 days (Novak et 
al., 1981) 
Choline  0.21±0.05 mmol/l  (Holmes et 
al., 2000) 
Phosphocholine 0.48±0.07 mmol/l  (Holmes et 
al., 2000) 
Glycerophosphocholine 0.41±0.08 mmol/l  (Holmes et 
al., 2000) 
Phosphatidylcholine  0.10±0.01 mmol/l  (Holmes et 
al., 2000) 
Sphingomyelin 0.10±0.01 mmol/l  (Holmes et 
al., 2000) 
Citrate mg/dL 41.9 ± 5.9, 116.7 ± 
5.7, 64.8 ± 8.8  
Days 2-3, 14-12, 120-
180.  
 
 
Prostaglandins 
 
pg/ml 
Prostaglandin E 149±37, 224±64  5-7 days, fore/ hind 
milk 
(Lucas and 
Mitchell, 
1980) 
Prostaglandin F 425±152, 671±322  5-7 days,  fore/hind 
milk 
(Lucas and 
Mitchell, 
1980) 
Prostaglandin E2 162 ± 135, 198±148  3 days post-partum 
Foremilk, hind milk 
(Alzina et 
al., 1986) 
6-ketoprostaglandin F1 
𝝰 
818 ± 386,  
795 ± 487  
3 days post-partum 
Fore/hind milk 
(Alzina et 
al., 1986) 
Thromboxane B2 3557 ± 2770,  
4476  ± 4053  
3 days post-partum 
Fore/hind milk 
(Alzina et 
al., 1986) 
PGF2𝝰 221 ± 70, 
534 ± 350  
Fore/hind milk (Reid et al., 
1980) 
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Nucleotides  
 
mg/dl 
 (Janas and 
Picciano, 
1982) 
CMP 461±17.9   
UMP 179±19.8   
AMP 175±12.8   
IMP 228±14.5   
GMP 138±8.5   
UDP 174±12.8   
CDP 474±41.5   
ADP 69±17.9   
GDP 96±8.9   
 
Polyamines  
 
nmol/L 
Putrescine 0-615  (Pollack et 
al., 1992) 
Spermidine 73-3512  (Pollack et 
al., 1992) 
Spermine 722-4458  (Pollack et 
al., 1992) 
Cadavenne Present  (Sanguanser
msri et al., 
1974) 
 
Enzymes 
Lysozyme 0.2mg/ml   
Secretory leukocyte 
protease inhibitor 
19 µg/l  (Semba et 
al., 1999) 
    
 
Monosaccharides  
 
g/dl 
Glucose 1.4   
Galactose 1.2   
Fucose    
 
Hormones  
Oxytocin 3.3-4.7mg/ml Increases with 
nursing 
(Takeda et 
al., 1986) 
Leptin 1.5 ± 0.87ng/ml  (Houseknec
ht et al., 
1997) 
Ghrelin 571 ± 128pg/mL  (Aydin et al., 
2007) 
Obestatin 528.5 pg/mL  (Aydin et al., 
2007) 
Resistin 375±29 pg/mL  (Ilcol et al., 
2008) 
Adiponectin 29.5 ± 6.4 ng/mL   (Dundar et 
al., 2010)          
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Progesterone 10-40ng/ml  (Koldovsky, 
1995) 
Pregnanediol 0-450ng/ml  (Koldovsky, 
1995) 
Prolactin 0.5 ng/mL  (Hines et al., 
2007) 
Estradiol 0.6 pg/mL  (Dawa et al., 
2009) 
Oestrogens 15-840ng/ml  (Koldovsky, 
1995) 
Transforming growth 
factor alpha 
0-8.4 ng/ml  (Koldovsky, 
1995) 
Gastrin 10-30pg/ml  (Koldovsky, 
1995) 
Gastric inhibitory 
peptide 
33-59ng/ml   
Gastric regulatory 
peptide 
31-55pg/ml   
Neurotensin 7-15pg/ml   
Peptide histidine 
methionine 
3-32pg/ml   
Peptide YY 15-30 pg/ml   
Insulin 21 ng/ml   
 
Lipids  
 
% weight 
  
(Specker et 
al., 1987) 
Saturates 
8:0 0.22±0.01   
10:0 1.57±0.09   
12:0 5.47±0.66   
14:0 6.54±0.73   
16:0 20.48±0.64   
18:0 8.14±0.55   
20:0 0.57±0.03   
Total % weight 42.99%   
Monounsaturates 
16:1 3.35±0.28   
18:1 34.7±0.86   
Total 38.08%   
Polyunsaturates  
18:2 14.47±1.98   
20:2 0.50±0.03   
20:3 0.56±0.03   
20:4 0.68±0.03   
18:3 1.85±0.16   
22:6 0.27±0.08   
Total 18.33%   
 % total of lipid  (Koldovsky, 
1995) 
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Triacylglycerol 58   
Diacylglycerol 8   
Monoacylglycerol 0.6   
Sterols 0.7   
Unesterified fatty acids 7.3   
Phospholipids 23   
 % phospholipid   
Sphingomyelin  26   
Phosphatidyl choline 30   
Phosphatidyl 
ethanolamine 
37   
Phosphatidyl inositol 5   
Phosphatidyl serine 1   
Lysophosphatidyl 
choline 
2   
Glycosylceramides 1–20 mg/L  (Jensen, 
1999)  
Type of triglyceride  % of total (mol/100 
mol TG) 
 (Jensen, 
1999)  
16:0-18:1-18:1  11.8    
16:0-18:1-18:2  10.0   
16:0-16:0-18:1  4.4   
18:1-18:1-18:2  3.3   
14:0-16:0-18:1  3.3   
16:0-18:2-18:2  3.2   
12:0-16:0-18:1  3.1   
16:0-18:0-18:1  3.1   
14:0-18:1-18:1  2.8   
16:0-16:0-18:2  2.4   
14:0-18:1-18:2 2.3   
18:1-18:1-18:1 2.1   
16:0-18:1t-18:1 2.1    
18:1-18:2-18:2 1.9   
16:0-16:1-18:1 1.9   
16:0-18:0-18:2 1.7   
14:0-16:0-18:2 1.5   
12:0-18:1-18:1 1.4   
12:0-16:0-18:2 1.3   
12:0-18:1-18:2 1.2   
12:0-14:0-18:1 1.1   
18:0-18:1-18:2 1.0   
    
Oligosaccharides  g/l  (Kunz et al., 
2000) 
Lacto-n-tetraose  0.5-1.5   
Lacto-n-fucopenatose I 1.2-1.7   
Lacto-n- fucopenatose I 0.3-1.0   
Lacto-n- fucopenatose I 0.01-0.2   
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Lacto-n- difucohexose I 0.1-0.2   
NeuAc(𝝰2-6)lactose 0.3-0.5   
NeuAc(𝝰2-3)lactose 0.1-0.3   
NeuAc-lacto-N-tetraose 
a 
0.03-0.2   
NeuAc-lacto-N-tetraose 
c 
0.1-0.6   
NeuAc2-lacto-N-
tetraose 
0.2-0.6   
    
Cytokines pg/mL  (Goldman et 
al., 1996) 
IL-1β 1130±478   
IL-6 151±89   
IL-8 3684±2910   
IL-10 3400±3800   
TNF-𝝰 620±183   
G-CSF ~358   
M-CSF 17120 U/mL   
EGF ~200,000   
TGF-𝝰 ~2200-7200   
TGF-β2 130±108   
sCD-14 5.08 μg/mL  (Collado et 
al., 2012) 
INF-y 196.57 pg/mL  (Collado et 
al., 2012) 
IL-4 20.6  (Collado et 
al., 2012) 
IL-2 22.73  (Collado et 
al., 2012) 
    
Cholesterol and 
precursors  
 2nd month of 
lactation 
 
Cholesterol 10-20mg/dl  (Jensen, 
1999) 
Squalene  386μg/dL   
Lanosterol   94μg/dL   
Dimethylsterol   45μg/dL   
Methostenol   48μg/dL   
Lathosterol  43μg/dL   
Desmosterol  1509μg/dL   
    
Bile Salts μmol/L  (Forsyth et 
al., 1983) 
Cholate 0.89±0.13   
Chenodeoxycholate 0.26±0.057   
    
Antioxidants    
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Appendix 2B (continued) 
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Appendix 2C (continued) 
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Appendix 2C (continued) 
 
*Ethnic origin was classified as; White British, White Other, Chinese, Japanese, Hispanic, Indian, 
Middle Eastern, Other Asian, Other mixed.  
 
 
 
 
 
 
 
 
 
 
* 
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Appendix 2C (continued) 
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Appendix 2D 
Protease inhibitor cocktail preparation  
Lyophilized powder from Sigma-Aldrich containing; AEBSF at 2mM, Aprotinin at 0.3μM, Bestatin at 
130μM, E-64 at 14mM, Leupeptin at 1mM and EDTA at 1mM. 
Dilute in 100ml distilled H2O;  
Aliquots 20µl into Eppendorf tubes and allow to dry; 
Freeze; 
Add 1 ml of breast milk once collected. 
Appendix 2E 
Buffer Preparation for urine for NMR spectroscopy (500ml)  
Reagents must be of analytical grade.  
Reagents: 
a) 1.5M KH2PO4/D2O, pH 7.4 (with KOD/D2O) 
b) 2mM NaN3 
c) 0.1% TSP (3-Trimethylsilyl propionic acid) 
 
Preparation: 
1) Dissolve 102g KH2PO4 in 400ml D2O 
2) Dissolve 500mg TSP and 65mg of NaN3 in 30-50ml D2O 
3) Mix both solutions very well under ultrasonication 
4) Adjust pH to 7.4 with KOH-tablets or strong KOD-solution (KOH-tablets in D2O) 
5) Fill to 500ml and mix well  
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Appendix 2F – CE-MS system parameters 
The software used to operate the CE unit was 3D-CE ChemStation Rev B.04.03 (Agilent Technologies, 
Wilmington, USA). Separations were carried out in normal polarity in a fused-silica capillary (Agilent) 
with an internal diameter of 50µm, a total length of 60cm and with a background electrolyte 
containing 0.1mol/l formic acid solution. The capillary was conditioned with a first flush of 300 seconds 
of 2M ammonium hydroxide (Sigma-Aldrich, UK), a second flush of 240 seconds of deionised water 
and a third flush of 300 seconds of run buffer. The temperature of the capillary was set at 25˚C. 
Samples were injected into the instrument hydrodynamically, at 50mBar for 3 seconds, in a stacking 
manner. A voltage of 25kV was applied for 20 minutes. The sheath liquid was delivered at a flow rate 
of 0.6ml/min with split 1:100, and comprised of methanol/water (70% v/v) containing 1.0mmol/l 
formic acid. Auxiliary liquid flow was set to 6μl/min. 
The software MassHunter WorkStation Acquisition B.02.01 was used to acquire the MS data (Agilent 
Technologies, Wilmington, USA). Data were collected in centroid mode with an acquisition rate of 5 
spectra per second. The nitrogen gas ﬂow rate was 10l/min, set to 200°C. The nebulizer was set to 
10psi 30 seconds after injection.  The fragmentor and octupole voltage were set to 150 and 750V 
respectively. A solution containing 10ml water, 90ml methanol, 100μl formic acid, with two reference 
masses; 600μl of 5mmol/l purine, and 600μl of 2.5mmol/l HP 0921 was infused directly into the ion 
source. The reference mass spectra were collected simultaneously with the analytical data and used 
for accurate mass correction and highly accurate mass measurement in the MS system. A mass 
acquisition range of 50-1700 m/z was used. 
CE-MS data processing 
Background noise and unrelated ions were cleaned from the CE-MS data by the Molecular Feature 
Extraction (MFE) tool in MassHunter (B.04.00, Agilent). The MFE creates a list of all possible 
components extracted from the full TOF mass spectral data and migration times. The following 
parameters were used to obtain these: target data type of small molecules (chromatographic); peaks 
with height ≥200 counts; Peak spacing tolerance=0.0025; m/z, ±7.0 ppm; isotope model =common 
organic molecular; limited assigned change=2.  
Alignment was performed first on all samples with QC samples, and later only for the samples under 
investigation. Corrections applied for the alignment were 2% migration time correction, and ±10 ppm 
mass correction. Data were normalised using total area normalisation. The filtering and alignment of 
the data were performed with GeneSpring version 12.6 (Agilent) selecting features in the range of 0.5 
minutes to 20 minutes. Filtering was performed by eliminating features present in the QC samples 
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with a coefficient of variation above 30%. SIMCA P+ 13.0 software (Umetrics, Umeå, Sweden) was 
used for multivariate analysis. Variables with a |t-statistic| ≥ 1.96 (z-score, corresponding to the 97.5 
percentile) [17] were considered significant. 
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Appendix 2G 
Experimental design of breast milk hormone analysis, adapted from; 
http://www.bio-rad.com/webroot/web/pdf/lsr/literature/10010747.pdf 
Reconstitute standards;  
1) Add 500μl of standard diluent and vortex for 5 seconds 
2) Incubate on ice for 30 minutes  
3) From each of the reconstituted vials add 128μl of standard to S1 and 72 μl standard diluent, 
then vortex for 5 seconds. 
4) Place 150μl of standard diluent into the remaining tubes S2-blank 
5) Starting at S1 transfer 50μl of Standards into tubes S2-S8. Vortex for 5 seconds after each 
volume transfer. 
Prepare coupled beads 
1) Vortex stock coupled beads at medium speed for 30 seconds 
2) Add required volume of assay buffer to each falcon as below and cover with foil 
3) Dilute beads according to table below combine with assay buffer  
 Plate 1  ~105 wells 
Volume μl 
Leptin 262 
Resistin          x20 262 
Ghrelin  262 
Insulin 262 
  
Assay buffer 4200 
Total volume 5250 
Prepare samples  
1) Take samples from -80 freezer and allow to thaw keep on ice 
2) Centrifuge at 4 degrees for 10 minutes at 10,000RPM 
Combine components 
1) Vortex beads at medium speed for 30 seconds  
2) Add 50μl of beads to each well 
3) Wash plate twice; add 100μl of wash buffer to each well, place plate on magnetic bead 
holder, wait 1 minute. Throw out solution, and dab on absorbent towels. Remove from 
magnetic bead bolder and wash again 
4) Vortex standards and samples for plates gently for 5 seconds 
5) Transfer 50μl to each well, different pipette tip after each transfer, making sure you adhere 
to plate map carefully 
6) Cover whole plate with sealing tape and foil. 
7) Incubate on plate shaker at 850RPM at room temperature for 1 hour  
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Appendix 2G (continued)  
Prepare detection antibodies 
1) Vortex stock antibodies before dilution for 15-20 seconds at medium speed 
2) Add Bioplex Detection Antibody diluent to the a falcon tube as detailed in table below: 
 Plate 1 (~105 wells) 
Volume μl 
Leptin antibody 132 
Insulin antibody 132 
Ghrelin antibody 132 
Resistin antibody 132 
  
Antibody diluent 2097 
Total volume 2625 
 
3) Add detection antibody to a falcon tube as above. 
4) Wash plate 3 times with 100μl wash buffer.  
5) Vortex diluted detection antibodies gently for 5 seconds and transfer 25μl of diluted antibody 
to each well 
6) Cover the plate with new sealing tape and foil. 
7) Incubate on shaker at 850+/- 50 rpm for 30minutes at room temperature 
Prepare and add Streptavidin-PE 
1) Vortex the 100xSA-PE for 5 seconds at medium speed 
2) Add assay buffer as below table into each labelled falcon tube: 
No. of Wells 100xSA-PE, μl Assay buffer, μl Total volume 
Plate 1 (105) 53 5197 5250 
Trial (50) 25 2475 2500 
 
3) Pipette the required SA-PE into each labelled falcon, then cover with foil until use. 
4) After incubation of antibody is completed, remove and discard sealing tape. 
5) Wash the plate 3 times Vortex diluted SA-PE medium at medium speed for 5 seconds. Pour 
into reagent reservoir and transfer 50 μl to each well using a repeat pipette. 
6) Cover with sealing plate and with foil. 
7) Incubate plate on shaker at 850 +/- 50rpm for 10 minutes at room temperature. 
8) After incubation step, wash plate three times 
9) Add 125 μl of assay buffer to each well, cover with foil. 
10) Take to Bioplex machine and read plate. 
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Appendix 2H 
 PCA  Models (Figure 23) R
2
 Components Outliers t[1] t[2] Scaling 
A NMR aqueous 0.406 2 3 0.27 0.128 UV 
B CE-MS; Positive mode  0.333 1 0 0.23  Par 
C NMR Lipid 0.484 2 3 0.35 0.12 UV 
D UPLC-MS; Positive mode lipid 0.567 2 0 0.39 0.17 Par 
E UPLC-MS; Negative mode lipid  0.331 2 0 0.23 0.1 UV 
        
  PLS-DA Models (Figure 24) R2 Q2 Components Outliers t[1] t[2] Scaling 
A NMR aqueous  0.429 0.304 2 1 0.20 0.19 UV 
B CE-MS; Positive mode  0.833 0.458 2 0 0.23 0.06 Par 
C NMR Lipid 0.295 0.104 2 1 0.30 0.12 UV 
D Lipid UPLC-MS; Positive mode  0.589 0.04 2 0 0.23 0.22 Par 
E Lipid UPLC-MS; Negative mode  0.659 0.09 2 0 0.2 0.08 UV 
       
  OPLS-DA Models (Figure 25) R2X R2Y Q2 Components Scaling 
A NMR aqueous  0.381 0.582 0.249 2 UV 
B CE-MS; Positive mode  0.331 0.984 0.766 2 Par 
C NMR Lipid 0.462 0.567 -0.327 2 UV 
D Lipid UPLC-MS; Positive mode  0.246 0.959 0.489 2 Par 
E Lipid UPLC-MS; Negative mode  0.294 0.932 0.127 2 UV 
       
  OPLS-DA Models (Figure 26) R2X R2Y Q2 Components Scaling 
A NMR aqueous  0.412 0.927 0.866 2 UV 
B CE-MS; Positive mode  0.34 0.967 0.735 2 Par 
C NMR Lipid 0.416 0.572 -0.05 2 UV 
D Lipid UPLC-MS; Positive mode  0.564 0.837 0.531 2 Par 
E Lipid UPLC-MS; Negative mode 0.356 0.938 0.43 2 UV 
       
  OPLS-DA Models (Figure 27) R2X R2Y Q2 Components Scaling 
 
 
295 
 
 
 
 
 
 
 
A NMR aqueous  0.41 0.813 0.713 2 UV 
B CE-MS; Positive mode 0.249 0.988 0.301 2 Par 
C NMR Lipid 0.443 0.455 0.167 2 UV 
D Lipid UPLC-MS; Positive mode  0.622 0.792 0.429 2 Par 
E Lipid UPLC-MS; Negative mode  0.346 0.962 0.165 2 UV 
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Appendix 3 
The effect of maternal body mass index on the concentration of appetite 
regulating hormones present in breast milk: a systematic review and in vitro 
analysis 
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Appendix 3A 
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Appendix 3B: Scatter plot displaying the outlier mother at 50kg/m2, outlined in red. This point 
unduly influenced results obtained, and was therefore excluded from further analysis.  
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Appendix 3C: Normal Q-Q plot for breast milk (A) Ln ghrelin concentrations (B) Ln Insulin 
concentrations (C) Ln leptin concentrations and (D) Ln resistin concentrations. 
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Appendix 4 - Breast milk metabonomic and nutritional analysis
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A B 
C D 
Appendix 4A: PCA scores plots of; A Fore milk samples collected at one week post-partum, R
2
=0.301, Q
2
=0.218. B Hind milk samples collected at one week 
post-partum, R
2
=0.28, Q
2
=0.197.  C Fore milk samples collected at 3 months post-partum, R
2
=0.384, Q
2
=0.312. D Hind milk samples collected at 3 months 
post-partum, R
2
=0.299, Q
2
=0.201 in positive ionisation mode. 
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Appendix 4B: PCA scores plot of; A Fore milk samples collected at one week post-partum, R
2
=0.319, Q
2
=0.246. B Hind milk samples collected at 
one week post-partum, R
2
=0.344, Q
2
=0.289. C Fore milk samples collected at 3 months post-partum, R
2
=0.421, Q
2
=0.347. D Hind milk samples 
collected at 3 months post-partum, R
2
=0.382, Q
2
=0.319 in negative ionisation mode. 
  
A B 
C D 
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Appendix 4C: Histograms displaying the distribution of macronutrients in fore milk samples 
collected at 3 months post-partum, fat (A), crude protein (B), carbohydrate (C) in g/100ml and 
energy content (D) Kcal/100ml of breast milk analysed.  
 
 
 
 
 
 
 
 
 
304 
 
Appendix 4D. Histograms displaying the distribution of macronutrients in hind milk samples 
collected at 3 months post-partum, fat (A), crude protein (B), carbohydrate (C) in g/100ml and 
energy content (D) Kcal/100ml of breast milk analysed. 
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Appendix 5 - Infant and maternal urinary metabolome
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Appendix 5A: PCA scores plots derived from NMR spectra of; (A) Maternal urine samples collected at recruitment, R2 = 0.215, Q2 = 0.137. (B) Maternal 
urine samples collected at one week postpartum, R2 = 0.2, Q2 = 0.08. (C) Maternal urine samples collected at three months post-partum, R2 =0.156, Q2 
=0.07. (D) Infant urine samples collected at recruitment, R2 = 0.272, Q2 = 0.152. (E) Infant urine samples collected at one week post-partum, R2 = 0.192, 
Q2 =0.127. (F) Infant urine samples collected at three months post-partum, R2 = 0.176, Q2 = 0.09. 
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Appendix 5B: Loadings plot corresponding to Figure 67, loadings to the right correspond to 
metabolites increased in the urine of mothers with a higher BMI whilst metabolites on the 
left of the plot correspond to metabolites increased in mothers with a lower BMI.  
 
 
 
Appendix 5C: Permutation testing of the first model in Table 47.  This figure strongly suggests the 
model is valid. Model comparing infants with an earlier gestational age, against infants born at a 
later gestational age. 
 
R2/Q2 value 
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Presented at the Neonatal Society 2013 spring meeting. 
 
Title: The association between leptin concentrations in breast milk and maternal 
characteristics 
Authors: Andreas NJ1, Parkinson JRC1, Hyde MJ1, Jeffries S1, Xiong R1, Fitz-Simon N1, Modi 
N1 
Institution: 1Section of Neonatal Medicine, Chelsea and Westminster campus, Imperial College 
London, UK 
 
Background/Introduction: Leptin plays a fundamental role in the development and subsequent 
control of key metabolic pathways. The aim of this study was to determine if there was a relationship 
between leptin concentration in breast milk and key maternal characteristics. 
Methods: This study was carried out under research ethics approval (REC: 12/LO/0203). Mothers 
were recruited to the study from the post-natal ward at Chelsea and Westminster Hospital. Breast 
milk samples (10ml) were collected seven days post-delivery from lactating mothers (n=37), with the 
aid of a breast pump. Timing of sample collection was standardised to the morning in order to reduce 
the influence of diurnal variations in breast milk composition. Samples were stored at -20°C. 1ml of 
sample was sonicated using an ultrasound probe prior to analysis. Leptin was measured using 
commercially available leptin ELISA kit (Millipore, UK). Concentrations of leptin in breast milk were 
correlated with maternal data (age, pre-pregnancy BMI, pre-pregnancy weight, duration of 
pregnancy, 28 week glucose tolerance test, weight and BMI at the time of sample collection). Linear 
regression was performed in SPSS 20. 
Results: Correlation analysis revealed a significant association between leptin and both maternal 
weight at sample collection (r=0.4, R2 = 0.15, p=0.015) (Figure 1) and maternal BMI at sample 
collection (r: 0.34, R2=0.12, p=0.05). Linear regression analysis revealed the change in leptin per 1kg 
increase in maternal weight at sample collection was 0.003ng/ml (95%CI: 0.001, 0.005). No 
association was observed between leptin and other maternal characteristics (age, pre-pregnancy 
BMI, pre-pregnancy weight, duration of pregnancy, 28 week glucose tolerance test). 
 
Figure 1 Plot of maternal weight at sample collection (kg) and leptin concentration (ng/ml). Line of 
best fit (solid) and 95% CI (hatched) are also shown. 
Conclusions: These data indicate an association between foremilk leptin concentration with 
maternal weight and BMI, at the time of sample collection. Though the bioactivity of breast milk leptin 
is unknown, we speculate that this may be part of a feedback mechanism serving to regulate infant 
milk intake. 
References: 
(1) Konstantinos M (2012) The complex interaction between obesity, metabolic syndrome and 
reproductive axis: A narrative review. Metabolism 
(2) Koo M et al. The effect of maternal BMI on the concentration of appetite regulating peptides in 
breast milk. Neonatal Society Autumn 2011. 
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Presented at the 21st European Neonatal Workshop, autumn 2013. 
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Presented at the Neonatal Society 2012 Summer Meeting. 
Propylene glycol: a natural protection against cold stress at delivery? 
Hyde MJ, Romero MG, Wijeyesekera AD, Perez IG, Jeffries S, Logan K, Andreas N, Gale C, 
Holmes E, Modi N 
Neonatal Medicine, Imperial College London, 369 Fulham Road, London, SW10 9NH, UK 
Background: We have previously used 1H NMR to study the hepatic metabolome in 7 day post-
partum piglets, delivered vaginally (VD) or by pre-labour Caesarean section (CS) (1). In the present 
study we aimed to evaluate the urinary metabolome during the first 7 days post-partum in human 
babies born by VD or CS. The study was conducted with Research Ethics Committee approval 
(08/H07/11/43). 
Methods: A urine sample was collected on cotton wool from 30 infants within 72 hours of birth, at 
Chelsea & Westminster Hospital, and stored at -80ºC until analysis. Samples were analysed using 
one-dimensional 1H NMR spectroscopy at 300K on a Bruker Avance 600 MHz spectrometer, using 
standard parameters and pre-processing algorithms, as previously described (2). The spectra were 
automatically phased; baseline corrected, referenced using an in-house routine written in MATLAB, 
normalised using probabilistic quotient normalisation to the median profile and aligned; continuous 
spectral data were used for statistical analysis. Spectra were analysed on the basis of experimental 
group using principal component analysis (PCA) and partial least square-discriminant analysis (PLS-
DA) to explore the variation between the groups. 
Results: Urinary samples were analysed from 15 VD and 15 CS infants (Pre-labour CS = 7; 
Emergency CS = 8) born between 37-42 weeks gestation. There was a significant difference in the 
urinary metabolome of infants born by CS and VD when examined using PLS-DA (Fig 1a). One of the 
metabolites with greatest difference between CS and VD babies was propylene glycol (doublet at 
1.14ppm; Fig 1b). As this was unexpected, we reviewed previously analysed data acquired from 15 
term baby urine samples. We classified these according to mode of delivery (6 VD and 9 CS) and 
found a similar difference in propylene glycol between CS and VD babies. 
 
Figure 1: a) PLS-DA scores plot of UV scaled data from 1H NMR spectra of urine collected from term infants born by CS (●; n 
= 15) vs. VD (▲; n = 15) infants. (R2 = 0.831; Q2 = -0.049). b) Representative NMR spectra (red = CS; black = VD) showing 
the doublet associated with propylene glycol. 
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Conclusion: In our previous work one of the metabolites which differed strongly between VD and CS 
delivered piglets was also propane-1,2-diol (propylene glycol), which was increased in the former. We 
previously attributed propylene glycol in the liver of VD animals to its use as a vehicle for sodium 
pentobarbital used for euthanasia, and hypothesised that differences between CS and VD piglets 
reflected altered underlying metabolism. We now show that propylene glycol is also increased in 
human infants born by VD compared to CS. Upon review of published literature we find reports of 
propylene glycol in cerebral in vivo 1H NMR spectra in the human neonate following asphyxial injury 
and also in urine; these authors concluded that the source of the propylene glycol was 
phenobarbitone vehicle (3,4). The presence of propylene glycol in healthy VD infants suggest an 
alternative hypothesis, namely that propylene glycol, through its involvement in lactate/pyruvate 
metabolism, may be produced in VD infants in response to the transient hypoxaemia associated with 
VD. Propylene glycol is commonly used as antifreeze, and though postulating a role as a natural 
protection against cold stress at delivery may be implausible, its significance to the physiology of the 
newborn is intriguing. Our finding is novel and demands further study. 
References 
1. Hyde, M.J. (2010) Clin Sci (Lond.). 118, 47-59.  
2. Beckonert, O. (2007) Nature Protocols. 2, 2692-703. 
3. Cady, E.B. (1994) MRM. 32, 764-7.  
4. Ma, S. (1995) Appl Biochem and Biotech. 53, 37-51. 
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Presented at the Neonatal Society 2012 Summer Meeting. 
Infants of mothers with diabetes have altered urinary metabolic profile at birth 
Logan KM, Wijeyesekera AD, Perez IG, Hyde MJ, Romero MG, Jeffries S, Andreas N, Gale C, 
Holmes E, Modi N 
Imperial College London, UK 
Background: In addition to their genetic risk, babies exposed to diabetes in the womb have greater 
risks of childhood obesity (1) and a fourfold increased risk of T2D (2). Identification of pathways and 
markers of T2D risk in infants of mothers with diabetes (IDM) could bring targeted surveillance and 
early detection nearer. Using metabolomics, large numbers of metabolites may be analysed in small 
volumes of urine. Metabolic profile has not been studied in newborn IDM and we hypothesised that 
this differs between IDM and control infants in the newborn period. The study was conducted with 
Research Ethics Committee approval (08/H07/11/43). 
Methods: Infants were recruited from the postnatal wards at Chelsea and Westminster Hospital 
between July 2010 and Jan 2012. A urine sample was collected within 72 hours using cotton wool 
and stored at -80ºC until analysis. Samples were analysed using one-dimensional 1H NMR 
spectroscopy at 300K on a Bruker Avance 600 MHz spectrometer, using standard parameters and 
pre-processing algorithms, as previously described (3). The spectra were automatically phased; 
baseline corrected, referenced using an in-house MATLAB routine, normalised using probabilistic 
quotient normalisation to the median profile and aligned; continuous spectral data was used for 
statistical analysis. Spectra were analysed on the basis of experimental group using principal 
component analysis (PCA) and partial least square-discriminant analysis (PLS-DA). 
Results: We analysed urine samples from 18 IDM and 12 healthy term control infants. The urinary 
metabolome of IDM and term neonates appears to differ (Fig 1). Differences appear to be seen in the 
following metabolites; glucose and formate, fumarate, succinate and citrate, which are involved in the 
TCA cycle. 
 
Figure 1: Partial least squares discriminant analysis (PLS-DA) scores plot of UV scaled, continuous data 
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from 1H NMR spectra of urine collected within 72 hours of birth from infants of diabetic mothers(●; 37+3 - 39+5 weeks GA; 
n=18) compared with healthy term infants (▲; born 39+2 - 42 weeks GA; n=12). R2=0.79, Q2=0.09. 
Conclusion: These preliminary data indicate differences in the metabolism of IDM and control infants 
in the newborn period. These findings require confirmation and reassessment in later infancy. The 
next step will be to study infant metabolite alterations in relation to the continuum of maternal 
glycaemia in pregnancy. 
References 
1. Phillips L et al (2011) Diabetologia 54:1957-1966 
2. Dabelea D, et al. (2000) Diabetes 49:2208-2211 
3. Beckonert O et al (2007) Nature Protocols 2: 2692-703 
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I am completing my PhD thesis at Imperial College London entitled ‘The influence of 
maternal metabolic phenotype on breast milk composition and on the maternal and 
infant urinary metabolome.’ 
I seek your permission to reprint, in my thesis an extract from: http://miris.se/human-
milk-analysis/why-analyse/. The extract to be reproduced is below:  
 
I would like to include the extract in the printed examination copy of my thesis and 
also the electronic version which will be added to Spiral, Imperial's online repository 
http://spiral.imperial.ac.uk/ and made available to the public under a Creative 
Commons Attribution-NonCommercial-NoDerivs licence. 
If you are happy to grant me all the permissions requested, please return a signed 
copy of this letter. If you wish to grant only some of the permissions requested, 
please list these and then sign. 
Yours sincerely, 
Nicholas Andreas  
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Figure 5. Structures of 2 and 3’-fucosyllactose 
